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Abstract
Bordetella pertussis is the causative agent o f the disease whooping cough in man, and 
although there is an effective whole-cell vaccine (WCV), recent efforts have focused on 
the development of the acellular vaccines (ACVs) to avoid the problems of 
reactogenicity associated with WCVs.
The cell-invasive toxin, adenylate cyclase toxin (CyaA), is an important virulence factor 
o f B. pertussis and, when used as a vaccine, is able to protect mice against intranasal 
challenge with B. pertussis. The project was designed to investigate the mouse immune 
responses to two forms of the toxin, an enzymically-active, acylated form (CyaA) and an 
enzymically-inactive, acylated form (CyaA*). These were expressed as recombinant 
forms in E. coli, purified and their enzymic, haemolytic and cytotoxic properties 
characterised. The adenylate cyclase (AC) and cytotoxic activities of CyaA* were low 
compared to CyaA, but the haemolytic activities of the two toxins were similar. This 
indicated that the toxic activity of CyaA is dependent on AC enzymic activity, but that 
haemolytic activity is independent of AC activity.
Mouse responses to intraperitoneal immunisation with CyaA or CyaA* were examined, 
initially when each toxin was administered alone and later when administered in 
combination with protective antigens commonly used in ACV preparations (pertussis 
toxin (PT), filamentous haemagglutinin (FHA), and pertactin (P.69)). Both forms of the 
toxin when administered alone produced a strong serum IgG response which was 
boosted by a second vaccination. Anti-PT, -FHA and -P .69 IgG levels, in response to 
immunisation with PT, FHA and P.69 mixture in the presence of CyaA* were all raised 
compared to mice immunised with just the antigen mixture alone when measured at five
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weeks post-immunisation, however only anti-P.69 levels were raised by co­
administration with CyaA. When detoxified PT (dPT) was co-administered alone with 
CyaA*, the anti-PTd levels decreased but if FHA or P.69 were also included in the 
antigen mixture, the anti-PTd levels increased in comparison to mice immunised with 
PTd alone. When either FHA or P.69 antigen was co-administered with CyaA*, both 
anti-FHA and anti-P.69 levels respectively were raised in comparison to those 
immunised with FHA or P.69 alone, again when measured at five weeks post­
immunisation.
Other work had shown that induction of cell-mediated immunity (CMI) was necessary 
for effective clearance o f B. pertussis in the mouse. In this study, nitric oxide 
production by peritoneal macrophages was measured as a marker o f macrophage 
activation. Macrophages collected from mice vaccinated with PT, FHA and P.69 
together with CyaA or CyaA* responded more to stimulation with B. pertussis heat- 
killed cells or CyaA* than those taken from mice immunised with just the antigen 
mixture alone. Increased protection following aerosol challenge with B. pertussis was 
also observed when mice received a vaccination of CyaA* co-administered with PT, 
FHA and P.69 mixture.
Taken together these results indicate that CyaA is a candidate antigen for inclusion in 
acellular vaccines, even in the detoxified CyaA* form. As well as being a protective 
antigen in its own right, it may also afford improved CMI responses than the cun*ent 
ACV formulations.
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CHAPTER 1 
INTRODUCTION
1.1 CHARACTERISTICS OF THE GENUS BORDETELLA
1.1.1 Taxonomy and association with disease
Bordetella spp, are minute, Gram-negative, aerobic, non-acid fast, non-sporing 
coccobacilli (0.2-0.5) x (0.5-2)pm, arranged singly or in pairs with an optimum 
growth temperature of 35-37°C. Currently there are 8  named species, of which B. 
pertussis is the type species. B. pertussis was first described by Bordet and Gengou 
(1906) as the cause of pertussis or whooping cough, a highly contagious acute 
bacterial disease involving the respiratory tract, (Per, meaning intensive or 
pernicious, and tussis, meaning cough). It was initially named Haemophilus 
pertussis and remained as such until 1952 when Moreno-Lopez created the new 
genus Bordetella in honour o f the work carried out by Jules Bordet (Moreno-Lopez, 
1990). B. bronchispetica, first obtained by Ferry (1910) from the respiratory tract of 
dogs, and B. parapertussis, isolated by Bradford and Slavin (1937) from mild cases 
o f whooping cough, were also included in the genus Haemophilus before the 
introduction o f the genus Bordetella.
B. pertussis and B. parapertussis are the aetiological agents of whooping cough in 
humans. B. pertussis is an obligate pathogen for humans but B. parapertussis strains 
are also found in sheep where they can cause cloronic pneumonia (Cullinane et a l,  
1987). B. bronchiseptica causes respiratory disease in various mammalian species 
including dogs, rodents and horses, but occasionally affects man (Woolfrey and 
Moody (1991). B. avium is a pathogen for birds causing severe respiratory problems
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in poultry, especially turkeys (Kersters et a l ,  1984) and B. hinzii is mainly found as a 
commensal of the respiratory tracts of fowl and recently has been reported as the 
causative agent of fatal human septicaemia (Katter et a l ,  2000). B. holmesii was 
included in the genus Bordetella on the basis of genetic and chemotaxonomic 
analyses and has been isolated repeatedly from blood of young adults and 
occasionally from sputum (Weyant et a l ,  1995). B. trematum, which was isolated 
from wounds and ear infections in humans, was the most recently described member 
o f this family (Vandamme et a l ,  1996) until B. petrii was isolated from a mixed 
anaerobic, dechlorinating culture. Comparative 16S rDNA sequence analysis, DNA 
base composition and DNA-DNA hybridisation experiments suggested that B. petrii 
should be assigned to the genus Bordetella as a novel species (von Wintzingerode et 
a l,  2001) and have also led to a new description of the genus Bordetella: Gram- 
negative, catalase-positive, asaccharolytic coccobacilli with a DNA G+C content of 
60-69 mol%. Growth occurs strictly aerobically although B. petrii is able to grow 
under anaerobic conditions favouring respiratory nitrate and selenate reduction. All 
species assimilate citrate under aerobic conditions and one species, B. petrii, 
assimilates D-gluconate. Based on comparative 16S rRNA gene sequence analysis, 
the Bordetella genus forms a distinct cluster separated from members of the genera 
Achromobacter and Alcaligenes within the fi-Proteobacteria (von Wintzingerode et 
a/., 2001).
1.2 The Disease Pertussis
Whooping cough is transmitted from patients (usually young children) to non- 
imniune individuals by means of the secretions in the mouth and nose but largely by 
droplet infection (Long et a l,  1990). After inhalation of these droplets, the first step
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of infection involves the bacterium attaching to the ciliated epithelial cells o f the 
bronchial tree. In the second step, the bacteria proliferate and colonise the mucosa of 
the respiratory tract. The ciliated cells will ultimately be damaged as a direct result 
of bacterial colonisation.
Typical pertussis disease can be divided into three symptomatic stages, 1) catarrhal, 
2) paroxysmal and 3) convalescent. After infection with B. pertussis, there is an 
incubation period of 6  to 20 days. The catarrhal stage lasts 1 -2 weeks and symptoms 
include only a mild cough, sneezing and occasionally conjunctivitis. During the 
paroxysmal stage (1-20 weeks) the cough is more forceful and more frequent (Cherry 
et a l ,  1988). In approximately 50% of patients, coughing ends with the 
characteristic inspiratory ‘whoop’, sometimes with vomiting and apnoea and also 
cyanotic attacks which is the most frequent cause of pertussis hospital admissions 
(Cherry et al., 1988). The convalescent stage is characterised by a reduction in the 
number and frequency of paroxysms, which may still occur sporadically for up to 6  
months post-infection, and the disappearance of viable B. pertussis organisms from 
the respiratory tract.
Worldwide, B. pertussis causes some 20-40 million cases o f pertussis, 90% of which 
occur in developing countries, and an estimated 200-300 000 fatalities each year 
(WHO, 1999). Although pertussis may occur at any age, most cases of serious 
disease and the majority of fatalities are observed in early infancy. Major 
complications are pneumonia, encephalitis, and malnutrition, due to repeated 
vomiting (Edwards et a l,  1999).
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1.2.1 Diagnosis
The major problem in diagnosing pertussis is the resemblance between the first stage 
of pertussis infection and a common cold, meaning that diagnosis may not be 
possible until the paroxysmal stage. Diagnosis during the catarrhal stage involves 
culture o f the bacteria from nasopharyngeal aspirates or swabs (Onorato et a l ,  1987). 
The specimen from the patient is usually cultured on freshly prepared Bordet Gengou 
(BG) agar and incubated at 37°C in a moist atmosphere for 5 to 7 days. The 
biochemical reactions of B. pertussis including a positive oxidase test, negative 
urease test or negative motility can be used for differentiation from other species of 
the Bordetella genus. Serological identification tests such as agglutination, 
complement fixation and ELISA are also available for use in identification of B. 
pertussis (Friedman, 1988). More recently a rapid, real-time multiplex PCR assay 
for detecting and differentiating B. pertussis and B. parapertussis in nasopharyngeal 
swabs was developed (Sloan et a l ,  2002), thereby significantly improving B. 
pertussis detection by decreasing the length of time taken to generate a result.
1.2.2 Epidemiology
Before the worldwide introduction o f pertussis vaccine into the routine childhood 
vaccination programmes, pertussis was o f considerable public health concern in 
developed as well as in developing countries. Due to the highly contagious nature of 
this disease, there is always a large number of secondary cases among non-immune 
contacts. There are several antibiotics, including erythromycin, chloramphenicol,
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and tetracycline, which are effective in vivo against pertussis but erythromycin is 
generally the drug of choice for treatment of pertussis patients (Hoppe, 1992). 
Although prophylactic antibiotic treatment in the early incubation period may 
prevent disease, the difficulty of early diagnosis and the costs involved, as well as the 
inherent ecological concerns related to induction of drug resistance, limit 
prophylactic treatment to selected individual cases.
1.3 Regulation of virulence
Bordetella pertussis possesses a genetic locus that encodes a biological ‘switch’ 
enabling it to change between different phenotypic states depending on the 
environment. This has also been shown to be the case in B. parapertussis, B. 
bronchiseptica and B. avium (Arico et a l,  1991; Gentry-Weeks et a l ,  1991). In the 
human respiratory tract, a subset of B. pertussis genes is expressed which allow the 
bacterium to colonise the host. In the laboratory, the virulence control switch can be 
manipulated to bring Bordetella species into an avirulent state by reducing the 
culture temperature from 37°C to 25°C or by the addition of sulphate ions or 
nicotinic acid to the culture medium (Melton and Weiss, 1993). Virulent and 
avirulent phases are now referred to as Bvg^ and Bvg" respectively.
Weiss et a l  (1983) used the transposon TnJ as a mutagen in order to produce a series 
of strains that were deficient in a single virulence-associated determinant, and from 
this, were able to identify a virulence regulatory locus. Weiss and Falkow (1984) 
proposed that modulating conditions were able to influence the expression of the 
regulatory locus, which they designated vir, that in turn was able to alter expression 
of virulence determinants. The vir locus was later termed the Bordetella virulence
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gene {bvg). This genetic locus encodes two proteins, which enable the bacterium to 
sense the prevailing environmental conditions, and then act accordingly by 
controlling the expression of specific genes. The sensor protein is termed BvgS and 
the activator is known as Bvg A. BvgS is a 135-kDa membrane-bound protein with 
an N-terminal periplasmic region flanked by two transmembrane sequences that hold 
the protein in position within the cytoplasmic membrane (Stibitz and Yang, 1991). 
Bvg A is a 23-kDa cytoplasmic protein. The 2-domain structure of Bvg A, consisting 
of a receiver at the N-terminus and a C-terminal helix-turn-helix (HTH) motif, is 
characteristic of response regulators (Arico et a l, 1989; Stibitz and Yang, 1991), and 
it is this HTH module that facilitates specific DNA sequence recognition and binding 
at the promoters of Bvg-activated genes (Boucher et a l, 1994). The heptameric 
consensus sequence of the BvgA binding site, TTTCCTA, first proposed by Roy and 
Falkow (1991), is present as either direct or inverted repeats upstream of various 
Bvg-regulated genes. The presence of these repeats in a number of virulence- 
activated promoters has been confirmed by DNase I protection studies (Marques and 
Carbonetti, 1997; Boucher and Stibitz, 1995).
1.3.1 BvgAS signal transduction
Together BvgA and BvgS belong to the two-component regulatory family of signal- 
transducing proteins that control bacterial gene expression via phosphorylation/de­
phosphorylation of component proteins (Arico et a l,  1989; Stibitz and Yang, 1991; 
Parkinson and Kofoid, 1992). The bvgA and bvgS genes are transcriptionally linked, 
whilst a third gene, bvgR, is transcribed separately on the opposing DNA strand. 
Transcription of bvgAS is controlled by 3 self-regulated promoters; Pi, P3 and P4 , and 
one Bvg-independent promoter, P2 (Roy et a l ,  1990) (see Figure 1.1). Transcription
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from P2 is constitutive, thereby maintaining low-level production of intracellular 
BvgAS.
BvgAS uses a complex phosphotransfer system to transmit signals between histidine 
and aspartate residues (His-Asp-His-Asp). When active, BvgS autophosphorylates at 
the histidine residue position 729 in the transmitter domain, followed by the transfer 
of the phosphate group to the aspartic acid residue position 1023 in the receiver 
domain, then on to the histidine residue position 1172 in the histidine phospho­
transfer output domain (HPT) before a final phosphotransfer to BvgA (Uhl and 
Miller, 1994; Uhl and Miller, 1996). The receiver and HPT domains of BvgS are 
essential for signal transduction to BvgA, thus the histidine kinase transmitter portion 
of BvgS is unable to pass the phosphate group to BvgA and only the 
phosphohistidine of the HPT domain can complete the transfer to BvgA (Uhl and 
Miller, 1994).
Figure 1.1 Schematic representation of the genetic region of B. pertussis 
covering the hvg operon and fhaB  gene.
fhaB  VfhaB P% Pi bvgA bvgS bvgR
<-----
{
P] P4 PbvgR
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The Bvg^ phase is characterised by the expression of all Bvg-activated adhesins and 
toxins and lack of expression of all Bvg-repressed phenotypes. The Bvg" phase is 
characterised by the absence of all Bvg-activated adhesins and toxins and the 
presence of all Bvg-repressed phenotypes. A third phase, Bvg intermediate (Bvg') 
has been assigned to wild-type B. bronchiseptica able to grow in submodulating 
concentrations of magnesium sulphate or nicotinic acid. This phase is characterised 
by the absence of Bvg-repressed phenotypes and the presence o f some but not all 
Bvg-activated virulence factors (Cotter and Miller, 1997; Cotter and DiRita, 2000). 
BvgAS is thought to control four classes of genes in response to enviromnental 
conditions 1 ) those that are expressed only in the Bvg^ phase, 2 ) those that are 
expressed in both the Bvg^ and Bvg' phase, 3) those that are expressed only in the 
Bvg' phase and 4) those that are expressed only in the Bvg" phase (Cotter and DiRita, 
2000). Examples o f the different classes include, ptx-ptl operon and cyaABDE 
operon, that belong to class 1 and encode pertussis toxin and adenylate cyclase toxin 
respectively, which encodes filamentous haemagglutinin and belongs to class 2 , 
bipA which belongs to class 3 and is predicted to encode a large outer membrane 
protein with a region of homology to the intimin protein of enteropathogenic E. coli, 
and the frlAB  operon belonging to class 4 and encodes flagellin genes in B. 
bronchiseptica. Dnase I protection studies indicate that in the presence of BvgA~P 
sufficient to activate transcription in vitro, the cyaA and ptx  promoter regions bound 
to BvgA-P extend from position 139 for cyaA and -168 for ptxA to the -35 regions, 
suggesting that binding of multiple BvgA-P dimers to multiple but relatively weak 
binding sites is important if not essential for transcriptional activation at the ptxA  and 
cyaA promoters (Karimova et al., 1996; Zu et al., 1996). Class 1 genes can be
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distinguished from class 2  genes on the basis that a significantly higher concentration 
o f BvgA~P is required to activate transcription.
1.3.2 BvgR and RisAS
While BvgA exercises direct control over the expression o f Bordetella virulence- 
activated genes {vag’s) by binding to promoter sequences, control over virulence- 
repressed genes {vrg’s) is indirect, implicating a Vag repressor protein. A gene that 
controls repression of the v rg ’s, has been identified in B. pertussis and termed BvgR 
(Merkel and Stibitz, 1995).
It has been shown that B. pertussis mutants lacking BvgR are less efficient colonisers 
than wild-type strains in a mouse aerosol challenge model, demonstrating that BvgR 
regulation of the vrg T makes a significant contribution to infection in mice (Merkel 
et a l ,  1998). The recent discovery in B. bronchispetica of a second two-component 
regulatory system distinct from bvg has furthered our knowledge of genetic 
regulation in Bordetella spp. Like bvg, this system, designated the ris locus 
(regulator of intracellular response) also consists of genes encoding a response 
regulator (RisA) and a sensor kinase (RisS) (Jungitz et a l,  1998). The ris locus is 
essential for bacterial resistance to oxidative stress and the production of acid 
phosphatase, as well as in vivo persistence. However the function of ris in B. 
pertussis has not been determined.
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1.4 Virulence factors of B, pertussis
The sets of genes expressed by B. pertussis^ which allow it to invade and persist 
inside the host, are termed, amongst others, virulence factors or determinants. 
Falkow and Moxon divided virulence into three main areas; 1) virulence consists of 
bacterial factors required for host and tissue tropism, 2 ) virulence includes factors 
required for multiplication within the host and 3) virulence includes factors involved 
in aspects of host toxicity (ASM news). The gene products include adhesins, which 
facilitate attachment to target host cells, and toxins, which enable the bacterium to 
evade the host immune system. At present the consensus with regard to the strategy 
for developing whooping cough vaccines seems to be to include a few purified 
immunogens in an acellular, multicomponent vaccine. Many of the virulence factors 
of B. pertussis have been considered for this purpose. Candidate antigens include 
filamentous haemagglutinin, serotype-specific fimbriae, pertactin, pertussis toxin and 
adenylate cyclase toxin. The properties of some B. pertussis virulence factors are 
described below and represented schematically in Figure 1.2, and their role in 
pathogenesis is summarised in Table 1.1.
1.4.1 Filamentous haemagglutinin (FHA)
The critical step in B. pertussis infection is attachment of the pathogen to the ciliated 
epithelium of the respiratory tract o f host cells (Tuomanen and Weiss, 1985), and 
FHA is consistently referred to as the major adhesin of this bacterium. It is 
synthesised as a 367 kDa precursor, FhaB, which possesses an N-terminal signal 
sequence and undergoes extensive C-terminal proteolytic maturation in the course of 
FHA secretion to form the mature 220 kDa FHA protein (Jacob-Dubuisson et a i.
10
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1996; Renauld-Mongenie et a l ,  1996). FHA has a filamentous structure, supported 
by electron microscopy studies, giving the dimensions of the molecule as 2  nm wide 
and 45-50 nm long (Aral and Sato, 1976; Maldiov et a l,  1994).
Maldiov and co-workers (1994) proposed that FHA consists of a polypeptide chain 
folded into a monomeric hairpin, comprising head, shaft and tail regions. The model 
predicts that whilst the head contains the terminal domains, and the tail the important 
RGD (arginine-glycine-aspartic acid) sequence for adhesion, the shaft is composed 
of tandem 19-amino acid residue repeat regions R1 (38 cycles) and R2 (13 cycles) 
which maintain the structural integrity o f the molecule. The carbohydrate-binding 
domain of FHA, which has a unique affinity for glycolipids, mediates attachment to 
cells in the respiratory tract region. This domain has been further narrowed down to 
amino acid residues 1141-1279 using monoclonal antiobodies (Prasad et a l ,  1993). 
Animal experiments, involving infection experiments with a B. pertussis mutant 
unable to produce FHA, have shown that the colonisation in the lung and persistence 
in the upper respiratory tract were significantly reduced (Weiss and Goodwin, 1989). 
However, Alonso et a l,  (2001) demonstrated that FHA-deficient mutants colonised 
the mouse respiratory tract nearly as efficiently as the parent strain. When B. 
pertussis is in suitable conditions for colonisation, FHA is one of the first proteins 
produced and is detected in a matter of minutes (Scarlato et a l ,  1991).
11
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Figure 1.2 Virulence factors of Bordetella pertussis. Taken from Weiss 
(1997)
Pertussis
toxin
F im b r ia e
Adenylate 
cyclase toxin
Dermonecrotic 
toxin
Pertactin
FHA, filamentous haemagglutinin 
BrkA, Bordetella resistance to billing 
TCF, tracheal colonisation factor 
TCT, tracheal cytotoxin
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The tail region of FHA includes a binding moiety specific for complement receptor 
3 (CR3) integrins present on the surface of macrophages. The RGD sequence in the 
tail region facilitates binding to CR3 and in turn leads to phagocytosis via CR3, 
which enables the bacteria to avoid triggering an oxidative burst and thereby 
permitting them to survive intracellularly whilst evading the immune system 
(Reiman et a l, 1990). FHA is also Imowii to bind the human serum protein C4BP. 
This protein is Imown as a regulator of complement activation and acts to inhibit the 
classical complement pathway, ceasing the formation of the membrane attack 
complex (Berggard et a l, 1997). How B. pertussis is able to make full use of this 
binding capacity is still unclear, but demonstrates the extent to which R. pertussis 
interacts with the immune system. A recent report by McGuirk and Mills (2000) 
showed purified FHA was able to stimulate the release of IL-10 and IL- 6  and to 
suppress IL-lO-mediated IT-12 secretion in J774 murine macrophages. This in turn 
suggests that FHA may delay the development of CMI, thereby facilitating the 
persistence of B. pertussis in the respiratory tract. Further work by Abramson et a l 
(2001) confirmed these findings by showing that FHA was able to stimulate 
secretion of TNFa and may induce apoptosis in human monocyte-like cells, 
macrophages and bronchial epithelial cells. Thus, as well as the important role FHA 
plays in adhesion, it may also modify the development of the host immune response 
to B. pertussis by contributing to pro inflammatory and proapoptotic responses, which 
could in turn favour the bacteria by providing a more favourable location for their 
adherence.
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1.4.2 Serotype-specific fimbriae
Fimbriae, also known as pili or agglutinogens, are long filamentous protrusions, 
which extend from the bacterial cell surface and facilitate a variety of binding 
capacities. Both major and minor sub-units are incorporated in the fimbriae. The 
major sub-units form the fimbrial strand, being grouped into pentameric repeat units, 
each 13 mn in length and comprising two full helical turns (Steven et a l,  1986). The 
major fimbrial subunits that form the two main serotypes Fim 2 and Fim 3 are 
encoded by chromosomal loci fim 2  and fim3, respectively (Livey et al., 1987; Mooi 
et al., 1987). A third locus,//wA, is expressed at very low levels (Riboli et al., 1991) 
and a fourth locus, fimN, has been identified in B. bronchiseptica (Kania et al.,
2000). The most noticeable aspect of the fimbrial promoters is the C stretch, a long 
run of cytosine residues that have been implicated in fimbrial phase variation. 
Insertion or deletion of extra cytosine residues in this C stretch is the source of 
fimbrial phase variation by slip-strand mispairing with the cytosine residues located 
between the -10  and -35 elements o f Jim2, fim3, f m X  and fim N  promoters (Willems 
et a l ,  1990). All fimbrial serotypes share a common minor fimbrial subunit, FimD, 
which forms the tip adhesin and is located within the fimbrial biogenesis operon, 
downstream of fim B  and fimC, genes that are thought to function as a periplasmic 
chaperone and outer membrane usher protein, necessary for fimbrial biogenesis 
(Locht et a l, 1992; Willems et a l,  1992). As with other virulence factors employed 
by B. pertussis to attach to host cells, the expression of fimbriae is controlled by the 
hvg locus.
Purified fimbrial proteins have been shown to protect mice against respiratory 
infection with different serotypes o f B. pertussis (Robinson et a l, 1989) and in vivo
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studies have shown that Fim" B. pertussis strains are defective in their ability to 
multiply in the nasopharynx and trachea of mice (Geuijen et a i,  1997). More 
recently, Mattoo et a l (2000), have shown that fimbriae are absolutely required for 
persistence in the trachea in both rat and mouse models of B. bronchiseptica 
infection.
1.4.3 Pertactin
Pertactin is Imown as P.69 or 69-kDa OMP because of its apparent MWT determined 
by SDS-PAGE (Montaraz et a l,  1985, Makoff et a l,  1990). It is actually a 60 kDa 
OMP involved in bacterial adherence (Makoff et a l,  1990; Leininger et a l,  1991). 
Other membranes of the Bordetella genus produce similar molecules, for example, 
P.70 in B. parapertussis and P.68 in B. bronchiseptica (Montaraz et a l ,  1985; Li et 
a l,  1991).
The prn  gene encodes a 95.5 kDa polypeptide comprising 910 amino acids. This 
precursor, termed p.93, later undergoes the removal of a 34 amino acid N-terminal 
signal peptide and cleavage of a 30 kDa polypeptide (p.30) from the C-terminus 
(Charles et a l,  1989). Emsley et a l (1996) determined the X-ray crystal structure of 
P.69 and showed that the protein folded to consist of a 16-stranded parallel (3-helix, 
the largest beta-helix Imown to date. The structure is described as a helix with 
several protruding loops that contain sequence motifs concerned with the biological 
activity of the protein. In particular, there is an RGD motif that is also found in 
attachment sites of fibronectin, vitronectin and fibrinogen, thereby indicating that 
pertactin may also bind integrins (Hynes, 1987). No accessory proteins are thought 
to be involved in the transport of pertactin across the outer membrane (Charles et al.,
1994). It is assumed that there are three domains within the autotransporter protein:
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the leader sequence, the amino-terminal passenger domain and the carboxy-terminal 
(3-barrel domain. It is proposed that the signal-cleaved amino-terminal domain is 
translocated thiongh a (3-barrel pore made by the C-terminal 30 kDa region to the 
cell surface, where either the protein remains intact with a carboxy-terminal 
membrane-bound domain and an amino-terminal domain extending into the 
environment, or the protein becomes autoproteolytic and cleaves itself, or is cleaved 
by an outer membrane protease (Henderson et al., 1998). Many other proteins, such 
as Vac A of Helicobacter pylori, IgAl protease of Haemophilus influenzae, Neisseria 
gonorrhoeae and N. meningitidis, have all been shown to use a similar mechanism in 
order to cross the membrane, and these have been collectively termed members of 
the autotransporter family (Henderson et al., 1998). Other Bordetella proteins with 
predicted auto transporter ability include TcfA (Fimi et a l, (1995), BrkA (Fernandez 
and Weiss, 1994) and Vag8 (Finn and Amsbaugh, 1998), all of which show 
significant amino acid sequence similarity in their C-termini and contain one or more 
RGD motifs within the N- or C-termini. In a comparison of the prn  gene sequences 
o f B. pertussis, B. parapertussis and B. bronchiseptica, the precursors of pertactin 
were found to be extremely homologous, with the C-termini displaying the most 
conserved regions, suggesting the functional relevance of P.30 to these organisms (Li 
et a l,  1992). Mutants deficient in pertactin have been shown to be 30-40 % less 
efficient in adherence to Chinese Hamster Ovary (CHO) cells and HeLa cells 
(Leininger et a l,  1991; Leininger et a l, 1992). However, recent work involving site- 
directed mutagenesis (aspartic acid to glutamic acid) to obtain a pertactin molecule 
with an RGB instead of RGD site showed no role for the pertactin RGD sequence as 
a mediator of eukaryote cell adhesion. Strains expressing the mutation displayed no
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difference in their ability to promote adhesion to HEp-2 or CHO cells (Everest et a l , 
1996).
Pertactin has been shown to be an immunoprotective antigen, being used in subunit 
vaccines to protect mice from respiratory challenge with virulent B. pertussis 
(Novotny et a l,  1991; Romanos et a l,  1991; Roberts et a l,  1993) and is now 
included in some commonly available acellular pertussis vaccines (See Section
1.5.2).
1.4.4 Pertussis toxin
Pertussis toxin (PT) was initially termed histamine-sensitising factor or mouse 
protective antigen according to its activities (Levine and Pieroni, 1966). In 1979 it 
was re-named pertussis toxin by Pittman (Pittman, 1979). PT has a wide range of 
biological activities both in vitro and in vivo. Activities of PT demonstrated in vitro 
include; ADP-ribosylation of G proteins, inhibition of chemotaxis and oxidative 
responses in neutrophils and macrophages, and adhesion and invasion of ciliated 
respiratory epithelial cells (Bockoch and Gilman, 1984; Meade et a l,  1984; Okajima 
and Ui, 1984; Lad et al., 1985; Tuomanen and Weiss, 1985). Activities o f PT 
demonstrated in vivo include; histamine and endotoxin sensitisation, enhancement of 
insulin secretion, adjuvanticity and acute toxicity (Pittman, 1984; Munoz, 1988; 
Kaslow and Burns, 1992). Of the Bordetella species, only B. pertussis synthesises 
and secretes PT. A cryptic PT operon is present in B. parapertussis and B. 
bronchiseptica, but a group of mutations in the promoter region leaves these opérons 
transcriptionally silent (Arico et a l, 1987). PT is a complex 106 kDa, hexameric 
protein comprising 5 distinct subunits, SI -  S5 in the ratio 1 ; 1:1:2:1. Each subunit is 
synthesised with an N-terminal signal sequence, which may suggest that transport of
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PT subunits into the periplasmic domain occurs via a general export pathway. The 
PT subunits are assembled in the periplasm into an A-B architecture, similar to 
cholera toxin, except that the binding subunit of PT is more complex. The A 
protomer, consisting of the S 1 enzymically-active subunit, sits above the ring-like B 
oligomer comprising the remaining subunits S2-S5. The B region of the protein 
facilitates attacliment of toxin to the host cells and increases the efficiency with 
which the SI subunit gains entry into host cells (Tamura et a l ,  1982). The genes 
encoding the PT subunits are clustered together in an operon and genetic analysis has 
revealed that each subunit is translated separately with an amino-terminal signal 
sequence, which is cleaved during transport to the periplasm where the holotoxin is 
then assembled (Locht and Keith, 1986). Secretion across the outer membrane 
involves a specialised transport mechanism composed of nine Ptl (pertussis toxin 
liberation) proteins (Covacci and Rappuoli, 1993; Weiss et a l, 1993; Farizo et a l,  
1996). The ptl locus located downstream of the ptx  operon is related to the 
Agrobacterium tumefaciens virB operon, which encodes a type IV secretion system 
to export the tumour-inducing T-DNA complex (Das, 1988; Ward et a l ,  1990; 
Kaldau et a l,  1990). It has been suggested that the two systems may function by a 
common mechanism, as both are involved in the transport of large protein 
complexes.
When in its reduced form, the SI subunit is able to catalyse the transfer of ADP- 
ribose from NAD to the alpha subunit of guanine nucleotide binding proteins (G 
proteins) in eukaryotic cells (Tamura et a l, 1982; Katada et a l, 1983). G proteins 
are molecular switches involved in many cell functions such as cell proliferation, 
tissue differentiation, signal transduction and protein synthesis. G proteins that PT 
has been shown to inactivate by ADP ribosylation are G, (inliibitory G protein), Gt
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(transdiicin) and Go. When active, Gj inhibits adenylate cyclase and activates 
potassium channels, Gt activates cyclic GMP phosphodiesterase and Go activates 
potassium channels, inactivates calcium channels and activates phospholipase C-beta 
(Ui, 1990). The disruption of these signalling pathways in vivo leads to effects such 
as histamine sensitisation and enhancement of insulin secretion in response to 
regulatory signals (Pittman, 1984; Munoz, 1988).
The vast diversity of the biological activities of PT can be accounted for by its 
enzymatic ADP-ribosyltransferase activity. However, some biological activities of 
PT including its mitogenicity and its ability to agglutinate red blood cells, are 
independent of the enzymatic activity. Based on the loiowledge of the molecular 
mechanisms of PT action, genetically-detoxified (enzymically inactive) derivatives 
were developed as vaccine candidates, in that they induced high levels of protection 
without causing harmful side effects (Pizza et a l, 1989). Overexpression and 
secretion of genetically detoxified PT has since been acheived in B. pertussis and 
made available for use as an acellular pertussis vaccine component (Zealey et al. 
1992).
1.4.5 Adenylate cyclase toxin
The adenylate cyclase of B. pertussis is the main subject of this thesis and will be 
discussed separately (Section 1.7).
1.4.6 Dermonecrotic toxin
Dermonecrotic toxin (DNT) was one of the first B. pertussis toxins described and 
originally named endotoxin (Bordet and Gengou, 1906). It was subsequently termed
20
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heat-labile toxin because it is completely inactivated by heating at 56°C for 10 min. 
The term DNT is due to the characteristic necrotic skin lesions caused by the toxin 
when it is injected subcutaneously into mice (Livey and Wardlaw, 1984) but the 
toxin also causes other side effects such as spleen atrophy, reduced weight gain and 
is considered to be a virulence factor for the production o f turbinate atrophy in 
porcine atrophic rhinitis (Wardlaw and Parton, 1983; Roop et a l,  1987). DNT is 
also lethal for mice at low doses after intravenous inoculation (lida and Okonogi, 
1971). The genes encoding the DNT’s of B. pertussis and B. bronchiseptica have 
been cloned and sequenced (Walker and Weiss, 1994; Pullinger et a l, 1996; 
Kashimoto et al., 1999) and the open reading frame of DNT shown to consist of 
4395bp coding for 1464 amino acids. Kashimoto et al. (1999) identified Cys 1305 as 
an essential amino acid for the enzymic activity of DNT, as the introduction of a 
mutation at Cys 1305 eliminated the activity. DNT belongs to a family of bacterial 
toxins that include CNFl and CNF2 o f E. coli (cytotoxic necrotising factor 1 and 2) 
(Falbo et al., 1993; Oswald et al., 1994) and the Pasteurella multocida toxin (PMT) 
(Rozengurt et al., 1990). The toxins serve as regulators of cell growth or division. 
There is limited homology among the group members at the amino acid level. PMT 
and CNF sequences and CNF and DNT sequences show regions of significant amino 
acid homology at their N and C-termini respectively (Lax et al., 1990; Falbo et a l, 
1993; Oswald et a l ,  1994; Walker and Weiss, 1994), but there is no significant 
homology between the sequences of DNT and PMT. It has been suggested that DNT 
targets and modifies Rho proteins (Oswald et a l,  1994; Horiguchi et a l,  1995), a 
family of GTP-binding proteins involved in the regulation of cell functions such as 
the formation of actin stress fibres and focal adhesins (Horiguchi et a l ,  1995). DNT 
deaminates Gin residue 63 of Rlio and the corresponding residues of the Rlio family
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proteins, Rac and Cdc42 (Horiguchi et al., 1997). This results in the reduction of its 
capacity to hydrolyse GTP to GDP and thus renders the Rlro family proteins 
constitutively active. The exact role of DNT in the pathogenesis of B. pertussis is 
still unclear, because although DNT is termed a virulence factor, mutants deficient in 
DNT do not exhibit any differences in virulence in mouse studies (Weiss and 
Goodwin, 1989).
1.4.7 Tracheal cytotoxin
Tracheal cytotoxin (TCT) is a low-molecular-mass glycopeptide, whose primary 
structure has been determined by mass spectrometry as a 921 Da, N- 
acetylglucosaminyl-l,6-anhydro-N-acetylmuramylalanyl-y-glutamyl- 
diaminopimelylalanine, identical to the Neisseria gonorrhoeae ciliostatic 
anhydropeptidoglycan (Cookson et a l ,  1989b). The destruction of cilia and ciliated 
epithelial cells by TCT results in ciliostasis and may be responsible for relentless 
coughing of the infected individual in order to remove accumulating mucus. It has 
been demonstrated in hamster trachea epithelial cells, that the lactyl tetrapeptide part 
of the molecule is responsible for full toxic activity (Luker et a l,  1995). The toxicity 
conferred by TCT is indirect, being caused by the induction of host cells to produce 
IL-1. This activates host cell nitric oxide synthase leading to high levels of nitric 
oxide radicals. The nitric oxide acts by destroying iron-dependent enzymes, 
eventually inhibiting mitochondrial function and DNA synthesis in nearby host cells 
(Heiss et a l ,  1994). TCT also has a toxic effect on other cells, impairing neutrophil 
function at low concentrations and conferring toxic activity in larger quantities 
(Cundell et a l,  1994). Such effects could explain the cause of some of the 
pathological events in pertussis infection such as coughing, excess mucus production
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in the airways and the predisposition to secondary bacterial infections (Wardlaw and 
Parton, 1988). TCT could just be termed a breakdown by-product of peptidoglycan 
manufacture, however it is considered an integral component in the pathogenesis of 
B. pertussis infection.
1.4.8 Lipopolysaccharide
Lipopolysaccharide (LPS) is present in most Gram-negative bacteria and generally 
comprises a lipophilic portion termed lipid A, the core oligosaccharide and a long 
polysaccharide O-antigen (0-specific chain). The structure of B. pertussis LPS is 
different to B. parapertussis and B. bronchiseptica, in that it lacks the O-antigen and 
because of this is sometimes referred to as lipooligosaccharide (Martin et a i,  1992; 
Preston et ai., 1996). B. pertussis produces two types of LPS, designated LPS-A and 
LPS-B, which resolve as two distinct bands on silver-stained SDS-PAGE gels 
(Peppier, 1984). LPS-A has a standard lipid A portion like the LPS of E. coli, 
whereas LPS-B has a distinctive lipid portion named Lipid X (2,3-diacylglucosamine 
1-phosphate). The two types of LPS also have different polysaccharide regions. 
LPS-A has a polysaccharide region containing an oligosaccharide core with 2-keto- 
3-octulosinic acid and LPS-B contains an oligosaccharide core with phosphorylated 
ketodeoxyoctulosonic acid (KDO). Although all Bordetella species produce LPS, 
their structures vary somewhat between the different species, which may reflect the 
differences in some of the biological activities among the Bordetella species. B. 
parapertussis strains isolated from humans and sheep display distinct LPS profiles, 
adding to the host-specific feature of this molecule (Porter et a l,  1995; van den 
Aldcer, 1998). The LPS produced by B. bronchiseptica is similar to that of B. 
parapertussis, as they both express O-antigen in a temperature-dependent manner
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(van den Aldcer, 1998). Recently, Allen and Masked identified, cloned and 
sequenced the genetic loci required for LPS biosynthesis in B. pertussis, B. 
bronchiseptica and human B. parapertussis, and went on to construct strains with 
mutant LPS phenotypes (Allen and Masked, 1996; Aden et al., 1998). When 
compared with their wild type parental strains, B. pertussis B. bronchiseptica and 
human B. parapertussis strains that synthesised only LPS-B, due to a deletion of the 
wbl locus that is required for the expression o f LPS-A, were found to be less efficient 
at colonisation of the trachea in a mouse model of respiratory infection (Harvid et 
al., 2000). The three mutants ad displayed a different degree of defectiveness in 
their colonisation. The B. pertussis wbl mutant was less able to colonise the nasal 
cavity than the wild type and the B. bronchiseptica mutant colonised the lungs like 
the wild-type initially but was cleared by the second week post-infection. Both B. 
parapertussis and B. bronchiseptica mutants were sensitive to killing by normal 
rabbit serum, whereas the parent strains were not, but both the B. pertussis mutant 
and wild-type were killed. These results indicate a difference in the host-pathogen 
interaction between the different Bordetella species. The data also conflict with the 
proposed role of BrkA of B. pertussis in resistance to complement-activated killing 
(see section 1.4.10).
1.4.9 Tracheal colonisation factor
Tracheal colonisation factor (TCF) is a ôvg-regulated protein, exclusively produced 
among the Bordetellae by B. pertussis. The gene encoding TCF, tcfA, has been 
cloned and sequenced, and the derived amino acid sequence predicts a 68.6 kDa 
precursor, the first 39 amino acids of which comprise a likely signal peptide, leaving 
a 64.4 kDa protein (Finn and Stevens, 1995). The precursors of the pertactins of
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Bordetellae species possess a C-terminus with significant homology to that of TCF, 
as does the serum resistance factor, BrkA (Section 1.4.10), (Fernandez and Weiss,
1994). The exact role that TCF plays in the pathogenesis of pertussis is yet to be 
fully understood, although experiments involving infection of mice with a strain of 
B. pertussis defective in TCF, demonstrated that the number of bacteria isolated from 
the trachea was decreased ten-fold in comparison to the wild type parent strain, 
indicating the importance that this protein has in colonisation (Finn and Stevens,
1995).
1.4.10 Serum resistance locus
The brk locus, which has homologues in B. parapertussis and B. bronchiseptica, 
consists of two genes transcribed in opposite directions, brkA and brkB (Fernandez 
and Weiss, 1994; Rambow et a l,  1998). The proteins predicted by these genes, 
BrkA and BrkB; are both required for serum resistance. BrkA, translated as a 
precursor molecule, is proteolytically cleaved to form 73 kDa and 30 kDa products. 
This cleavage pattern is very similar to that of pertactin, the protein to which BrkA is 
most closely related, and Tcf (Finn and Stevens, 1995). Mutant strains of B. 
pertussis deficient in the expression of the serum resistance {brk) locus are 
significantly less virulent in mice than the wild-type strains (Weiss and Goodwin, 
1989). These strains have also been shown to be more susceptible to complement- 
activated killing in the presence of human serum (Fernandez and Weiss, 1994). A 
recent study has demonstrated that B. pertussis clinical isolates were serum-resistant, 
suggesting that circulating strains gain an advantage in vivo by evading complement- 
activated killing (Fernandez and Weiss, 1998).
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1.4.11 Invasion
It is well known that different Bordetella species are able to invade and survive 
within a range of cell types in particular; epithelial cells (Ewanowich et al., 1989; 
Savelkoul et al., 1993), dendritic cells (Guzman et al,, 1994) and macrophages 
(Bromberg et al., 1992; Friedman et al., 1992; Forde et al., 1998). This capacity of 
persistence within a cellular enviromuent that Bordetella species possess, may allow 
them to escape any host clearance mechansims that they would otherwise be 
susceptible to, and also provide them with a habitat rich in nutrients and devoid of 
competing microorganisms (Finlay and Falkow, 1989). B. bronchiseptica strains 
have been shown to differ to other Bordetella species, as both wild type and Bvg' 
strains are able to invade and survive within eukaryotic cells (Guzman et al., 1994; 
Schipper et al., 1994), whereas intracellular survival in other Bordetella species is 
dependent on 6vg-activated products (Banemann and Gross, 1997; Friedman et al., 
1992). Jungitz et al. (1998) generated bacterial mutants in order to identify genes 
encoding proteins invovled in the intracellular survival process, which subsequently 
led to the identification of a novel 2-component regulatory system (Ris) (Section
1.3.2). The sensitivity of B. bronchispetica to superoxide dismutase (SOD) and 
hydrogen peroxide (H2O2) was analysed using the compound paraquat. Paraquat 
generates intracellular free-oxygen radicals, which by further reduction, can 
accumulate as toxic hydroxy-radicals, whereas H2O2 is an important compound of the 
respiratory burst and can also generate hydroxy-radicals. Jungitz and co-workers 
demonstrated that the ris mutants were susceptible to both compounds thereby 
proposing that ris regulates a protein required to survive the accumulation of such 
hydroxy radicals and necessary for intracellular survival.
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1.5 Vaccination against pertussis
Given that antibiotics are not very effective for the prevention or control of pertussis 
due to the fact that diagnosis usually occurs after the bacteria have already damaged 
the respiratory tract and released the toxins responsible for severe symptoms, the best 
current alternative is vaccination, with either WCV or the newer ACY’s.
1.5.1 Whole-cell vaccine
Whole-cell vaccines (WCV) have been available for many years and are 
manufactured in several countries. An effective vaccine against whooping cough 
was developed in the 1940’s and although the basic preparation procedures are 
similar between different vaccines, the vaccines frequently elicit markedly different 
immune responses to various B. pertussis antigens. In general, B. pertussis is grown 
in bulk culture, harvested, concentrated by centrifugation, and suspended in a 
buffered saline solution (Cherry et a l,  1988). Concentrated bacteria are killed and 
partially detoxified by heat or a chemical agent or by a combination of these 
methods. Currently available WCVs are usually given in a combined preparation 
that contains diphtheria and tetanus toxoids and a suspension of killed B. pertussis 
cells, which are adsorbed onto an aluminium adjuvant to enhance the 
immunogenicity and efficacy of the vaccine. All whole-cell pertussis vaccines 
contain both endotoxin and other active toxins, so it is not surprising that reactions 
occur.
Immunisation of infants following approved schedules, with WCV vaccines, has 
shown an efficacy of 80% or more. An accelerated immunisation schedule at two.
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tliree and four months of age, was introduced in the UK in 1990 in an attempt to 
increase the protection given to very young children in whom pertussis is most 
severe (DOH, 1990). In countries with good vaccination coverage, morbidity and 
mortality from pertussis have gradually been reduced to low levels. However, in 
recent years an increase in the incidence of pertussis has been reported from a 
number of countries, including the US, Australia, Canada, and several countries in 
Europe. The reasons for this increase are largely unlmown, but sub-optimal quality of 
the involved WCV and cyclical variation in disease patterns may have added to the 
effect of waning vaccine-derived immunity in certain countries. It has also been 
suggested that the increase could be due to antigenic divergence between vaccine 
strains and circulating strains (Willems and Mooi, 1996). Mooi et a l (1999) 
conducted an analysis of B. pertussis strains from Finland and reported that different 
alleles of pertactin (prn-l, prn-2, prn-3 and prnA )  were present in isolated strains. 
The results from the study suggested the possibility that, pertussis vaccines, which 
used a strain with a prn-l genotype, protected less well against prn-3, which 
predominate in some countries such as The Netherlands, but are less common in 
Finland. A more recent report indicates an antigenic divergence between clinical 
isolates and vaccine strains in The Netherlands, particularly with respect to pertactin 
and pertussis toxin, therefore suggesting that B. pertussis has been able to adapt and 
remain endemic and thereby contribute to the re-emergence of pertussis in The 
Netherlands (Mooi et a l, 2001).
In the UK, after a 1974 report ascribing neurological reactions to WCV 
(Kulenkampff et a l,  1974), public confidence in the vaccine fell and a sharp 
reduction in coverage followed. Although the health authorities resisted pressure to 
withdraw the vaccine, the decrease in confidence resulted in pertussis epidemics
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(incidence at approx. 150 per 100,000). Confidence was eventually restored and the 
disease incidence declined to approx. 1 in 100,000 and has since been low (Gangrosa 
et a l ,  1998). Following the pertussis epidemic in The Netherlands in 1996, and the 
demonstration by Mooi and co-workers (1998, 1999) of a clear shift in the genetic 
composition of prn  and ptx  genes of B. pertussis in circulating B. pertussis strains, a 
similar study was undertaken to investigate whether such variation had occurred in 
the UK (Fry et a l,  2001). Isolates of B. pertussis in the UK were examined both 
before and after the introduction of the UK WCV. The precise year of emergence in 
the UK of prn  types distinct from those in the UK WCV cannot be determined, 
however prn-2 and prn-3 were found in strains from 1982 onwards. Data from The 
Netherlands and Finland show that by the 1990’s, approximately 90% of isolates 
were o f a non-vaccine prn  type (Mooi et a l,  1998; Mooi et a/., 1999), whereas data 
from the UK showed that although non-vaccine prn types had increased, almost half 
of all circulating strains remained of the vaccine prn  type. These results have led to a 
possible hypothesis that a WCV containing prn-l may protect better against B. 
pertussis with prn-2, than against B. pertussis strains with prn-3, thereby suggesting 
why there is a continued low level of pertussis in the UK compared to The 
Netherlands (Fry et a l, 2001). A further study was carried out by Weber et a l  
(2001) using genotyping with pulse-field gel electrophoresis (PFGE) to investigate 
the influence of temporal and geographic factors on the French population of B. 
pertussis isolates circulating over different periods of time. Chi'omosomal DNA 
from isolates collected from different parts of France was analysed by PFGE and 
distinguished into groups by clustering anlaysis. These groups correlated well with 
the P.69 type expressed by the isolates and one group conatining isolates that 
expressed prn-2 could be further divided; a group composed of isolates circulating
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between 1993 and 1996 and a second group composed of isolates circulating since 
1997. These results are consistent with a shift in the circulating B. pertussis 
population every 3 years, which may correspond to periodic pertussis incidences 
observed in different countries (Weber et al., 2001),
A recent study on antigen expression of vaccinal strains in the Pasteur Merieux 
(Aventis Pasteur) french WCV from multiple lots stored since 1984 showed that all 
lots of the vaccinal strains expressed the major adhesins such as FHA and P.69, 
together with CyaA and PT, indicating that, despite lyophilisation being performed 
on the strains for over 30 years, they still continued to express the toxins and 
adhesins expressed by currently circulating isolates (Njamkepo et al., 2002), Since 
neither the vaccine quality nor the coverage has changed in France, the most likely 
cause of a pertussis resurgence is a waning immunity in the absence of booster 
vaccination. France therefore decided to introduce a booster dose of acellular 
pertussis vaccine (see below) at 13 years of age, which, at this age, has been shown 
to protect adolescents against B. pertussis infection (Anonymous, 1998).
1.5.2 Acellular pertussis vaccine
Vaccination in Japan against pertussis began in 1947. By 1974, there were few cases 
and no deaths, however during a national debate about the adverse events resulting 
from smallpox vaccine, news reports of neurological reactions after DTP 
vaccination, gave rise to Japan’s movement against whole-cell pertussis vaccines, 
resulting in claims that vaccination would no longer be needed because there was 
practically no more pertussis in the community (Kimura et a l ,  1990, Kanai,, 1980), 
In response to this, the Okayama Perfectural Medical Association switched from
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DTP to DT only vaccine. Pertussis vaccination coverage for infants fell from nearly 
80% in 1974 to 10% in 1976 (Kimura et a l,  1990). A pertussis epidemic occurred in 
1979 with more than 13,000 cases and 41 deaths.
Following adverse publicity concerning the side effects associated with WCV, in 
particular the severe effects such as brain damage and death, the World Health 
Organisation (WHO) recommended continuing vaccination with WCV but with a 
greater emphasis on the development of new vaccines devoid of side effects. In 
order to develop a new vaccine, the composition of the WCV was studied. It is 
composed of many different molecules, including lipopolysaccharide, nucleic acids, 
lipids and proteins, some of these being important for the virulence of B. pertussis. 
Therefore the first step in the vaccine development was to identify and isolate the 
antigens that conferred protection. Sato and co-workers were the first to identify and 
separate PT and FHA from the culture supernatant of B. pertussis, before moving on 
to detoxify them by formaldehyde treatment. This led to the development of the first 
ACV containing PT and FHA (Sato and Sato, 1984). Japan began replacing whole­
cell with ACV in 1981, and a striking fall in pertussis incidence followed (incidence 
was approx. 1 per 100,000). To evaluate the efficacy of this vaccine (Takeda 
vaccine) and another Japanese preparation containing only purified PT (Biken 
vaccine), a field test was organised in Sweden in 1986. The results of this trial 
showed that both vaccines were able to protect children with an efficacy similar to 
that of the WCV (Ad Hoc group, 1988; Olin and Storsaeter, 1989). One other result 
o f the trial was the ability of the formaldehyde-inactivated PT to revert to the active 
toxic form (Storsaeter et al., 1990). In order to reduce the risks associated with 
detoxification, better methods were required and Rappuoli and co-workers 
approached this problem using recombinant-DNA technology (Rappuoli et al..
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1991). They developed genetically detoxified pertussis toxin molecules containing 
amino acid substitutions that were able to abolish the enzymatic activity of the SI 
sub-unit, the best Arg9 to Lys and Glul29 to Gly. This was then used as a 
component of new acellular vaccines, one containing only 15pg of the mutant PT- 
9K/129G and the other containing 7.5pg of the mutant PT-9K/129G, lOpg of FHA 
and lOpg of 69K. Results from a trial involving over 1000 infants receiving thi'ee 
doses of the vaccines alone or combined with diphtheria and tetanus toxoids, showed 
both vaccines to be safe and highly immunogenic (Rappuoli et al., 1992).
As a result of these trials, plans were made for further trials o f different ACV’s. One 
of these took place in Sweden and compared a two-component vaccine with a five- 
component vaccine and a conventional WCV used in the USA (Gustafsson et ah,
1996). The two-component vaccine (SmithKline Beecham (SKB)) consisted of 25pg 
PT detoxified by glutaraldehyde and formalin treatment, plus 25pg o f formalin- 
treated FHA and the five-component vaccine (Connaught) consisted of lOpg 
glutaraldehyde-inactivated PT, 5pg FHA, 5pg Fim 2 and 3 combined and 3pg of 
P.69. Infants received 3 injections, the first at two months and the second and third 
at eight-week intervals. The results of the trial showed both ACV to be highly 
immunogenic with regard to each antigen studied, although overall the five- 
component vaccine was more efficacious against mild disease. They concluded that 
the multi-component vaccine was more protective against both typical pertussis and 
mild disease than the one and two-component vaccines, results that were also 
confirmed in earlier trials (Edwards et al., 1995; Greco et al., 1996). A further study 
by Olin and co-workers investigated the effects of a two, three or five-component 
vaccine and a UK whole-cell DTP vaccine (Olin et al., 1997). The two-component 
vaccine was from SKB as before, the three-component vaccine (Chiron) consisted of
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5pg of the genetically detoxified PT (9K/129G), 2.5pg of FHA and 2.5pg of P.69, 
and the five-component vaccine (Pasteur-Merieux-Connaught) consisted of 20pg 
glutaraldehyde-inactivated PT, 20pg of formalin-treated FHA, 3pg P.69 and 5pg of 
fimbriae 2 and 3 combined. The two and five-component vaccines contained 
phenoxyethanol as a preservative, whereas the three-component and WCV contained 
thiomersal. The DTP vaccines were given in a series of tliree intra-muscular 
injections at 3 months, 5 months and 12 months, according to previous Swedish 
vaccination schedules for DT. Overall the main finding was that the WCV and the 
five-component vaccine had similar efficacy against culture-confirmed typical 
pertussis, whereas the three-component vaccine was less effective than the five- 
component or WCV vaccine, again suggesting that the multi-component vaccines are 
more protective and efficacious. However a more recent report contradicted this and 
suggested that a mono-component acellular vaccine containing pertussis toxoid was 
sufficient (Taranger et a l, 2001). The trial was a double-blinded, placebo-controlled 
one with pertussis toxoid compounded with diphtheria and tetanus toxoids. The 
results indicate that the level of efficacy is as good as the multi-component acellular 
vaccines, with an average efficacy of 71%, although this value is usually between 90 
and 95% for WCV, and that the correlation between the levels of pertussis toxoid- 
induced antibodies and protection against pertussis were statistically significant. 
This result possibly highlights the different serological criteria set by various 
organisations when diagnosing pertussis and suggests that a standard set of criteria 
should be set. Contradictory results from the various acellular vaccine trials further 
emphasise the necessity to identify the most important compounds and to try and 
assign a clear method of correlating protection.
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At present, all of the acellular vaccines used in the trials described above have been 
licensed for use in various countries. Booster doses of the multi-component pertussis 
vaccines given to adolescents or adults could possibly have an epidemiological 
impact through reducing the prevalence of mild, clinically uiu'ecognised infection in 
the adult population (parents), thereby reducing the risk of spreading disease to 
young children or babies. However, the role of adults in transmission of the disease 
to susceptible individuals is unclear. Whilst pertussis has traditionally been thought 
of as an infant or childhood illness, recent attention has shifted more to the 
occurrence of respiratory illness caused by B. pertussis in adolescents and adults. 
The advent of acellular pertussis vaccines has now provided an opportunity to give a 
late booster dose to stimulate antibody levels in adolescents and young adults. The 
best ways of providing this booster will vary in different settings. The less 
reactogenic acellular pertussis vaccine, may, therefore, be used as a booster dose to 
maintain immunity against pertussis among older children, adolescents and adults in 
the future. Campins-Marti et al. (2002) put forward some strategies for reducing the 
burden of pertussis, the ideal one being a booster vaccination programme for adults 
and adolescents throughout life. However, as this is unrealistic, a more achievable 
programme would be one targetted at adolescents still at school and adults likely to 
come into contact with very young children. A consensus group consisting of 
international experts from different countries recommended that the decision of who 
to vaccinate be made on an individual country basis and that the combined 
diphtheria, tetanus, pertussis acellular (DTPa) vaccine be used, or when tetanus 
and/or diphtheria immunity is not indicated, a monovalent pertussis vaccine may be 
made available. The U.K Joint Committee on Vaccination and Immunisation (JCVI) 
also considered the introduction of a booster dose of pertussis to redue the levels of
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morbidity and mortality, and as of November 2001 the DTPa vaccines were 
determined safe to use as a routine booster for school children in England (DOH, 
2001).
1.6 Repeat in Toxin (RTX) toxins
Bacterial pore forming toxins represent a heterogeneous group of exotoxins. Those 
belonging to the Gram-negative bacteria are commonly synthesised as inactive 
protoxins, which are subsequently converted into the active form by either 
modification or proteolytic processing. Examples of Gram-positive and Gram- 
negative pore-forming toxins are listed in Table 1.2, The Repeat in Toxin (RTX) 
toxins represent the largest family of bacterial pore forming cytoiysins (Welch, 1991; 
Coote, 1992; Ludwig and Goebel, 1999). Examples of toxins belonging to the RTX 
family are listed in Table 1.3.
Table 1.2. Pore-forming toxins
Bacterium Toxin Reference
Streptococcus pyogenes Streptolysin 0 Alouf and Geoffroy, 1988
S. pneumoniae Pneumolysin Saunders et aL, 1989
Bacillus alvei Alveolysin Geoffroy and Alouf, 1988
Clostridium tetani Tetanolysin Blumenthal and Habig, 
1984
C. perfringens Perfringolysin 0 Tweten et aL, 1991
Listeria monocytogenes Listeriolysin 0 Mengaud et al., 1988
Aeromonas hydrophila Aerolysin Buckley, 1991
Staphylococcus aureus Alpha toxin Bhakdi and Tranum- 
Jensen, 1985
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Table 1.3 Example of some toxins belonging to the RTX family
Bacterium Toxin Reference
E. coli HlyA Welch et al., 1981
Proteus vulgaris PvxA Strathdee and Lo, 1987
Morganella morganii MmxA Koronakis et al., 1987
Actinobacillus
actinomycetemcomitans
AaltA Kraig et al., 1990
Pasteurella haemolytica LktA Strathdee and Lo, 1987
B. pertussis CyaA Glaser et al., 1988
V. cholerae RtxA Nagamune et al., 1996
1.6.1 Characteristics of RTX toxins
RTX toxins are synthesised by Gram negative bacteria as inactive proteins with 
molecular masses typically around 100 to 120 kDa, with the exception of adenylate 
cyclase toxin from B. pertussis and RtxA from Vibrio cholerae, which have 
predicted sizes of 177 kDa and 500 kDa respectively. The C-terminal half o f the 
RTX toxin proteins includes a tandem array of glycine and aspartate-rich nonameric 
repeats with the consensus sequence UXGGXG(N/D)DX, where U is a large 
hydrophobic amino acid and X is an arbitrary amino acid. The designation ‘RTX 
toxins’ refers to these characteristic repeats. The number of repeats varies among the 
RTX toxins between about 10 and 40 (Welch, 1991; Coote, 1992).
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The RTX toxins lack a cleavable N-terminal signal peptide and their secretion is not 
sec-dependent; therefore they are not exported via the general secretory pathway. 
The extracellular secretion of the RTX toxins rather proceeds via the type-1 secretion 
pathway, which allows direct translocation of the toxins across both the inner and the 
outer membrane in one step, without any detectable periplasmic intermediate. 
Secretion of RTX toxins therefore depends upon specific, highly conserved export 
systems, composed of tliree envelope proteins. One is an inner membrane ATPase 
belonging to a family of ATP-binding cassette (ABC) transporters. The ABC protein 
provides energy for the secretory proeess through hydrolysis o f ATP. The second 
protein is also anchored in the imier membrane and belongs to a family of membrane 
fusion proteins (MFP). These are transport aecessory proteins found mostly in 
Gram-negative bacteria, where they function in conjunction with imier membrane 
transporters such as the ABC proteins. The third component of the exporter is an 
outer membrane protein with a typical N-terminal signal sequence. The entire 
secretion apparatus comprising the tlmee proteins is usually designated as an ABC 
exporter. The genes specifically required for synthesis, activation and secretion of 
the RTX toxins are clustered either on the bacterial chromosome or on a plasmid and 
usually represent a single operon. This operon typically contains four genes in the 
order C-A-B-D. Gene A is the structural gene of the toxin protein, Gene C encodes 
the activator protein and the genes B and D encode the ABC protein and the MFP 
component, respectively, of the ABC exporter. The gene encoding the outer 
membrane component of the secretion apparatus is, in most cases, not linlced to this 
gene cluster but located elsewhere on the chromosome (Ludwig and Goebel, 1990).
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1.6.2 E. coli a-haemolysin
E. coli a-haemolysin (HlyA) is one of the best-characterised members o f the RTX 
toxin family (Welch et al., 1981) and was the first RTX toxin to be cloned and 
characterised. It is frequently produced by E. coli strains causing urinary tract and 
other extra-intestinal infections and contributes significantly to the virulence of these 
strains. The synthesis and secretion of E. coli HlyA are determined by the hlyCABD 
operon (Issartel et a l,  1991) (Figure 1.3). The HlyA secretory apparatus comprises 
HlyB and HlyD (an inner membrane traffic ATPase and inner membrane protein) 
and TolC (an outer membrane protein) (Wandersman and Delepelaire, 1990). In E. 
coli and most other pathogens TolC, or its equivalent protein, is encoded by a gene 
separated from the operon, but in B. pertussis, the operon includes a tolC equivalent 
(cyaE) (Section 1.7.1). HlyA is synthesised as a non-toxic pro-haemolysin (pro- 
HlyA) that is activated intracellularly by a mechanism dependent on the co­
synthesised HlyC. HlyC alone camrot activate proHlyA, but requires a cytosolic 
activating factor, namely the acyl carrier protein (ACP). Activation to the mature 
toxin is achieved by the transfer of a fatty acid acyl group, from the acyl carrier 
protein to pro-HlyA (Issartel et a l, 1991).
E. coli a-haemolysin was the first protein shown to be exported via a type-I secretion 
system, a sec-independent mechanism (Wagner et a l, 1983; Blight and Holland, 
1994), a-Haemolysiii lyses erythrocytes from many species, but also exhibits strong 
cytotoxic and cytolytic activity against a variety of nucleated cells. In particular, it 
causes lysis of immune cells involved in first-line defence mechanisms, including 
polymorphonuclear leukocytes (PMN) and monocytes (Cavalieri and Snyder, 1992). 
The lytic action of a-haemolysin on red blood cells may promote bacterial growth in
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Figure 1.3 Comparison of the B. pertussis cya and the E. coli hly loci (Mock 
and Ullmann, 1993).
cvaC cvaA cvciB cyaD cvaE
B. pertussis —  —
E. coli
hlyC hlyA hlyB hlyD tolC
Arrows indicate the direction of transcription and homologous genes are shaded in the 
same colour.
39
Introduction
the host as it further increases the concentration of the available iron. Complete loss 
of pore formation is observed when HlyA is mutated in the hydrophobic domain 
between amino acids 299 and 327, suggesting an essential function in pore formation 
for this part of HlyA (Ludwig et a /.,1996).
1.6.3 Leukotoxins
The leukotoxins of Pasteurella haemolytica (LktA) and Actinobacillus 
actinomycetemcomitans (AaltA) share high sequence identity to E. coli HlyA 
(Strathdee and Lo, 1997; Kraig et aL, 1990). Both of these toxins have little 
erythrolytic activity but possess potent cytotoxic activity towards phagocytic cells of 
particular animals, for example LktA lyses leukocytes from cattle, sheep and other 
ruminants (Shewen and Wilkie, 1982) whereas AaltA lyses human and primate 
polymorphonuclear lymphocytes only (Zambon et al., 1983). As in E. coli, the P. 
haemolytica and A. actinomycetemcomitans toxins are encoded by a cluster of four 
genes in which the A gene encodes the toxin and the products of the B, C, and D 
genes are involved in post-translational modification of the toxin and its membrane 
insertion and secretion. The A. actinomycetemcomitans leukotoxin is not secreted but 
remains associated with the bacterial membrane, possibly tlrrough a hydrophobic 
domain at the carboxyl terminus, which distinguishes it from the E. coli and P. 
haemolytica toxins (Lally et a l ,  1989).
When bovine alveolar macrophages (BAM) are exposed to low concentrations of 
LktA, an increase in cytokine gene expression and intracellular calcium elevation is 
observed (Hsuan et al., 1999). Increased calcium levels contribute to the release of
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leukotriene B4 (LTB4), an important chemotactic agent responsible for the influx of 
neutrophils into infected lungs (Henricks et a l, 1992, Cudd et a l,  1999). These non- 
lytic effects seen at low toxin concentrations, may be relevant to the in vivo situation 
where toxin produced at the site o f infection will lyse phagoytic cells, but 
dissemination of toxin through the host cell will allow signalling effects on 
mammalian cells.
1.7 Adenylate cyclase toxin
Utsumi et al. (1978) noticed that a urea extract of B. pertussis contained a new factor 
that inhibited phagocytosis to opsonised targets and chemotaxis of PMN’s and 
named it polymorphonuclear leukocyte-inhibitory factor (PIF) of B. pertussis. The 
partially-purified extract showed little histamine sensitising and cytotoxic activities. 
Confer and Eaton (1982) demonstrated that this toxic activity was due to an 
adenylate cyclase, which was able to enter human phagocytes and catalyse the 
um'egulated formation of cyelic 3 ’-5’AMP, an intracellular mediator of hormone 
action and a signalling molecule.
1.7.1 Structure and synthesis of CyaA
Native CyaA from B. pertussis has been isolated in multiple forms with reported 
molecular masses ranging from 43 to greater than 200 kDa. The toxic form of B. 
pertussis CyaA has an apparent molecular mass of 220 kDa (Hewlett et a l, 1989; 
Rogel et a l,  1989); and is able to release a catalytically-active 43 kDa form of
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adenylate cyclase following proteolytic digestion (Bellalou et a l ,  1990). Glaser et 
al. (1988a) and Brownlie et al. (1988) both reported the cloning and expression of 
CyaA in E. coli. The nucleotide sequence of the cyaA gene showed CyaA to be 
synthesised as a large molecule of 1706 amino acids, with the calmodulin-stimulated 
adenylate cyclase activity residing in the amino-terminal 400aa and the haemolytic 
and invasive activities located in the 1306 carboxy terminus (Classer et al., 1988a) 
(Figure 1.4). The catalytically-active region of CyaA is organised into two domains, 
the N-terminal domain of 25 kDa which carries the catalytic site and the 18 kDa C- 
terminal domain which carries the calmodulin-binding site. Ladant et al. (1989) 
characterised the calmodulin binding and catalytic domains of CyaA by cleavage of 
the 43 kDa N-terminal portion into tryptic fragments (T25 and T18 peptides). They 
concluded that: (1) the catalytically-active 43 kDa form of B. pertussis CyaA lies 
within the first 400 residues of the protein encoded by the cya gene, (2) T18, which 
is the main calmodulin binding domain, occupies the C-terminal segment of the 43 
kDa (residues 236/238-399) and is devoid of catalytic properties and (3) the 
complementary peptides, T25 and T18, re-associate only in the presence of 
calmodulin, leading to significant recovery of the original activity. Figure 1.4 shows 
the structural organisation of the CyaA toxin. Glaser et al. (1988a) showed that the 
1250 C-terminal aa of the precursor showed 25% similarity with the E. coli alpha- 
haemolysin (HlyA) and 22% similarity with Pasteurella haemolytica leukotoxin. 
Tlu'ee open reading frames were identified downstream from the cyaA gene, cyaB, 
cyaD and cyaE (Figure 1.3) (Glaser et al., 1988b). As for E. coli HlyA, secretion of 
B. pertussis CyaA requires the expression of additional genes. The genes cyaB and 
cyaD, similar to hlyB/D, are necessary for the transport of CyaA across the cell 
envelope and for its release into the external medium.
42
uCQ
o
B
SÜS
vo
o
X0
<a
U
1
Ci,
û3
co
"CCQ(/)
'c
&Uo
"wim3
C43L.
C/]
2i
3bl
O
O
O
o
or~
o
om
o
oTj-
so
l i
B0
'S d
1 Q.04
OC
X
u
X
Q
X
O
X
Üo
o
«
O,
II
■3 W) 04 C/5
00
H
u
-----
= ■
_c
’c5
E
■§U<
(N
H
3T3O
E
C3
CJ
1C o
(U o \
a -.2 g
C/3 3
I IùO 3SI
0 0  .22C/i
H >.
1  -03 Q
10 C (N
11
I I
I t
i l
2  S
T3
(U
OU iC
1 =
04 T 3
.E §
< -✓ (/)
•s *03 o
B
11
'Z 3  04
 ^-"El i
s i
43
Introduction
Complementation and functional studies indicated that B. pertussis CyaA is secreted 
by a similar mechanism to that of HlyA, requiring the presence of a third gene 
product. In E. coli, TolC is the outer membrane product encoded by tolC, which is 
separated from the hlyCABD locus however, in B. pertussis, tolC (cyaE?) is included 
on the toxin locus (Glaser et a i, 1988b). Rogel et al. (1989) showed that expression 
of the cyaA gene in E. coli led to the production of a catalytically-active, 200 kDa 
CyaA but devoid of invasive and haemolytic activities. They described how post- 
translational modification confers the toxic properties upon CyaA. Further work 
showed that the cyaC gene in B. pertussis, homologous to the hlyC gene in E. coli, 
was required for the haemolytic and toxic activities of the cyaA gene product (Barry 
et ah, 1991). Sebo et al. (1991) reconstructed in E. coli, an expression system 
consisting of cyaA and cyaC, which enabled production of active CyaA toxin, 
endowed with catalytic, haemolytic and invasive activities.
1.7.2 Interaction of CyaA with target cells
Rogel et al. (1989) showed that extracellular calcium was absolutely essential fo r  B. 
pertussis adenylate cyclase entry into target cells, and the penetration was blocked by 
neutralising anti-.S. pertussis adenylate cyclase antibodies. They also demonstrated 
that calmodulin-mediated inhibition of enzyme penetration was dose-dependent and 
inversely proportional to the CaM-dependent stimulation of the enzymatic activity of 
the toxic form.
The haemolytic features of CyaA were characterised by purifying the 200 kDa 
protein. It was demonstrated that full haemolytic activity required the structural 
integrity of the CyaA protein, whether the protein was cell-associated or secreted into
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the culture medium. The haemolytic activity of CyaA was calcium-dependent but 
very weak in comparison to previously characterised haemolysins. Bellalou et al. 
(1990) constructed in-phase deletion mutants within the cyaA gene. These mutants 
had reduced haemolytic activities and their toxin activity was abolished; however 
these proteins did not lose their capacities to be transported without processing 
across the bacterial cell envelope, suggesting that the structural integrity of the CyaA 
protein is necessary for toxin activity and that different structural determinants are 
required for secretion and pore-forming functions (Bellalou et a l ,  1990). Hewlett et 
al. (1991) demonstrated that the CyaA molecule exhibits a conformational change 
when free calcium concentrations exceed 100 pM, as demonstrated by a shift in 
intrinsic tryptophan fluorescence. This conformational change was associated with 
an alteration in binding of an anti-CyaA monoclonal antibody and a structural 
modification that could be observed by electron microscopy. They proposed that an 
increase in the ambient calcium concentration to a critical point and the ensuing 
interaction of the toxin with the calcium induced a conformational change that is 
necessary for its insertion into the target cell and for the delivery of its catalytic 
domain to the cell interior. The process of CyaA toxin penetration into sheep 
erythrocytes was further shown by Rogel and Hanski (1992) to be carried out in three 
stages; insertion, translocation and intracellular cleavage. Insertion into the 
membrane occurs over a wide temperature range (4°C to 36°C) whereas 
translocation across the membrane was highly temperature-dependent and occurred 
only above 20°C. The N-terminal fragment of the toxin was cleaved in the cell, 
releasing the active 45-kDa portion of CyaA into the cytosol. Intoxication is a rapid 
process and an increase in eAMP levels in target cells can be detected within seconds 
of adding the CyaA toxin, evidence which supports the theory of direct translocation,
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as entry of toxins through a trafficking mechanism or endocytosis would require a 
much longer exposure time (Rogel and Hanski, 1992). Work by Gray et al. (1999;
2001) demonstrated that a particular monoclonal antibody Mab 3D1, directed against 
an epitope within amino acids 373 to 399, was able to both prevent delivery of the 
catalytic domain to the target cell interior when bound to CyaA, and enhance the 
haemolytic activity of CyaA thereby suggesting that the catalytic domain be defined 
as ending at amino acid 399.
1.7.3 Activation of CyaA by CyaC
Using the teclmique of mass spectrometry, Hackett et al. (1994) demonstrated that 
wild type B. pertussis CyaA toxin was modified by amide linked palmitoylation on 
the epsilon-amino group of lysine 983. A synthetic palmitoylated peptide 
eorresponding to the tryptic fragment (glutamine 972 to arginine 984) that contained 
the acylation, blocked CyaA toxin-induced accumulation of adenosine 3 ’-5’- 
monophosphate in target cells, whereas the non-acyiated peptide had no effect. 
These data suggest that palmitoylation at this site represents the modification that is 
required for the toxicity and haemolytic activity of CyaA. Heveker et al. (1994) 
demonstrated that undirected transfer of lauric, myristic, or palmitic acid chains to 
the CyaA pro-toxin in vitro, conferred both haemolytic and toxic activities to CyaA. 
However, both activities were shown to be low in comparison to CyaA modified in 
vivo, suggesting that in vitro fatty acylation of the pro-toxin may involve random 
modification of nucleophilic residues present in the toxin. Westrop et al. (1996) 
observed similar differences in the in vitro activated CyaA. Full AC enzymic 
activity was obtained but the level of haemolytic activity was less than 10% of that
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expected from its invasive enzymic activity. A possibility suggested for this 
observation was the use of a non-speeicifc S 100 extract as a asource of acyl-ACP in 
an in vitro system. In contrast to CyaA, the HlyA from E. coli was found to be 
acyl ate d at two sites, Lys 564 and Lys 690 (Stanley et al., 1994). The CyaC- 
activated recombinant ACT produced in E. coli is palmitoylated at Lys 860 as well as 
acylation of Lys 983. Basar et al. (1999) demonstrated, by replacing Lys 860 with 
either arginine, leucine or cysteine residues, that Lys 860 and Lys 983 from E. coli 
CyaA, are acylated independently in vivo and that mutations of Lys 860 did not 
affect the quantitative acylation of Lys 983 by palmitic and palmitoleic fatty-acyl 
groups, nor the invasive nor haemolytic activity of CyaA.
1.7.4 CyaA as a virulence factor
CyaA has been shown to be an important virulence factor in animal models of 
pertussis. Weiss et al. (1984) demonstated how B. pertussis mutants deficient in 
either, PT, CyaA, or all toxins, had a reduced ability to cause lethal infection in 
infant mice. Further work by Weiss and co-workers examined the proliferation of B. 
pertussis in the lungs of infant mice challenged by the intranasal route. They 
demonstrated how an adenylate cyclase mutant (BP348) was rapidly cleared from the 
lungs with no viable bacteria remaining 10 days post challenge, suggesting that 
CyaA is critical for colonisation and initiation of infection (Weiss and Goodman, 
1989; Goodwin and Weiss, 1990). This data was also confirmed by Brownlie et al. 
(1988) following mouse intranasal challenge with B. pertussis BP348, a Tn5- 
insertion mutant deficient in adenylate cyclase and haemolytic activities. The mutant 
was considerably less virulent than the wild-type strains of B. pertussis but virulence
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could be restored when the recombinant plasmid, pRM Bl, containing both these 
activities was expressed. Klielef et al. (1992) showed that mutants deficient in 
CyaA were unable to adhere to and multiply in the lungs, suggesting that CyaA is 
required to initiate infection. They subsequently showed that there was no overall 
cellular influx into the brochoalveolar lavage (BAL) fluids of infected mice, in 
particular PMNs, when compared with parental virulent strains, indicating an 
important role that CyaA plays during B. pertussis infection (Khelef et al., 1994).
1.7.5 Immune response to infection
In dealing with extracellular pathogens, the immune system aims to destroy the 
pathogen itself and neutralise its products. In response to intracellular pathogens, 
there are two main options; either the cytotoxic T cells can destroy the infected cell 
or the T cells can activate the infected cell to deal with the pathogen itself. Because 
many pathogens have both intra and extracellular phases o f infection, different 
mechanisms are usually effective at different times. In vertebrates, immunity against 
pathogens or against other foreign substances is divided into two categories; innate 
or non-specific immunity (natural) or acquired immunity. Innate immunity is present 
from birth and includes such functions as physiologic barriers, cellular defenses and 
inflammation; whereas acquired immunity develops as a consequence of an 
encounter with a foreign substance. B and T lymphocytes are responsible for the 
specificity exhibited by the acquired immune response. All lymphocytes are derived 
from the bone-marrow stem cells, but T lymphocytes then develop in the thymus, 
while B lymphocytes develop in the bone marrow. B lymphocytes (B cells) combat 
extracellular pathogens and their products by synthesising and secreting into the 
bloodstream antibodies, which, specifically recognise and bind to particular target
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molecules known as the antigen. This type of immunity is termed humoral 
immunity. T lymphocytes (T cells) perform various effector functions when antigen 
presenting cells (APC) bring antigens into the secondary lymphoid organs. T cells 
also interact with B cells and help the latter make antibodies; they activate 
macrophages and have a central role in the development and regulation of acquired 
immunity. Acquired immunity mediated by T cells is termed cellular or cell- 
mediated immunity (CMI). CMI was originally used to describe localised reactions 
to intracellular pathogens mediated by lymphocytes and phagocytes, rather than 
humoral immunity which is mediated by antibodies. However it is now no longer 
reasonable to consider cell-mediated and antibody-mediated responses separately, as 
no cell-mediated response is likely to occur in the total absence of antibodies.
The interaction between B and T cells is a two-way process, in that B cells present 
antigen to T cells and also receive signals from T cells for division and 
differentiation. B and T cells both recognise antigens in different ways. Antibodies 
recognise antigen in solution or on cell surfaces, but always in their native 
confirmation; whereas T cell receptors only recognise the unique combination of 
MHC plus the antigenic peptide when presented by APCs.
Immunoglobulins are a group of glycoproteins present in the serum and tissue fluids 
of all mammals. Some are carried on the surface of B cells where they act as 
receptors for specific antigens. Others (antibodies) are free in the lymph or blood. 
Contact between B cells and antigen is needed to cause the B cells to develop into 
antibody forming cells (AFC). The basic structure of all immunoglobulin molecules 
is a unit consisting of two identical heavy and light polypeptide chains linked by 
disulphide bonds. The heavy-chain type determines the class and subclass of an 
immunoglobulin molecule. The primary function of an antibody is to bind antigen.
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In order for an antigenic determinant (epitope) and an antibody-combining site 
(paratope) to combine, the shape of the combining site must fit the epitope (Roitt et 
al., 2001), T cells can be distinguished by their different T-cell antigen receptors 
(TCR), of which there are two types. One contains two disulphide-linked 
polypeptides (a  and p), the other contains y and 5 polypeptides. Between 90 and 
95% of T cells in the blood are ap , the remaining 5-10% are yô T cells. The ap  TCR 
cells can be sub-divided into two distict populations; a subset that carries the CD4 
marker (T-helper cells) and a subset that carries the CDS marker (cytotoxic T cells). 
CD4^ T cells recognise their specific antigens in association with MHC Class II 
molecules, whereas CD8^ T cells recognise antigens in association with MHC Class I 
molecules. Two groups of CD4^ T cell clones have been identified namely, Thl and 
Th2. CD4^ T-helper cells provide help for B cells in proliferation and antibody 
production, and secrete a range of cytokines that are involved in a variety of 
immunoregulatory functions. Thl cells secrete IL-2, IFN-y and TNF-p and are 
involved in delayed type hypersensitivity and inflammatory responses, and display 
cytotoxic T-lymphocyte activity in vitro. A  key function of this population in the 
immunological defence mechanism in vivo is the activation of macrophages, which 
are stimulated to take up and kill invading microorganisms. IFNy is a particularly 
important cytokine during the early phase of infection with intracellular pathogens 
and when in combination with TNFa, is able to activate macrophages, which results 
in them being better able to control the growth and/or kill intracellular organisms. 
Th2 cells secrete IL-4, IL-5, IL-6 and IL-10 and these secreted cytokines play an 
important role in immunoglobulin class switching and B cell differentiation. IL-10 
inlribits the production of IFNy, antigen presentation and macrophage production of 
IL-1, IL-6 and TNFa. The production of IFN-y without IL-4 or IL-5 is considered to
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be the most reliable indicator of a Thl response and conversely IL-4 or IL-5 
production without IFN-y is indicative of a Th2 response (Swain et al., 1988). T 
cells expressing cytokines of both Thl and Th2 cells are termed ThO cells (Mosmann 
et al., 1989). Figure 1.5 illustrates the cytokine control of the Thl and Th2 subsets. 
CDS’* cytotoxic T lymphocytes (CTL) are important immune effectors arising in 
response to intracellular pathogens such as viruses and intracellular bacteria (Lin and 
Askonas, 1981). CD8"  ^ T cells can be divided into specific subsets, one of these 
expresses CD28 molecules and produces IL-12 in response to activation signals. 
Another subset responds to IL-12 and expresses the GDI lb/CD 18 cell receptor 
molecule. GDI lb/CD 18 or GR3 is a member of the p-integrin family and is 
expressed on monocytes, PMNs and some B and T cells. GR3 (alpha M beta 2, 
GDllb/GD18) has been shown to mediate macrophage binding and uptake of 
infectious agents including B. pertussis (Reiman et al. (1990). GD8^ T cells mediate 
their effector function tlu'ough the production of cytokines such as IFNy and TNFa. 
T cell activation involves the transduction of signals from both the TGR and GD28. 
Glustering of surface receptors upon ligand binding leads to activation of associated 
tyrosine kinases. These kinases become activated by dephosphorylation and are then 
able to phosphorylate y chains of GD3 which permits association with other kinases. 
The end result of these complex pathways is the induction of gene synthesis by the 
activation of transcription factors (Roitt et al., 2001).
Natural killer (NK) cells also play an essential role in killing pathogens through 
cytotoxic attack, mediated through the release of perforin or through the induction of 
receptor-mediated ap opto sis, or activation of macrophages via IFNy production.
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Figure 1.5 Cytokine control of T hl and Th2 CD4 subsets 
Adapted from Benjamini et al. (2000)
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Experiments in vitro implicate that the dose of antigen administered can dictate the 
development of a Thl - or Th2-like phenotype. As the dose of peptide was increased, 
the development of Thl-like cells producing IFNy was observed. However, at very 
high doses of peptide (greater than lOpM) or very low doses (less than O.OSpM) the 
development was switched to Th2-like cells and the production of increasing 
amounts of IL-4 but less IFNy. Affecting the balance of cytokine production, 
brought about by altering the antigen dose, may determine the class and strength of 
the immune response to foreign antigens (Hosken et al., 1995).
1.7.5.1 Immunity in pertussis
B. pertussis has the ability to invade and survive intracellularly within murine and 
human macrophages (Cheers et aL, 1969; Masure, 1993; Friedman et al., 1992) 
suggesting that the intracellular localisation may be an important mechanism in the 
disease process. Because of these different habitats it is likely that the bacterium 
employs a variety of both humoral and cell-mediated immune evasion strategies to 
prolong survival in the host.
Antibodies may function either by neutralising bacterial toxins, inhibiting 
extracellular bacteria from binding to cells in the mucosal tracts or by enabling 
bacterial uptake and destruction by macrophages and neutrophils. Evidence of a role 
for antibodies has been shown in the murine model, particularly for PT and FHA. 
Munoz et al. (1981) compared the protective activities of FHA and PT and found, 
tlu'ough protection studies, that antisera known to contain antibodies to PT was able 
to protect mice against intracerebral challenge, whereas sera lacking anti-PT
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antibodies but containing anti-FHA antibodies was unable to protect mice. Sato and 
Sato, (1984) correlated the titres of specific IgG antibodies against PT and FHA 
following intracerebral and aerosol challenge with B. pertussis. They demonstrated 
that in the intracerebral system FHA did not elicit a protective response but was able 
to increase the response generated by immunisation with PT. Further evidence for 
the role of antibodies was provided by the use of Ig defective mice. Mahon et al. 
(1997) demonstrated that B cell-deficient mice were unable to clear bacteria after 
aerosol infection when compared with the control mice. The Ig 7‘ mice, which lack 
mature B cells, failed to mount an IgG antibody response whereas the wild-type mice 
developed B. pertussis specific serum antibody by day 24 after aerosol challenge, 
indicating a requirement for complete bacterial elimination from the lungs. The 
nature of the protective immunity to pertussis was investigated further by Leef et al. 
(2000). They found that mice given subcutaneous or intranasal WCV did have 
pertussis-specific antibodies in both serum and lung-lavage samples that exceeded 
the levels found in naturally infected mice. Nonetheless, passive transfer o f immune 
serum obtained after immunisation intranasally with formalin-fixed B. pertussis 
(FFBP) had minimal effects on the bacterial burden. However, repeated 
immunisation of B cell knockout mice resulted in partial protection and transfer of 
pertussis-immune serum achieved complete protection, thereby indicating the 
importance of B cells in protective immunity. Canthaboo et al. (2001) investigated 
both the cellular and humoral responses to immunisation with WCV and ACV. It 
was demonstrated that mice immunised with WCV were found to have lower 
antibody titres to PT, FHA and P.69 compared to those immunised with the ACV. 
However, immunisation with the WCV had a strong effect on macrophage activation 
and was associated with a fast clearance of bacteria from the lungs from a very early
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stage. In contrast, mice immunised with ACV generated humoral responses, which 
were associated with inliibition of bacterial growth in the first stage but delayed 
bacterial clearance following aerosol challenge. These results infer that antibody 
responses may have a greater role in immunity generated by ACV vaccines and that 
IgG may confer protection by inliibition of bacterial adherence and neutralisation of 
toxins.
The first direct evidence for the importance o f T cells in immunity to B. pertussis 
was provided by the demonstration that severe combined immunodeficient (SCID) 
mice devoid of T and B cells, failed to clear the bacterium from the respiratory tract, 
whereas immunocompetent BALB/c mice cleared the infection after about 5 weeks, 
demonstrating that T and/or B cells contribute to bacterial elimination (Mills et a l, 
1993). Mills and co-workers also demonstrated that B. pertussis-s^Qcifxc CD4+ T 
cells from mice primed by infection were capable of conferring protection to athymic 
mice. Redhead et al. (1993) used a mouse respiratory challenge model to examine 
the induction of cellular and humoral immune responses and their role in protection 
against B. pertussis following immunisation or previous infection. They found that 
spleen cells taken from mice convalescing from a previous infection, secreted high 
levels of IL-2 and IFNy but not IL-4 or IL-5, characteristic of a CD4^ Thl cytokine 
profile. In contrast, mice immunised with an acellular vaccine had high levels of 
spleen cells secreting IL-5 but not IFNy, a profile characteristic of CD4"  ^ Th2 cells. 
They also found that after exposure to a respiratory challenge with B. pertussis, the 
convalescent mice and those immunised with the WCV eliminated the bacteria faster 
than those immunised with the ACV. Peppoloni et al. (1991) demonstrated that 
human CD4^ T cell clones specific for pertussis toxin and other B. pertussis antigens 
produced mostly IL-2 and IFNy. Further evidence for a role of CD4^ T cells was
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provided by the demonstration that CD4^ laiockout mice could not be protected by 
intra-nasal challenge with inactivated bacteria, whereas in contrast, CD8^-depleted 
mice did not differ from wild-type mice in their ability to control aerosol pertussis 
challenge (Leef et al., 2000).
B. pertussis has been shown to be capable of down-regulating local cell-mediated 
immunity as a means of prolonging its survival in the respiratory tract (McGuirk et 
al., 1998). The majority of T cells from the lungs of naïve mice express the co­
stimulatory molecule CD28, which interacts with B7 on APCs, as an essential second 
signal for T cell activation. However during murine infection with B. pertussis, 
McGuirk et al. demonstrated a significant decrease in the number of T cells in the 
lungs expressing CD28, especially at the peak of the bacterial load.
Respiratory infection or immunisation of mice with WCV, selectively primes Thl 
cells (Mills et al., 1993; Redhead et al., 1993), whereas immunisation o f mice with 
ACV generates T cells that secrete IL-4 an IL-5, plus low levels of IFNy (Barnard et 
al., 1996). B. pertussis-SY>Qcific T-cell response in mice primed with ACV, shifted to 
a mixed Thl/Tli2 profile after respiratory infection with B. pertussis (Mahon et al., 
2000) and addition of IL-12 to an ACV formulation resulted in the induction of IFNy 
secreting T cells (Mahon et al., 1996). McGuirk and Mills (2000) examined the 
protection mediated in mice following immunisation with Thl and Th2-inducing 
pertussis vaccines. They found that the Thl-inducing WCV resulted in a significant 
neutrophil influx after aerosol bacterial challenge whereas in contrast the 
inflammatory response was suppressed following immunisation with the Th2- 
inducing 3 component acellular vaccine. They suggested that Th2 cells provide help 
for IgGi, IgG and IgA production, whereas Thl cells activate the antimicrobial
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activity of phagocytic cells and also stimulate B cells to produce opsonising and 
complement-fixing antibodies of the IgG2a subclass.
IFNy has been shown to enhance the ability of macrophage to kill B. pertussis in 
vitro (Torre et al,, 1994; Mahon et al., 1999). It has also been demonstrated that NO 
is produced in vitro by peritoneal or alveolar macrophages stimulated with B. 
pertussis and in vitro by spleen cells and peritoneal macrophages following 
immunisation with WCV, or by alveolar macrophages following immunisation with 
ACV (Xing et al., 2000; Torre et al., 1993; Torre et al., 1996). NO and reactive 
nitrogen intermediates are associated with the antimicrobial functions of 
macrophages (Ding et al., 1988) and macrophage activation, as measured by NO 
synthesis, correlates closely with protection in vivo against B. pertussis challenge. 
By using NO production as a marker of macrophage activation it is possible to 
identify the relevant components of any vaccine that are responsible for activation of 
macrophages (Xing et al., 2000).
McGuirk and Mills (2000) demonstrated that FHA is capable of suppressing IL-12 
production by macrophages and that this inhibition was dependent on an IL-10 
mechanism. Agglutinogens 2 and 3 and PT did not suppress IL-12 production, 
suggesting that B. pertussis is able to increase its survival in vivo by stimulating the 
production of inhibitory cytokines which, in turn, subvert the protective cellular 
immune responses. McGuirk et al. (2002) investigated the hypothesis that FHA may 
contribute to the suppression of Thl responses during acute infection with B. 
pertussis by the induction of T cells with regulatory activity, as a result of its 
interactions with cells of the innate immune system. They demonstrated that FHA 
interacts directly with dendritic cells to induce IL-10 and inhibit LPS-induced IL-12 
production. The DCs generated after interaction with FHA selectively stimulates the
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induction of T regulatory (Tr) cells from naïve T cells. Results of this study 
demonstrate that activation of DCs that secrete IL-10 but not IL-12, can direct naïve 
T cells to a Trl subtype and that FHA can provide the stimulus.
Mielcarek et al. (2001) studied the interaction of B. pertussis with mast cells using 
the technique o f transmission electron microscopy. They were able to demonstrate 
that bone marrow-derived mast cells (BMMCs), following in vitro exposure to B. 
pertussis, were able to release increased levels of TNFa and IL-6 compared with 
BMMCs incubated with medium alone. These pro-inflammatory cytokines are 
Imown to be released by mast cells and are thought to play a critical role during 
infection (Gordon and Galli, 1990; Van Snick, 1995; Malaviya et al., 1996) therefore 
mast cells may participate in the immunity against B. pertussis in the lungs via the 
production of cytokines, in particular TNFa and IL-6, possibly by enhancing 
phagocytosis.
1.7.6 Delivery of multiple epitopes by CyaA
Recombinant CyaA toxoids with disrupted catalytic activity have been shown to be 
capable of delivering vaccinal CD8^ T cell epitopes into the cytosol of MHC class I 
APCs and have been successfully used for antigen delivery and induction of 
protective antiviral and therapeutic antitumour CD8^ CTLs in mice (Sebo et al., 
1995; Saron et a l ,  1997; Fayolle et al., 1999, Guermonprez et al., 1999). Dadaglio 
et al. (2000) investigated the potency of recombinant CyaAs carrying between one 
and four copies of the MHC class I and class II T-cell epitopes from the 
nucleoprotein of the lymphocytic choriomeningitis virus (LCMV), to induce T cell
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responses characterised by IL-2 and IFNy production and a lack of detectable levels 
of IL-4 and IL-5, indicative o f a Thl-like cytokine profile. From this it was found 
that CyaA molecules bearing CD8^ and CD4^ T cell epitopes were able to induce 
both CTL and Thl-like responses. Thl responses play an important role in 
protection against intracellular pathogens (Section 1.7.5.1), therefore this is very 
useful observation in view of development of CyaA as an antigen delivery system. 
They also showed that peptides of more than 60 amino acids inserted into the 
catalytic domain, did not affect the efficiency of CTL induction. This is useful, in 
that insertion of multiple peptides into the same site may lead to CTL responses with 
broad MHC class restriction. Further work by Fayolle et a l (2001) showed that 
CyaA was able to deliver simultaneously three immunodominant CTL epitopes from 
LCMV, FIIV type 1 and chicken ovalbumin and induce epitope-specific cytotoxic 
responses in vivo against each epitope.
1.7.7 Protection by CyaA
Antibody-mediated protection against intracellular pathogens is important in vaccine 
design and there is conclusive evidence that antibodies can protect against a variety 
of intracellulai' pathogens for which CMI has also been shown to play a crucial role 
in host defence. Antibodies may function by neutralising bacterial toxins or by 
enabling bacterial uptake and destruction by macrophages and neutrophils. Confer 
and Eaton (1982) demonstrated the ability of CyaA to inliibit the functions of 
neutrophils, namely phagocytosis and killing of microorganisms. The development 
o f a method to quantify phagocytosis using B. pertussis labelled with green 
fluorescent protein (GFP) and differential staining, led to the discovery that 98% of
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phagocytosed B, pertussis bacteria by human neutrophils were killed and few, if any, 
B. pertussis cells were capable of surviving within these neutrophils (Lenz et a l, 
2000). Further work by Weingart and Weiss (2000) examined the role that B, 
pertussis virulence factors and the presence or absence of opsonising antibodies 
played in phagocytosis by human neutrophils. They showed that B. pertussis 
mutants lacking FHA were unable to attach to neutrophils and were not 
phagocytosed, thereby demonstrating a major role for FHA in promoting attachment 
to neutrophils and therefore antagonising phagocytosis by these neutrophils. They 
also showed that CyaA was able to block phagocytosis, as proven by the efficient 
phagocytosis of mutants that failed to express CyaA. More recently Weingart et a l 
(2000) demonstrated that antibodies which neutralised CyaA enhanced phagocytosis, 
but only when combined with human opsonising antibodies. B. pertussis is an 
unusual organism, in that opsonisation does not appear to promote phagocytosis of 
wild-type B. pertussis, and the bacteria remain extracellular. However when CyaA 
toxin activity is absent or diminshed by the presence of neutralising antibodies, 
inceased phagocytosis occurs, suggesting that the increase in cAMP production 
inhibits the signalling that normally occurs following the interaction of the antibody 
and Fc receptor. These results suggest that neutralising antibodies to CyaA in 
conjunction with opsonising antibodies could increase the immune response 
generated by enhancing the phagocytic defence mechanisms.
Guiso et a l (1989) showed that active immunisation with 3pg of purified B. 
pertussis CyaA by the subcutaneous route, three times, at one-week intervals, 
protected mice against lethal challenge by the intranasal route with 10  ^ B. pertussis 
18.323 bacteria. In a subsequent study using the mouse respiratory challenge model, 
they demonstrated that two subcutaneous immunisations with 4qg o f purified CyaA
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holotoxin at two-week intervals, induced protection against colonisation with B. 
pertussis (Guiso et al., 1991). Betsou et al. (1993) showed that recombinant CyaA 
expressed in the presence of the CyaC product was able to protect mice after an 
intranasal challenge with B. pertussis, whereas the recombinant CyaA expressed in 
the absence of the CyaC product had no protective ability. They further showed, 
using a set of truncated recombinat CyaA proteins, that the palmitoylated Lysine 983 
residue was an essential component for protective activity, haemolytic and cytotoxic 
activities; as these functions were absent when either acylation did not occur or the 
last amino acids were removed (Betsou et al., 1995). Hormozi et al. (1999) showed 
that mice exhibited protective activity against intranasal challenge with a sublethal 
dose of B. pertussis 18.323 after receiving two immunisations subcutaneously with 
15pg of purified active (acylated) CyaA, either the native active form from B. 
pertussis or the recombinant active form. This was shown by low lung to body 
weight ratio and low bacterial numbers in the lungs compared to mice vaccinated 
with purified inactive (non-acylated) CyaA. These results confirm that CyaA 
modification by CyaC is critical for the protective ability of CyaA. The group also 
investigated the adjuvanticity o f purified active or inactive recombinant CyaA on the 
co-administered antigen, ovalbumin (OA). They found that anti-OA IgG levels were 
enhanced several fold when active CyaA was co-administered with OA, whereas the 
enhancement was less marked when the inactive recombinant CyaA was co­
administered. This suggested that the invasive activity of CyaA, via increases in the 
levels of cAMP, may be responsible for the enhancement o f specific antibody 
responses to OA.
The ultimate goal of a vaccine is to deliver long-lived immunological protection by 
an enhancement of memory responses. In some situations protective immunity can
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be mediated by just antibodies or CD8^ T cells, but for optimal control both the 
humoral and cellular immune responses need to be activated (Casadevall., 1998; 
Bromberg et al., 1991).
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B. pertussis has been shown to invade and survive within intracellular cells therefore 
whilst humoral immunity has traditionally been considered to play the central role in 
immunity it may not be totally effective and instead the induction CMI may be 
necessary for complete bacterial clearance. Adenylate cyclase toxin (CyaA) invades 
target cells where host-cell calmodulin activates the adenylate cyclase enzymic moiety 
to produce high levels o f cAMP. High levels of cAMP impairs functions such as 
chemotaxis and phagocytosis, therefore assists in the survival of, and colonisation of, 
this bacterium in the respiratory tract. Directing an immune response toward CyaA may 
therefore be an important anti-colonisation factor. Following vaccination this project 
aimed to define the immune response to CyaA and compare it with other protective 
pertussis antigens, thereby furthering the understanding of the nature o f immunity to 
pertussis.
The main objectives were to firstly produce and purify two forms o f CyaA, an 
enzymically active and an enzymically inactive form. Following vaceination of the two 
different forms the relevance and importance of the enzymic moiety could be 
determined with respect to 1) protection against B. pertussis or B. parapertussis 
challenge; 2) any potential adjuvant effect to stimulate the immune response to other 
antigens present in the ACV and 3) direction of the immune response towards cellular 
immunity and a Thl type of response.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 BACTERIAL STRAINS AND PLASMIDS
The E. coli host strain used for expression vectors was BL21/DE3. This strain 
contains chromosomally-iocated A.DNA expressing the gene encoding T7 RNA 
polymerase under the control of the inducible lacUV5 promoter. Addition of 
isopropyl-1-thio-p-D-galactoside (IPTG) to a growing culture induces the polymerase 
which, in turn, transcribes the target DNA in the plasmid via a T7 promoter.
The CyaA pro-toxin, which has adenylate cyclase activity, and the CyaC protein 
required for post-translational activation of cytotoxic activity, were expressed from 
separate compatible plasmids, pGW44 and pGW54 respectively, initially from 
pETl la  (Westrop et al., 1996, 1997) (Figure 2.1). The plasmid encoding CyaA pro­
toxin lacking adenylate cyclase activity, pGW44/188, was constructed (S, Bailie and 
J.G Coote, unpublished) by replacing a 1.1 kb Ndel/BstBl fragment at the 5’ end of 
the cyaA gene in pGW44 with the equivalent fragment from pACM188 (Ladant et 
al., 1992). This creates a pro-toxin that is catalytically inactive due to insertion of the 
dipeptide Leu-Gln between codons 188 and 189 within the ATP-binding site (Ladant 
et al., 1989). Co-expression of pGW 44/l 88 with pGW54 led to the production of the 
invasive toxin devoid of catalytic activity. The stock of bacterial cells and competent 
bacterial cells for transformation of plasmids were stored at -70°C  in 50% (v/v) 
glycerol.
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Figure 2.1 Schematic representation of plasmids used for expression of 
different forms of CyaA in E, coli
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pTllac
I ►
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2.1.1 Growth of E. coli
E. coli strains were routinely grown overnight at 37°C on Luria Beilani (LB) agar 
(Appendix A .l). Where necessary, 500 nil LB broth (Appendix A .l) in a 2 L flask 
was inoculated from such plates and incubated overnight at 37°C with shaking at 
between 150 and 200 rpm. Ampicillin (Amp) at a final concentration of 75pg/ml 
was included in all cultures inoculated with E. coli containing pGW44 or 
pGW44/188, and chloramphenicol (Chlor), at a final concentration of 12.5pg/ml, was 
added to E. coli cultures inoculated with cells containing pGW54.
2.1.2 Growth of B. pertussis and B. parapertussis
B. pertussis and B. parapertussis (strains 18.323 (NCTC 107399) and NCTC 5952 
respectively) were grown on Charcoal agar base (Oxoid Ltd, UK) containing 10 % 
(v/v) defibrinated horse blood (E+0, UK). Plates were incubated in a humidified 
atmosphere at 37°C for 2 to 3 days.
2.2 DNA EXTRACTION
2.2.1 Plasmid purification
Plasmid DNA was extracted using the QIAprep® Miniprep purification system 
(Qiagen, UK) according to the manufacturer’s instructions. Briefly, 5 ml of 
overnight culture of E. coli was centrifuged at 10,000 x g for 10 min (Biofuge, 
Heraeus). The resultant bacterial pellet was re-suspended in 250 pi of Buffer PI and 
lysed using 250 pi of Buffer P2 (alkaline detergent solution) for 5 min at room 
temperature. The lysate was subsequently neutralised and adjusted to high salt
66
M aterials and M ethods
binding conditions by the addition of 350 pi of Buffer N3, followed by centrifugation 
at 10,000 X g for 10 min. The supernatant was added to a QIAprep® spin column and 
centrifuged at 10,000 x g for 1 min. The flow-tlirough was discarded and the final 
wash was performed with 750 pi of Buffer PE, with a further centrifugation as 
described previously, to ensure efficient removal of salts. Finally, the DNA was 
eluted by centrifugation after the addition of 50 pi of sterile distilled water heated to 
65°C.
2.3 AGAROSE GEL ELECTROPHORESIS 
2.3.1 Sample preparation
The sample DNA (5-20 pi) was mixed with 6x DNA loading buffer (Appendix B.2) 
in a ratio of 5:1 prior to loading into the wells. Molecular weight markers (1 Kb 
ladder, Gibco BRL, UK) were utilised according to manufacturer’s instructions.
2.3.2 Gel preparation
Agarose Type II-A (Sigma) was suspended in Ix Tris acetate EDTA electrophoresis 
(TAE) buffer (Appendix B .l) to give a 1 % (w/v) solution and heated until the 
agarose was completely dissolved. The solution was allowed to cool, ethidium 
bromide (BioRad) added to a final concentration of 1.0 pg/ml, then poured into an 
appropriate gel tray. Upon setting, the gel was immersed in Ix TAE in a horizontal 
gel electrophoresis tank (Bethesda Research Labs, USA)
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2.3.3 Electrophoresis
A powerpack (DeltaElektronika) was used to provide a current of 100 mA tlii'ough 
the agarose gel. Electrophoresis was carried out until the marker dye migrated an 
appropriate distance to enable visualisation of the DNA.
2.3.4 Visualisation of DNA
A high performance ultraviolet transilluminator (Ultra Violet Products, Cambridge, 
UK) coupled to an image acquisition and analysis software package (LabWorks) was 
used to visualise and store electronically, images of the ethidium bromide-stained 
DNA. Images were printed using a video graphic printer (model UP-860, Sony) and 
edited using Adobe Photoshop Version 4.
2.4 STANDARD TRANSFORMATION
2.4.1 Preparation of electroporation-competent cells
A culture of E. coli grown overnight in LB at 3 T C  was diluted 1 in 100 in 500ml of 
LB in a 2 L dimpled flask. The flask was shaken at 200 rpm at 37°C until an 
ODôooiim of between 0.6 and 1.0 was obtained. The flask was chilled on ice and cells 
harvested at 5,000 x g for 15 min in a Sorvall superspeed (rotor GS-3). The resultant 
bacterial pellet was suspended in 500 ml ice-cold sterile distilled water and 
centrifuged as previously described. The cell pellet was then suspended in 250ml 
ice-cold sterile distilled water, centrifuged as before and resuspended in 10 ml cold 
sterile glycerol 10 % (v/v) and 100 pi aliquots were snap frozen on dry ice and used 
immediately or stored at -70°C.
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2.4.2 Electroporation procedure
Prior to electroporation, a 0.2cm electroporation cuvette (Flowgen, UK) was chilled 
at -20°C. A mixture of 1.5 pi of plasmid DNA and 40 pi of competent cells were 
added to the cold cuvette and shaken to the bottom of the cuvette. Cells were pulsed 
once in a Bio-Rad Gene Puiser (model 1652078, Bio-Rad laboratories, UK) set at 2.5 
kV, 25pFD and connected to a Bio-Rad pulse controller (model 1652098) set to 
200Q. Immediately following electroporation, 1 ml of pre-warmed SOC (Appendix 
A.2) medium was added and the cells were incubated at 37°C for 1 h. After 
incubation of the transformed cells in SOC, 100 pi was spread onto LB agar plates 
containing appropriate antibiotics and the plates were incubated at 37°C overnight. 
Resultant colonies were cultured and plasmid DNA was extracted (Section 2.2.1).
2.4.3 Expression of recombinant proteins
An overnight culture of E. coli BL21/DE3 containing the relevant plasmid DNA was 
diluted 1 in 100 in 1 L of LB containing appropriate antibiotics. The culture was 
shaken at 200 rpm at 37*^ C until an OD^oonm of between 0.5 and 0.8 was obtained. 
IPTG was then added to a concentration of 1 mM and the culture shaken at 37°C for 
a further 4 h. Cells were harvested at 5,000 x g for 15 min in a Sorvall superspeed 
centrifuge (rotor GS-3).
2.4.4 Urea extraction of inclusion bodies
After expression of recombinant proteins, the resultant cell pellet was re-suspended 
in 20 ml ice-cold Buffer A (Appendix C .l). The cell suspension was disrupted using
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a One-Shot sonic cell disrupter (Constant Systems Ltd, UK) for 15 sec and repeated 
between three and five times until all the suspension had passed through the 
disrupter. The resultant lysate was centrifuged at 17,000 x g in a Sorvall superspeed 
centrifuge (rotor SS34) for 30 min to allow inclusion bodies to be pelleted. Pellets 
were re-suspended in 10 ml of Buffer B (Appendix C.2) and inclusion bodies 
solubilised with rotation at room temperature until the suspension cleared, 
approximately 3 hours. A final centrifugation step of 100,000 x g for 90 min at 4°C 
was performed and the supernatant, containing urea-soluble protein, was retained and 
stored at -20°C.
2.5 PURIFICATION OF CyaA
2.5.1 DEAE Sepharose Chromatography
A 10 ml volume of DEAE Sepharose Fast Flow (Sigma) was applied to a glass 
Econo-Column (1.5 cm x 20 cm) (BioRad) and washed with 30 ml water to remove 
excess ethanol. The column was equilibrated at room temperature by washing with 
20, 50 and 30 ml volumes of Buffer 1, 2 and 3 (Appendix C.3.1, C.3.2, C.3.3) 
respectively. The urea extract was adjusted to give a final concentration of 50 mM 
NaCl and then applied directly to the column. The column was then washed with 25 
ml o f Buffer 3 adjusted to 130 mM NaCl and then eluted in aliquots with Buffer 3, 
gradually increasing the NaCl concentration from 250 mM up to 2 M (Appendix
C.3.4). The eluted extracts were then stored at -20°C until aliquots could be analysed 
by SDS-PAGE for the presence o f CyaA.
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2.5.2 Phenyl Sepharose Chromatography
Eluted fractions from the DEAE Sepharose chromatography were analysed by SDS- 
PAGE and the relevant fractions containing CyaA were pooled and diluted 1:4 in 
Solution A (Appendix C.4.1). A clean Econo-column (1.5 cm x 20 cm) was filled 
with 2 ml Phenyl Sepharose CL-4B (Sigma) and washed with 30 ml water to remove 
excess ethanol, followed by an equilibration with 20 ml Solution A. The diluted 
fractions were applied to the column in 20 ml aliquots and washed with Wash buffer 
(Appendix C.4.2). Elution was performed with Solutions B1 to B3 (Appendix
C.4.3), gradually decreasing the NaCl content from 0.5 M to zero and increasing the 
urea content from 2 M to 8 M. Fractions were analysed by SDS-PAGE.
2.5.3 Concentration of CyaA samples
Centricon (Millipore) centrifugal concentrators with a molecular weight cut-off value 
of 100 IcDa were used to concentrate CyaA samples. A 2ml volume of CyaA was 
applied to the centricon sample reservoir (Millipore) and centrifuged at 1000 x g for 
30 min at 4°C as per the manufacturers’ instructions. The filtrate was left in the 
filtrate vial and the retentate transferred to a microfuge tube, and both were subjected 
to SDS-PAGE analysis.
2.6 ENDOTOXIN REMOVAL
2.6.1 Polymyxin B
A polypropylene disposable column (0.8 cm x 9.0 cm) (Bio-Rad) was packed with 2 
ml Affi-Prep Polymyxin Matrix (BioRad) and washed with 3 column volumes of 0.1
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M NaOH, followed by ten to fifteen bed volumes of pyrogen-free water (Baxter). 
The column was then equilibrated with pyrogen-free PBS at room temperature until 
the eluate was at neutral pH. Purified CyaA was loaded onto the column in 2 X 2.5 
ml volumes and the eluate recovered. A sample of the recovered solution was sent 
for endotoxin content analysis (Division of Endocrinology, NIB SC), the remainder 
stored at -20°C.
2.6.2 Triton X-114
Purified ACT sample was diluted in a ratio of 1:1 in 50mM Tris, pH 8.0. To a 0.5 ml 
volume of sample, 5pi Triton X-114 (Sigma) was added, the mixture voitexed and 
placed in an ice bath for 5 min. The chilled sample was vortexed again then warmed 
to 37°C for 10 min, before being centrifuged at 10,000x g for 10 min. After 
centrifugation, the detergent phase was presented as an oily droplet at the bottom of 
the tube and the remaining supernatant was retained for endotoxin content analysis.
2.6.3 Sephacryl chromatography
Sephacryl® S-200 High Resolution gel filtration media (Pharmacia Biotech) was 
prepared by centrifugation at 6,000 x g and repeated re-suspension in 8M urea 
(Buffer B, Appendix C.2), until the volume of the packed slurry was approximately 
20 ml. A volume of between 2 and 3 ml of urea buffer was added to the sephacryl 
slurry to enable packing of the column. The buffer was allowed to flow through the 
column and 1 ml of purified CyaA was applied followed by 20 ml o f buffer. Twenty 
1 ml aliquots were collected and protein content was estimated by measuring the 
OD280nm- The samples with the highest protein content were analysed by SDS-PAGE
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to determine the amount of CyaA and an aliquot of each column fraction was sent for 
endotoxin analysis.
2.6.4 END-X®
END-X® B15 (Associates of CapeCod Incorporated, USA) contains immobilised
endotoxin neutralising protein from Limulus polyphemus as the affinity ligand which 
enables the removal of Gram-negative endotoxins from solutions. A volume of 
between 1 and 1.5 ml of purified CyaA was added directly to the tube containing the 
affinity resin and the mixture incubated at 4°C for 4 h with gentle agitation. After 
incubation, the sample was centrifuged at 12,000 x g for 2 min to pellet the resin. 
The supernate was transferred to an endotoxin-free receiver tube and sent for 
endotoxin analysis.
2.7 Protein quantification
The Coomassie® Plus-200 protein assay kit (Pierce, USA) provided a colourimetric 
method for total protein quantification, according to the microtiter plate protocol. 
When Coomassie® dye binds protein in an acidic medium, an immediate absorbance 
shift occurs from 465 nm to 595 nm with a simultaneous colour change of the reagent 
from green/brown to blue. Briefly, Bovine Serum Albumin (BSA) standards and 
urea-extracted test proteins were diluted in the range 100 to 1,500 pg/ml and 10 pi 
volumes added to wells o f a microtiter plate (Nunc). To each well, 300 pi of 
Coomassie® Plus reagent was added and mixed on a plate shaker for 30 sec. The 
ODôoonm was measured with a plate reader and protein concentrations determined 
from a standard curve.
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2.8 SDS-PAGE
SDS-PAGE was performed according to the method of Laemmli (1970) in a vertical 
gel electrophoresis tank (Hoefer Scientific Instruments, USA). Glass plates were 
assembled according to the manufacturer’s instructions. Resolving gels, containing 
7.5-10% acrylamide (Appendix D .l), were poured between the assembled plates until 
the gel was approximately 4cm below the top of the plates and 100% ethanol was 
used as an overlay. The gel was left undisturbed for approximately 1 hour at room 
temperature until set. A stacking gel containing 6% acrylamide (Appendix D.2) was 
poured onto the polymerised separating gel and a comb placed into the gel solution 
and allowed to set. The wells were filled with 1 X electrode buffer (Appendix D.3), 
protein samples loaded with sample buffer (Appendix D.4) and the gel assembled 
into the electrophoresis tanlc. The lower buffer reservoir containing 1 X electrode 
buffer was stirred with a magnetic stirrer during vertical gel electrophoresis. The gel 
was run at 20 mA until the tracker dye entered the separating gel at which point the 
current was increased to 50 mA. The gel was removed when the tracker dye reached 
the bottom of the separating gel and stained for protein visualisation or blotted as 
appropriate. For staining, 1 % (w/v) Coomasie blue stain solution (Appendix D.5) 
was used for a minimum of 2 h on a rotating platform before being replaced with de­
stain solution (Appendix D.5) until the background was decolourised.
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2.9 WESTERN BLOTTING
2.9.1 Western Blotting transfer
After SDS-PAGE, proteins were transferred to nitrocellulose membrane (Hybond-C, 
Amersham-Pharmacia Biotech) according to the method described by Towbin et al. 
(1979). Briefly, the stacking gel was removed and the separating gel soaked in 
electroblotting buffer (Appendix D.6) for 5 min. The blot was then assembled and 
placed in electroblotting apparatus (Trans-Blot cell, Bio-Rad, USA) containing 
electroblotting buffer and a voltage of 20 volts applied for several hours.
2.9.2 Development of blots
After transfer onto the membrane, proteins were visualised by staining in 0.5 % (w/v) 
Ponceau S (Sigma) solution in water for 5 min. Background colour was removed by 
de-staining in water for 2 min and the position of the molecular weight markers noted 
with indelible ink. The membrane was then de-stained in PBS (Appendix A.4) for 10 
min and incubated in blocking buffer (Appendix D.7) for 1 h at room temperature 
with gentle agitation. Primary antiserum (kindly supplied by R. Parton), was 
obtained after innoculation i.m of a rabbit with purified CyaA followed by four 
booster injections at monthly intervals (Hormozi et al. 1999). Antiserum was diluted 
in blocking buffer and incubated with the membrane for 1 h at RT. The membrane 
was washed twice in fresh PBS for 15 min at RT. Horse-radish peroxidase- 
conjugated secondary antibody (Scottish Antibody Production Unit, UK) was then 
diluted 1 in 1000 in blocking buffer and incubated with the membrane for 1 hour at 
RT. The membrane was washed in PBS for 2 X 15 min at RT before being 
immersed in freshly prepared 0.05% (w/v) 3, 3’diaminobenzidine (DAB) (Sigma)
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solution (Appendix D.8) for approximately 2 min. Washing the membrane in 
distilled water stopped the staining reaction.
2.10 CHARACTERISATION OF CyaA
2.10.1 Haemolysis assay
Turkey erythrocytes (Division of Virology, NIB SC) were washed in PBS and 
adjusted to give a final concentration of 0.7 % (v/v). CyaA samples were diluted in 
Hanlc’s Balance Salt Solution (HBSS) (Gibco) containing 0.4M urea, starting at 1 /20 
dilution of toxin. CyaA samples were added to 96-well u-bottomed plates (Nunc) 
and, to a final volume of 50 pi toxin sample, 50 pi turkey eiytlii'ocytes were added, 
the samples mixed and the plate incubated for 24 h at 37°C. A positive control of 1 
% saponin was used to demonstrate 100 % haemolysis and a negative control 
containing only erythrocytes in HBSS plus 0.4M urea was used to demonstrate 0 % 
haemolysis. After incubation, samples were transferred to microfuge tubes and 
centrifuged at 600rpm for 5 min. The supernates were transferred to a fresh 96-well 
plate and the OD540nm measured on an Anthos ELISA plate reader (Life Science Int, 
UK).
2.10.2 MTT dye reduction assay
Cytotoxic activity was determined by the MTT assay as deseribed by Mosmami 
(1983) using the CellTitre 96™ assay (Promega) kit. This assay is based on the 
reduction of a yellow tétrazolium dye (3-(4,5-di-methylthiazol-2-3yl)-2,5-diphenol 
tétrazolium bromide, MTT) to insoluble purple formazan crystals by dehydrogenases 
in the mitochondria of living cells. The activity of toxin on cells inliibits this
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reaction. Mouse macrophage-derived (J774.2) cells were prepared in phenol red-free 
Roswell Park Memorial Institute (RPMI) medium (Gibco, UK) plus additions 
(Appendix E .l) to a concentration of 5 X 10  ^ cells/ml. Cell viability was checked by 
Trypan blue exclusion before and after incubation. For this, 50 pi of 0.2 % (w/v) 
Trypan Blue solution (Appendix E.2) was added to 50 pi cell suspension and 
incubated for 5 min at RT. Cells that remained clear and had not taken up the blue 
stain were counted using an improved neubauer haemocytometer (Webber, UK). 
Urea extracts were diluted in RPMI medium in serial 2-fold dilutions starting with 
1:20 dilution. A volume of 50 pi of each dilution was transferred in duplicate to 
wells o f 96-well flat bottom microtitre plates (Nunc), before the addition of 50pl/well 
of cell suspension. The plate was incubated at 37°C for 2 h in a humidified 5 % CO2 
atmosphere before the addition of 15 pl/well o f MTT dye (Promega) and a further 4 h 
incubation. Following incubation, 100 pl/well of solubilization / stop solution 
(Promega) was added and incubation continued for a further hour. The contents of 
each well were mixed, avoiding bubble formation and the OD540nm was measured 
using an Anthos ELISA reader (Life Science Int, UK). A negative control containing 
only the cell suspension in urea buffer was included. 100% cell viability was taken 
as the mean absorbance value for the control wells. This value was used to calculate 
the percentage cell viability of the different CyaA preparations.
2.10.3 AC enzymic assay
AC enzymic activity was measured according to the method of Salomon et al, 
(1974). CyaA samples were diluted 1:1000 and 1:10,000 in Tris buffer, and 10 pi of
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samples with 80 pi of reaction mix (Appendix F .l) were pre-incubated in a water 
bath at 30°C for 1 min. A control containing 10 pi of urea buffer without CyaA was 
also included. 10 pi of substrate mix (Appendix F.2) containing 20 mM ATP and 
approximately 3000Ci/mmol ^^a-P ATP and 50Ci/mmol ^H-cyclicAMP (Amersham) 
was added and incubation continued for a further 5 min. The latter component was 
used as an internal control to calculate the recovery o f cAMP after chromatography. 
In this first step ^^P-ATP was converted to ^^P cAMP. The reaction was stopped by 
the addition of 200 pi 0.5 M HCl before neutralising with 200 pi 1.5 M imidazole 
(Sigma). The neutralised solution (0.5 ml) was loaded onto a polypropylene 
disposable column (Bio-Rad) containing alumina powder (Merck), which acts to 
separate ^^P-cAMP from residual ^^P-ATP, the latter being retained on the column. 
^^P-cAMP and ^H-cyclicAMP were eluted from the column with 3 ml of 10 mM 
imidazole pH 7.6, and added to scintillation solvent. ^^P-cAMP and ^H-cAMP 
radioactivity was counted in a liquid scintillation counter for all samples (Wallac). 
To calculate the moles o f cAMP formed, a calulation must firstly be done to correct 
for variation in recovery between alumina columns. The value from this formula can 
be substituted into the equation below (Ladant et a l, 1988).
Corrected value = Total input ^H-cAMP X measured ^^P-ATP
Totallecovered "^H-cAMP
Example; over page
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Sample cpm cpm
Reaction mix 10534 18
Substrate solution 7312 181028
CyaA dilution 8636 5780
10534 X 5780 = 7050 cpm
8636
200 nmol ATP yields 181028 cpm, therefore lOOOcpm corresponds to 1.1048 nmol 
7050 cpm corresponds to 7.789 nmol cAMP formed during the incubation, therefore 
7,789/5 = 1.558 nmol/min for lOpl o f sample dilution, 
which is equivalent to 155.8 nmol/min.ml of sample dilution.
2.10.4 Conductimetric assay
An alternative method for the measurement of adenylate cyclase activity employs a 
method where the conductance of a sample solution is measured. This assay was 
developed by Lawrence et al (1998). Briefly, the apparatus consists of 8 conductivity 
cells each containing platinum electrodes which have been fused into the walls of a 
glass tube (Figure 2.2). The cells are all linlced to computer software that processes 
conductimetric readings and enables drawing of tangents to curves in order to 
determine slopes and reaction rates, and to measure total displacement between the 
initial and final baselines. A 2 ml volume of Bicine buffer (pH 8.0) (Appendix F.3), 
containing 0.5mM ATP, was added to each cell, followed by 0.5 pi pyrophosphatase 
(1 U/ pi, Sigma), 2 pi calmodulin (7.5mg/ml, kindly provided by Dr. A. Lawrence, 
Glasgow University) and the reaction was started by addition of 2 pi o f CyaA
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sample. 1 I.U inorganic pyrophosphatase hydrolyses the substrate at a rate of 
Ipmol/min. Hydrolysis of the substrate (PPiMg)^' generates four new mobile 
charged ions resulting in a conductance change (see below),
(ATPiMg)^' + Bicine" -►  cAMP- + (BicineH) + (PPiMg)^'
(P P iM g f 2 Pi^' +
There is no change in conductance unless the (PPiMg) product is cleared to release 
the ion from chelation.
The total conductance changes and tangents to curves were measured by an on-screen 
line drawing. Thus for a substance concentration of ImM giving a total change of x 
units and an initial slope of y units per minute, the initial rate is;
Initial rate = (y/x) pmol/ml/min
2.11 In vivo ASSAYS
2.11.1 Animals
Female NIH mice, age 3 to 4 weeks, were obtained from Harlan UK Ltd, Oxford, UK 
and maintained in pathogen-free conditions.
2.11.2 Vaccines
Whole cell pertussis vaccine (WCV) (NIBSC reagent, 88/522) and a commercially 
available three component acelhilar pertussis vaccine (ACV) containing 25pg of PT 
chemically detoxified with formaldehyde and glutaraldehyde, 25pg of filamentous 
haemagglutinin (FHA) and 8pg of pertactin (P.69) were used for immunisations at 
either 0.1 single human dose (SHD)/mouse or 0.025 SHD/mouse respectively.
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Figure 2.2 Conductimetric apparatus used to measure AC activity
V, ' *■
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2.11.3 Immunisation
Mice were immunised intraperitoneally with 0.5 ml of CyaA, individual acellular 
pertussis components or whole cell or acellular pertussis vaccines. Control groups 
received 0.5 ml of PBS or PBS containing LPS where stated. For antibody assays, 
mice received 15 pg of CyaA per dose and either 10 pg/dose of each o f detoxified PT 
(PTd), FHA and P.69 or native PT, FHA and P.69 at 120 ng/dose, 25 pg/dose and 10 
pg/dose, respectively, singly or together. For protection assays, mice received 25 pg 
of CyaA per dose and in some cases, the other protective antigens as noted.
2.11.4 Preparation of B. pertussis suspension for aerosol challenge
B. pertussis 18.323 was grown on charcoal agar containing 10% (w/v) defibrinated 
horse blood for 18 h followed by 2 further sub-cultures at 37°C for 16 to 18 h. The 
bacterial cells were re-suspended in 1 % (w/v) casamino acid solution (CAS) 
(Appendix A.3) and adjusted to 0.2 ODgisnm using a spectrophotometer (MSB, 
Fisons) to give 4 X1 0 ^  cfu/ml. The suspension was kept on ice until used for aerosol 
challenge.
2.11.5 Aerosol infection of mice with B, pertussis
The mice were challenged at either 4 or 6 weeks after the initial vaccination using the 
aerosol apparatus described by Xing et a l, (1999) (Figure 2.3). Briefly, aerosol 
infection of mice with B. pertussis was performed as follows unless otherwise stated. 
Groups of 10 mice were exposed to aerosols produced from B. pertussis suspension 
by fitting the noses of mice into the 10 nose ports on the metal animal exposure 
section of the aerosol apparatus for a period of 5 min. Five mice from the PBS-
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immunised group were sacrificed under anaesthesia on day 0 o f challenge to 
determine the level of exposure. Mice from the remaining groups were sacrificed on 
day 7 post challenge. The lungs and trachea were removed together and 
homogenised in 1ml 1% (w/v) CAS with a mini-beadbeater (Biospec Products, PA, 
USA) with 2.5-3.5mm glass beads (BDH, Poole, UK) for 10 sec at 4600 rpm at RT. 
Viable counts were then performed on the homogenate by diluting in 1% (w/v) CAS 
across microtiter plates and transferring 4 x 25pi aliquots per dilution onto charcoal 
agar plates, which were then incubated for 5 days at 37°C. Agar plates showing clear 
individual colonies were used for viable count estimates.
2.11.6 Preparation of B. parapertussis suspension for intranasal challenge
B. parapertussis CN5952 was prepared as for B. pertussis, except a final suspension 
of 1.5 X 10  ^cfu/ml was used.
2.11.7 Intranasal infection of mice
Miee were anaesthetised with a volume of 0.05ml/mouse Ketamine mixture (NIBSC) 
injected i.p, followed by an inoculation with a total volume of lOpl/nostril o f B, 
parapertussis suspension containing 1.5 X 10  ^ cfu/ml, using a 20pl pipette. Mice 
were sacrificed under anaesthesia on either day 0 post-challenge for the PBS- 
immunised control group, or day 5 post-challenge for the remaining groups. Viable 
counts were performed as described in section 2.11,5.
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2.11.8 Preparation of mammalian ceils
Peritoneal lavage and spleen removal was performed 14 days post immunisation. 
Macrophage cultures were prepared according the method described by Beckerman et 
a l  (1993). In brief, mice were terminally bled at different times. The peritoneal 
cavity was then lavaged with sterile PBS to recover macrophages. Cells were pooled 
from 5 mice and recovered by centrifugation at 800 x g for 10 min. The cell pellets 
were re-suspended in RPMI medium with L-giutamine (Gibco, UK) supplemented 
with 10 % (w/v) PCS, 1 % (w/v) penicillin and 1 % (w/v) streptomycin, placed in 24- 
well tissue culture plates at 2 X 10  ^ cells per well, and incubated at 37°C under 5 % 
CO2 in 90 % humidity for 2 h. The cells were washed 3 times with the RPMI 
medium to remove non-adherent cells.
Spleen cells were prepared from whole spleens by passing the tissue through a cell 
strainer (Falcon) with sterile PBS. The spleen cell suspension was centrifuged at 
1000 X g for 20 min and pellets re-suspended in PBS and re-centrifuged as before. 
Cell pellets were re-suspended in RPMI medium and placed in 24-well tissue culture 
plates at 2 X 10  ^cells per well.
2.11.9 Culture and treatment of macrophages
Macrophages and spleen cells were cultured in a total volume of 1 ml per well with 
and without 2 X 10*^  heat killed B. pertussis cells/ml as described by Xing et a i, 
(1998) or CyaA antigens at 2 jug/ml in PBS. Cultures were incubated at 37°C under 
5 % CO2 in 90 % humidity for 24 h for macrophages and 48 h for spleen cells. Cell 
viability was checked by Trypan blue exclusion before and after incubation. For this, 
50 j l l I  of 0.2 % (w/v) Trypan Blue solution (Appendix E.2) was added to 50 pi cell 
suspension and incubated for 5 min at RT. Cells that remained clear and had not
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taken up the blue stain were counted using an improved neubauer haemocytometer 
(Webber, UK).
2.11.10 Determination of nitrite production
Nitrite determinations were made on 50 pi volumes of either spleen or macrophage 
cell culture supernatants following treatment as described in section 2.11.9, A 
solution of NaNOi at lOOpM was used to calculate the levels of NO generated. 
Doubling dilutions o f the standard were prepared in sterile H2O and 50pl volumes of 
each dilution were added to one column of a 96-well microtitre plate. The supernates 
and standard dilutions were mixed with 50 pi of Greiss reagent (Appendix E.3), and 
the OD540mii measured after an incubation period of 5 min at room temperature using 
an Anthos ELISA reader (Life Science Int, UK). A standard curve was obtained 
which enabled the calculation o f the nitrite production in the unknown samples.
2.12 RNA ANALYSIS
2.12.1 RNA extraction
The supernates from spleen cells taken from immunised mice were removed after the 
cells had been incubated with or without antigen as described in section 2.11.9. The 
cells were lysed with 500 pi Tri Reagent™ (Sigma) per 2 X 1 0 ^  cells by repeated 
pipetting. After mixing, 200 pi chloroform per ml of Tri Reagent'^'^ was added and 
the solution was then vortexed for 15 sec before being allowed to stand at room 
temperature for 15 min. The resulting mixture was centrifuged at 10,000 x g for 15
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min at 4°C and the upper aqueous layer containing RNA was transferred into fresh 
tubes. The RNA was mixed with 200 pi isopropanol per ml o f Tri Reagent™, 
allowed to stand at room temperature for 10 min, followed by centrifugation at 
13,000 rpm for 10 min at 4°C. The supernate was removed and the RNA pellet 
washed with 1 ml of 75 % ethanol then centrifuged at 13,000 rpm for 5 min. The 
RNA pellet was dried by placing in a hot block at 60°C for approximately 10 min. 
Once diy, the pellet was re-suspended in 10 pi diethyl pyrocarbonate (DEPC)-treated 
water.
2.12.2 First-strand cDNA synthesis using Oligo (dX)
Following RNA extraction, 1 pi of Oligo (dT) (0.5 pg/ml) (Gibco, Life 
Teclmologies) and 1 mM dNTP solution (Gibco, Life Technologies) (containing 
dATP, dCTP, dGTP and dTTP at 1 mM concentration) was added to 10 pi of RNA 
solution and the mixture transferred to a 0.2 ml thin-walled PCR tube. The mixture 
was incubated at 65°C for 5 min and then placed in ice before 9 pi o f reaction mix 
(see below) was added (all components Gibco, Life Technologies). Incubation was 
continued at 42°C for 2 min. To each tube, 1 pi of Superscript™ II Reverse 
Transcriptase (Gibco, Life Technologies) was added and then incubated at 42°C for 
50 min. The reactions were terminated by heating to 70°C for 15 min and then 
chilled on ice. To each tube, 1 pi of RNase H (Gibco, Life Technologies) was added, 
followed by incubation at 37°C for 20 min, before proceeding to the amplification of 
target cDNA by PCR.
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Reaction mix Volume per single reaction
10 X Reverse Transcriptase (RT) buffer 2pi
25 mM MgCh 4 pi
0.1 M D TT 2pl
RNase Out recombinant RNase inhibitor 1 pi
2.13 Polymerase Chain Reaction (PCR)
PCR amplification of cDNA was performed on a Techne thermal cycler (Genius, 
Cambridge Ltd), using cytokine primer pairs (Applied Bio systems, UK) based on 
published sequence data (Appendix Table H). The following mastermix was 
prepared immediately before use (per reaction):
10 X PCR Buffer (minus MgCL) 5 pi
50mM MgCl] 1.5pl
1 OmM dNTP mix Ipl
5’ primer (20pM) Ipl
3’ primer (20pM) Ipl
Taq DNA polymerase 5U/pl (Gibco) 0.4pl
dHzO 38.1pl
Total volume 48pl
2pl of each sample cDNA was added to a 48pl volume of mastermix.
The following thermo cycling parameters were used on each 50pl sample:
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Initial activation step
30 cycles of
Dénaturation
Annealing
Extension
94°C 2 min
95°C
60°C
72°C
30 sec
30 sec
45 sec
Followed by;
Final extension step 72°C 5 min
2.14 IMMUNOLOGICAL METHODS
2.14.1 ELISA (IgG)
ELISA plates (Maxisorp, Nunc) were coated with 100pi per well of antigen (kindly 
supplied by GSK) diluted to 2 pg/ml in coating buffer (Appendix G .l) and incubated 
overnight at room temperature. The plates were then washed 3 times in washing 
buffer (Appendix G.2) containing 0.05% Tween in PBS then blocked with lOOpl of 
diluent per well (Appendix G.3) for approximately 1 h. Plates were washed 3 times 
as above and dried thoroughly by repeated blotting on to paper towels. A volume of 
100 pi of diluent per well was added into the plates from rows B to H and 148.5pi to 
row A. Serum samples in a 1.5 pi volume were added to the wells o f row A, except 
for the first 2 columns, which were used for addition of reference serum containing 
known levels of antisera to PT, FHA and P.69 (97/642, NIB SC) (Gaines Das et a l,  
2001) or diluent as a blank. Samples were mixed and 50 pi was transferred from row
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to row making 3-fold dilutions down the plate (Rows B-H). The last 50 pi from row 
H was discarded and the plates incubated for 2 h at room temperature. Plates were 
washed 3 times as above and lOOpl of Sheep anti-mouse IgG peroxidase conjugate 
(Sigma) at 1:1000 dilution was added per well. Plates were incubated for 2 h at room 
temperature before being washed and dried as above. Substrate solution (Appendix 
G.4.1) in 100 pi volumes was added to all wells and left to develop at room 
temperature for approximately 15 min. The reaction was stopped by the addition of 
50pl of 1 M sulphuric acid per well and the OD450nm was measured in an Anthos 
ELISA plate reader (Life Science Int, UK).
To calculate the titres, the OD450nm reading for each dilution o f mouse sera and 
reference was plotted against the logj reciprocal dilution. This generated a straight- 
line graph to which a trend line, calculated by Microsoft Excel, could be applied. To 
obtain the logs reciprocal dilution (x value) at an OD450nm = 0.5 (cut-off level to 
standardise results), 0.5 was substituted for the y value in the trend line equation. An 
example of the calculation to obtain the logs reciprocal dilution and hence the 
geometric mean is detailed below.
Example (Taken from Fig 3.8.3.1)
Trend lines obtained for 5 mice
y = -1.0603x + 5.2295 ie 0.5 = -1.0603x + 5.2295 .'. x = 4.461 
y = -0.9773X + 5.0399 x = 4.645
y = -0.9l66x + 4.8123 x = 4.705
y = -1.0240x4-5.3238 x = 4.711
y = -0.9354x 4-4.9504 x = 4.758
Geometric mean (GM) = antilog (1/n X Zlog3 reciprical dilution)
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GM = antilog (1/n X 23.28 
= antilog (1/5 X 23.28)
= antilog 4.656 
= 45289.76
When the reference serum containing known levels of antisera to PT, FHA and P.69 
(97/642, NIBSC) was included, a further calculation was performed to obtain the 
ELISA units (EU)/ml.
The trend line for the reference serum was obtained in the same method as detailed 
previously and as before a value of 0.5 was substituted for the y value. The 
following calculation makes use of the same results in the previous example plus a 
further trend line for the reference.
Trend line for reference serum 
y = -1.071x + 3.9851 .'. x = 3.257 
GM = antilog 3.257 
= 1807
GM for unlcnown samples (previous example) = 45289.76
Specific EU/ml for PT, FHA, P.69 = 17, 143, 30 respectively
GM of antibody levels (EU/ml) = GM of unknown samples X specifc EU
GM of refernce serum 
GM of anti-PT IgG = 45289.79 X 17
1807 
= 426.08 EU/ml
2.14.2 ELISA (IgGi and IgGza)
The same procedure as section 2.14.1 for the measurement of IgG was performed 
except that sheep anti-mouse IgG subclass biotin conjugate (Pharmingen) in diluent 
was used in the primary reaction and streptavidin-horseradish peroxidase conjugate
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(Pharmingen) at 1:1000 dilution in diluent was used as secondary antibody. Plates 
were washed 3 times as before followed by the addition o f lOOpl of substrate 
(Sigmafast, tablets of o-phenylenediamine di-hydrochloride (OPD) plus 
urea/hydrogen peroxide, dissolved in 20 ml of sterile distilled water, Sigma) to each 
well for an incubation period in darkness of 20 min. The reaction was stopped by the 
addition of 50pl of 3M HCl per well and the OD492nm was measured in an Anthos 
ELISA plate reader (Life Science Int, UK). 97/642 has only been asigned unitage to 
total IgG and not the subclasses, therefore the specific EU/ml could not be calculated 
and instead only the geometric mean. As for IgG, the geometric mean was calculated 
as follows,
Geometric mean (GM) = antilog (1/n X Zlog3 recipricol dilution)
2.14.3 ELISA (IFNy)
The same procedure as section 2.14.1 for the measurement of IgG was performed 
except that rat anti-mouse IFN-y biotin conjugate (Pharmingen) in diluent was used 
in the primary reaction and streptavidin-horseradish peroxidase conjugate 
(Pharmingen) at 1:1000 dilution in diluent was used as secondary antibody. Plates 
were washed 3 times as before followed by the addition of 100pi of substrate 
(Sigmafast, tablets of o-phenylenediamine di-hydrochloride (OPD) plus 
urea/hydrogen peroxide, dissolved in 20 ml of sterile distilled water, Sigma) to each 
well for an incubation period in darlmess o f 20 min. The reaction was stopped by the 
addition of 50pl of 3M HCl per well and the OD492nm was measured in an Anthos 
ELISA plate reader (Life Science Int, UK).
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CHAPTER 3 
RESULTS
3.1 PREPARATION OF CyaA FROM RECOMBINANT E. coli STRAINS
Recombinant CyaA toxin was produced using the E. coli BL21/DE3 strain (section
2.1). The CyaA pro-toxin and the CyaC protein were expressed in E. coli BL21/DE3 
from two separate compatible plasmids, pGW44 and pGW54 (section 2.1). Co­
expression of cyaA and cyaC in the presence of ImM IPTG in E. coli BL21/DE3 
harbouring both pGW44 and pGW54 resulted in the production of biologically- 
active CyaA. Expression of CyaA without CyaC from E. coli harbouring only 
pGW44, resulted in the production of biologically-inactive (non-acylated) CyaA. 
Active and inactive forms of CyaA, together with CyaC alone, were extracted as 
inclusion bodies that could be solubilised in 8M urea from IPTG-induced cultures of 
BL21/DE3 harbouring the relevant plasmids. The resulting urea extracts of strain 
BL21/DE3 (pGW44), BL21/DE3 (pGW54) and BL21/DE3 (pGW44,54) contained 
predominantly a 200 kDa protein, a 23 kDa protein and both a 200 and 23 kDa 
protein respectively, as shown in Figure 3.1.1. Lane 7 does not appear to show the 
presence of CyaC. This is due to the lower optical density of the culture at the point 
of IPTG-induction and therefore a lower level of expression of both CyaA and CyaC. 
A third compatible plasmid, pGW44/188, encoding the CyaA pro-toxin lacking AC 
activity due to a modification in the N-terminal end, was co-expressed with pGW54 
to produce catalytically inactive CyaA (CyaA*). Urea extraction of BL21/DE3 
(pGW44/188, pGW54) resulted in the production of 200 kDa and 23 kDa proteins as 
the major bands, as for BL21/DE3 (pGW44, pGW54) (Figure 3.1.2).
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3.2 PURIFICATION OF CyaA FROM CRUDE UREA EXTRACTS
Crude extracts of CyaA from E. coli were purified initially by phenyl sepharose 
column clii'omatography alone (Section 2.5.2) (Figure 3.2.1). This method, however, 
was not effective in adequately removing other proteins or breakdown products of 
CyaA found in the crude extract. DEAE sepharose chi*omatography was more 
effective in removing lower molecular weight proteins (Figure 3.2.2). Ultimately a 
combination of DEAE sepharose column chromatography followed by phenyl 
sepharose column chromatography was found to be the best method (section 2.5.1,
2.5.2). Figure 3.2.3 shows the results of combined DEAE sepharose and phenyl 
sepharose column chromatography purification of CyaA from E. coli BL21/DE3 
(pGW44, pGW54), indicating a predominant 200 kDa band along with only a limited 
amount of lower molecular weight proteins. An intermediate step, between DEAE 
sepharose and phenyl sepharose chromatography, was ultimately employed which 
made use of Centricon® centrifugal filter devices (Section 2.5.3). The filters used 
had a molecular weight cut-off of 100 kDa and functioned to concentrate proteins 
greater than this weight (Figure 3.2.4). SDS-PAGE analysis and Western blotting of 
the final purified CyaA with rabbit polyclonal antiserum raised against the 200 kDa 
protein is shown in Figures 3.2.5 and 3.2.6.
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Figure 3.1.1 SDS-PAGE analysis of crude CyaA and CyaC preparations from E. 
coli.
Crude urea extracts, at approximately 2mg/ml in a 50pl volume, from two cultures of E. 
coli expressing CyaA pro-toxin, CyaC or acylated CyaA were subjected to 
electrophoresis on a 10 % polyacrylamide gel and stained with 1% (w/v) Coomassie 
blue solution (section 2.8). Arrows indicate the positions of the molecular weight 
standards.
Lane 1 ; 1 OkDa molecular weight marker
Lanes 2, 3: CyaA pro-toxin from E. coli BL21/DE3 (pGW44)
Lanes 4, 5: CyaC from E. coli BL21/DE3 (pGW54)
Lanes 6,7: CyaA and CyaC from E. coli BL21/DE3 (pGW44,54)
Lane 8: 1 OkDa molecular weight marker
Results
kDa 1 2 3 4 5 6 7 8
2 0 0 — ►
5 0 —► 
4 0 —►
CyaA
30
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Figure 3.1.2 SDS-PAGE analysis of crude non-induced and induced CyaA 
preparations from E. coli.
Crude urea extracts o f CyaA from E. coli BL21/DE3 (pGW44/188, pGW54) and E. coli 
BL21/DE3 (pGW44, pGW54) in a 50pl volume, were analysed by electrophoresis on a 
10% polyacrylamide gel and stained with 1% (w/v) Coomassie blue. Aliquots for each 
preparation were removed from the flask prior to and after induction with IPTG for 3 
hours (non-induced and induced) preparations respectively. Arrows indicate the 
positions of the molecular weight standards.
Lane 1: 1 OkDa molecular weight marker
Lane 2: Non-induced CyaA* from E. coli BL21/DE3 (pGW 44/l88,54)
Lane 3: Induced CyaA* from E. coli BL21/DE3 (pGW 44/l88,54)
Lane 4: Non-induced CyaA from E. coli BL21/DE3 (pGW44,54)
Lane 5: Induced CyaA from E. coli BL21/DE3 (pGW44,54)
Results
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Figure 3.2.1 SDS-PAGE analysis of CyaA fractions prepared by phenyl sepharose 
column chromatography.
A crude urea extract o f recombinant CyaA was purified using phenyl sepharose (section
2.5.2), The initial crude extract and aliquots from the column washes and elutions in a 
50pi volume, were subjected to electrophoresis on a 10% polycacrylamide gel and 
stained with 1% (w/v) Coomassie blue. Arrows indicate the position of the molecular 
weight standards.
Lane 1:
Lane 2:
Lane 3 :
Lane 4:
Lane 5:
Lanes 6, 7, 8:
Lanes 9, 10, 1 
Lanes 12,13:
Broad range molecular weight marker
Crude CyaA from E. cf?/z BL21/DE3 (pGW44,54)
Flow-thi'ough from equilibrated column
Flow-through from first column wash
Flow-tlirough from second column wash
First, second and third fractions eluted with 500mM NaCl
(Solution B; Appendix C.4.3)
Fourth, fifth and sixth fractions eluted with 25OmM NaCl 
Seventh and eighth fractions eluted with 8M urea without NaCl
Results
kDa 1 2 3 4 5 6 7 8 9 10 11 12 13
250
37
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Figure 3.2.2 SDS-PAGE analysis of CyaA fractions prepared by DEAE sepharose 
column chromatography.
A crude urea extract of recombinant CyaA was purified using DEAE sepharose (section
2.5.1). The initial cmde extract and aliquots from the column wash and different 
elutions in a 50pi volume, were subjected to electrophoresis on a 10% polycacrylamide 
gel and stained with 1% (w/v) Coomassie blue. Arrows indicate the position o f the 
molecular weight standards.
Lane 1:
Lane 2:
Lane 3:
Lanes 4, 5 :
Lanes 6, 7: 
Lanes 8, 9: 
Lanes 10, 11: 
Lanes 12, 13:
Broad range molecular weight marker
Crude CyaA from E. coli BL21/DE3 (pGW44,54)
Flow-tlri'ough from column wash
First and second fractions eluted with 250mM NaCl (Buffer 3; 
Appendix C.3.4)
Third and fourth fractions eluted with 500mM NaCl 
Fifth and sixth fractions eluted with IM  NaCl 
Seventh and eighth fractions eluted with 1.5M NaCl 
Ninth and tenth elution eluted with 2M NaCl
00
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Figure 3.2.3 SDS-PAGE analysis of CyaA fractions prepared by phenyl sepharose 
column chromatography after purification by DEAE sepharose 
column chromatography.
The sixth and seventh elution fractions from the previous CyaA purification using 
DEAE sepharose (Figure 3.2.2) were pooled together and subjected to phenyl sepharose 
column clii’omatography. Aliquots in a 50pl volume from each elution fraction were 
subjected to electrophoresis on a 10% polyacrylamide gel and stained with 1% (w/v) 
Coomassie blue solution. Arrows indicate the positions of the molecular weight 
standards.
Lane 1:
Lanes 2, 3, 4, 5;
Lanes 6, 7, 8, 9:
Lanes 10, 11, 12, 13, 14, 15:
Broad range molecular weight marker
First to fourth fractions eluted with 500mM NaCl
(Solution B; Appendix C.4.3)
Fifth to eighth fractions eluted with 25OmM NaCl 
Ninth to fourteenth fractions eluted without NaCl
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Figure 3.2.4 SDS-PAGE analysis of concentrated CyaA prepared by 
centrifugation with Centricon® centrifugal filter devices.
CyaA preparations purified by DEAE sepharose and phenyl sepharose chromatography 
were concentrated further using Centricon® centrifugal filter devices (section 2.5.3). 
Aliquots of 50pl volumes from the concentrated retentate and the residual filtrate were 
subjected to electrophoresis on a 10% polyacrylamide gel and stained with 1% (w/v) 
Coomassie blue solution. Arrows indicate the positions of the molecular weight 
standards.
Lane 1 : Broad range molecular weight marker
Lane 2: Retentate of purified CyaA from & coli BL21/DE3 (pGW44)
Lane 3: Filtrate of purified CyaA from E. coli BL21/DE3 (pGW44)
Lane 4: Retentate of purified CyaA from E. coli BL21/DE3 (pGW44/l 88,54)
Lane 5: Filtrate of purified CyaA from E. coli BL21/DE3 (pGW44/l 88,54)
Lane 6: Retentate of purified CyaA from E. coli BL21/DE3 (pGW44,54)
Results
kDa 1 2 3 4 5 6
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Figure 3.2.5 SDS-PAGE analysis of purified CyaA prepared by DEAE and phenyl 
sepharaose column chromatography, Centricon® column
centrifugation and a further phenyl sepharose column
chromatography stage.
CyaA preparations retained in the Centricon® columns after centrifugation were 
purified by a final phenyl sepharose column chromatography step. The eluted fractions 
in a 50pl volume were subjected to electrophoresis on a 10% polyacrylamide gel and 
stained with 1% (w/v) Coomassie blue solution. Arrows indicate the position o f the 
molecular weight standards.
Lane 1 : Broad range molecular weight marker
Lane 2: Purified CyaA from E. coli BL21/DE3 (pGW44)
Lane 3: Purified CyaA from E. coli BL21/DE3 (pGW44/l 88,54)
Lane 4: Purified CyaA from E. coli BL21/DE3 (pGW44,54)
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Figure 3.2.6 Western blot analysis of purified CyaA preparations using anti-CyaA 
polyclonal antiserum.
CyaA preparations purified by DEAE and phenyl sepharose column chromatography 
and Centricon® centrifugation methods as described in the legend to Figure 3.2.5 were 
subjected to electrophoresis on a 10% polyacrylamide gel and transferred to Hybond-C 
nitrocellulose membrane (section 2.9.1). The nitrocellulose blots were probed with 
rabbit anti-CyaA polyclonal antibody (section 2.9.2). Arrows indicate the position o f the 
molecular weight standards.
Lane 1 : Broad range molecular weight marker
Lane 2: Purified CyaA from E. coli BL21/DE3 (pGW44)
Lane 3: Purified CyaA from E. coli BL21/DE3 (pGW 44/l88,54)
Lane 4: Purified CyaA from E. coli BL21/DE3 (pGW44,54)
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3.3 SUMMARY OF SDS-PAGE ANALYSIS
CyaC produced from plasmid pGW54 migrated on a 10% polyacrylamide gel at 
approximately 23kDa and CyaA proteins at approximately 200kDa (Figure 3,1.1). 
Crude urea extracts displayed additional bands that indicated the presence of 
contaminating proteins or CyaA degradation products. The majority of these were 
eliminated by further purification using DEAE and phenyl sepharose column 
clu'omatography followed by Centricon® concentration (Figure 3.2.5) and a further 
phenyl sepharose chromatography step. The three different preparations of CyaA 
(CyaA pro-toxin, CyaA* and CyaA) displayed very similar banding patterns on 
polyacrylamide gels although the extent of purification varied a little between 
preparations.
3.4 SUMMARY OF WESTERN BLOTTING
All purified CyaA proteins, when probed with anti-CyaA polyclonal antibody, 
displayed a major band at approximately 200kDa, although some minor bands were 
also detected at lower molecular weights (Figure 3.2.6), Given that the proteins had 
been through several purification procedures, the minor bands were likely to 
represent CyaA degradation products.
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3.5 CHARACTERISATION OF CyaA TOXINS
3.5.1 Adenylate cyclase enzymic activity
Adenylate cyclase (AC) activity of purified urea extracts from E. coli BL21/DE3 
(pGW44) (CyaA pro-toxin, non-acylated), E. coli BL21/DE3 (pGW44/188, pGW54) 
(CyaA*, acylated) and E. coli BL21/DE3 (pGW44, pGW54) (CyaA, acylated) were 
determined by two methods, the conventional ^^aP-ATP radioactive assay and a 
novel conductimetric assay (section 2.10.3, 2.10.4). The conductimetric assay can 
produce greater deviations between replicate assays, particularly when the enzymic 
activity is high. The results (Figure 3.5.11) show both CyaA pro-toxin and CyaA to 
be enzymically active as expected. The CyaA* toxin has a dipeptide amino acid 
insertion within the ATP binding site, and therefore should lack AC enzymic 
activity. This preparation did in fact demonstrate a very low, almost negligible value 
for cAMP production, presumably indicating a basal level of enzymic activity with 
some degree of experimental error in the measurement at such low levels.
3.5.2 Haemolytic activity of CyaA preparations on turkey erythrocytes
The haemolytic activities of purified CyaA pro-toxin, CyaA and CyaA* toxins were 
determined using turkey erythrocytes (section 2.10.1). Both forms of the acylated 
CyaA toxin showed a similar pattern of haemolysis (Figure 3.5.2) although the data 
in Figure 3.5.2 demonstrates the weak haemolytic nature of this toxin, as 50% 
haemolysis is only produced at protein concentrations of 30-40 pg/ml after 
incubation with erythrocytes for 24 hours (Figure 3.5.2; Table 3.5).
104
Results
Figure 3.5.1
Comparison of CyaA adenylate cyclase enzymic activity from different toxin 
preparations
Enzymic activity in purified CyaA preparations was determined by two different 
methods, the conventional ^^aP-ATP radioactive assay and a novel conductimetric 
assay. Enzymic activity was measured in duplicate for each sample and the results 
represent the mean ± standard deviation for each method.
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Figure 3.5.2
Percentage haemolysis of turkey erythrocytes by CyaA preparations
The haemolytic activities o f the two purified CyaC-acylated proteins were 
determined in two fold serial dilutions using turkey erythrocytes. Percentage 
haemolysis was measured in triplicate for each sample and the results represent the 
mean ± SEM.
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3.5.3 Cytotoxic activity of CyaA preparations on J774.2 macrophage cells
The effect of purified CyaA pro-toxin, CyaA* and CyaA preparations on cell killing 
o f J774.2 mouse macrophage-derived cells was determined by the MTT dye 
reduction assay (section 2.10.2) (Table 3.5, Figures 3.5.3.1 and 3.5.3.2). CyaA pro­
toxin is non-acylated and no cell killing was observed, as expected. CyaA 
demonstrated a high level of cytotoxic activity, which is in keeping with its enzymic, 
haemolytic and invasive activities. The N-terminally modified CyaA* toxin, with 
little AC enzymic activity, demonstrated some cytotoxicity at the highest protein 
concentrations tested. The possibility that this may have been due to an effect of 
urea in the prepai'ation was excluded by the results obtained using CyaA pro-toxin. 
Both toxins were prepared in the same way and both contained the same 
concentration of urea, indicating that the cytotoxic effect of CyaA* on the cells was 
indeed a true reflection of the ability of this A C  protein to kill J774.2 cells at high 
protein concentrations. The results of this assay would imply that cell killing by 
CyaA toxin is due mainly to the intrinsic AC activity of the protein. If this activity is 
removed, only residual toxicity is observed (100-fold less, Table 3.5), perhaps due to 
the very low, residual AC activity of the protein or, more likely, to its pore-forming 
activity as shown by haemolysis.
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Figure 3.5.3.1 Cytotoxic activity of CyaA preparations on J774.2 mouse 
macrophage cells
The cytotoxic activity o f the purified CyaA preparations was determined by the MTT 
dye reduction assay using mouse macrophage-derived J774.2 cells. The percentage 
cell viability at different CyaA protein concentrations was determined using 
duplicate samples (Section 2.11.9) and the results represent the mean absorbance at 
each dilution ± standard deviation.
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Figure 3.5.3.2 Demonstration of the MTT reaction
The MTT dye reduction assay was used to demonstrate the cytotoxic activity o f 
CyaA on J774.2 mouse macrophage cells. Viable cells are indicated by the purple 
colour. Cells which have been incubated with the enzymic, invasive form o f CyaA, 
are yellow, as the cells have been killed and were unable to convert the MTT to the 
purple formazan, following the reduction o f the tétrazolium dye (Section 2.11.9).
Rows A+B: CyaA pro-toxin from E. coli BL21/DE3 (pGW44)
Rows C+D: CyaA from E. coli BL21/DE3 (pG W 44/188,54)
Rows E+F: CyaA from E. coli BL21/DE3 (pGW 44,54)
Row G (wells 1+2): RPMI medium only
All wells contain J774.2 mouse macrophage cells at 5 X 10  ^ cells/ml and rows A-F 
contain doubling dilutions o f the toxin starting at a protein concentration o f 65|Ltg/m l. 
Each dilution is done in duplicate.
on-
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3.5.4 Summary of characterisation of CyaA preparations
The different preparations were subjected to 4 different assays, to investigate 
adenylate cyclase enzymic activity, haemolytic and cytotoxic activities. Two 
different methods were investigated to assay enzymic activity, the conventional 
^^aP-ATP radioactive assay and a novel conductimetric assay. Although the results 
for the 2 assays were not identical the overall pattern was similar. In preparations 
where greater amounts of cAMP were likely to be produced, measurement by the 
conventional method appeared to be more consistent as deviations between replicate 
samples were lower. However, the conductimetric assay is quicker and easier and is 
a good indication of whether AC activity is present or absent and is probably better 
suited for samples producing lower amounts of cAMP, as at these levels the 
deviations between replica samples were much smaller. The results in Table 3.5 
show both CyaA pro-toxin and CyaA to be enzymically active and CyaA* to be only 
very slightly enzymically active.
The haemolytic activity was recorded as the amount of protein required to give 50% 
haemolysis of turkey red blood cells. CyaA pro-toxin was expected to be non-pore 
forming and, in fact, no haemolysis was detected. Both forms of CyaA gave similar 
levels of haemolysis, albeit very weak, indicated by the high protein concentrations 
required to obtain 100% haemolysis in 24 hours (Figure 3.5.2).
The cytotoxic nature o f CyaA preparations was recorded as the amount of protein 
required for 40% killing of J774.2 macrophage cells in vitro in 4 hours. CyaA pro­
toxin is non-acylated and therefore should be non-invasive, and, in fact, no cell 
killing was observed. CyaA was found to be highly cytotoxic, whereas CyaA* had 
only a degree of cytotoxicity at high protein concentrations.
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Table 3.5: Properties of different CyaA preparations from E. coli
Preparation AC activity 
(pmol
c AMP. min/mg 
protein) 
^^aP-ATP 
radioactive 
assay ^
Enzymic 
activity (pmol 
c AMP. min/mg 
protein) 
Conductimetric 
assay ^
Haemolytic 
activity (pg 
protein/ml 
required for 
50% haemolysis 
of turkey red 
blood cells) ^
Cytotoxic 
activity (pg 
protein/ml 
required for 40% 
killing of J774.2 
macrophage 
cells) ^
CyaA pro­
toxin
169.53 + 6.46 118.80 + 7.87 not measured non-cytotoxic
CyaA* 2.18 ±0.60 1.84 + 0.36 42.15 ±0.42 58.50 ± 1.98
CyaA 453.49 ± 1.51 194.46 ±54.60 30.83 ±0.90 0.51 ±0.06
Results are the mean values ± standard deviation of 2 determinations 
 ^Results are the mean values ± SEM of 3 determinations
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3.6 ENDOTOXÏN REMOVAL FROM CyaA PREPARATIONS
LPS is the term used to refer specifically to the endotoxin component of the outer 
membrane in Gram-negative bacteria. Outer membrane LPS is a complex molecule 
consisting of 3 covalently linlced regions. Lipid A is a glycolipid that is largely 
responsible for the endotoxic activity of LPS and for the ability of LPS to act as a 
polyclonal activator. Core oligosaccharide is a complex oligosaccharide usually 
United to lipid A via 2-keto-3-deoxyoctonate (KDO) and the 0-specific chain is the 
immunodominant part of the LPS molecule (Section 1.4.8).
The Limulus amoebocyte lysate test (LAL test) is commonly used for the detection 
and quantification of LPS. The test depends on the ability of minute amounts of LPS 
to cause gelation of a lysate of the amoebocytes from the horse-shoe crab, Limulus 
polyphemus. In preliminary studies, all CyaA preparations were found to be highly 
contaminated with endotoxin as measured by the LAL test (Table 3.6), a fact that 
represented potentially serious problems for any immunological studies, due to the 
loiown immunostumulatory properties o f LPS. Different approaches for endotoxin 
removal were considered.
3.6.1 Affi-Prep® polymyxin matrix as a method of endotoxin removal
The Affi-Prep polymyxin support (Bio-Rad) consists o f polymeric macroporous 
beads with polymyxin B covalently attached. The main application of this support is 
the removal of endotoxin molecules from biological solutions by affinity 
chromatography. CyaA protein solutions in PBS were allowed to permeate through 
the affinity column (section 2.6.1) but, on final analysis by the LAL test, the samples
112
Results
showed no significamt reduction in endotoxin levels, only a slight reduction in 
protein concentration.
3.6.2 Size exclusion chromatography as a method of endotoxin removal
LPS molecules consist o f monomers with a molecular mass ranging between 10 and 
20 kDa, but these normally form very stable aggregates, either in the form of 
micelles, with a molecular mass of between 300 and 1000 kDa, or vesicles which can 
have a mass greater than lOOOkDa. Aggregation is mediated by non-polar 
interactions between the alkyl chains as well as by bridges among negatively-charged 
phosphate groups and bivalent cations. Size exclusion chromatography (section 
2.6.3) was thought to be good candidate to remove the larger LPS aggregates, but no 
reduction in endotoxin content was obtained, indicating that perhaps the size of the 
aggregates was similar in size to CyaA or that the LPS was tightly bound to CyaA 
and could not be separated by size exclusion.
3.6.3 Addition of detergent as a method of endotoxin removal
Above the critical micelle concentration (CMC) of detergents, endotoxins can be 
accommodated in the micelle structure. In this way, detergents are able to aid in the 
disruption of larger LPS structures, vesicles and micelles, and also break protein-LPS 
links formed via calcium bridges or hydrophobic interactions. Triton X-114 was 
used to investigate this property (section 2.6.2). Triton X-114 is miscible with water 
and, at a temperature of 22°C, known as the cloud point, the detergent micelles 
aggregate. At a temperature of 4°C, the detergent is able to separate the protein and
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LPS molecules and, at temperatures above the cloud point, the solution separates into 
aqueous and detergent-enriched phases (Aida and Pabst, 1990). CyaA was expected 
to be present in the aqueous phase but no phase separation was observed and as a 
result of this, further endotoxin analysis could not be completed, as CyaA was 
contaminated with Triton X-114, which in turn inhibited the LAL test.
3.6.3 END-X® B15 resin as a method of endotoxin removal
END-X® B15 is an immobilised affinity resin for the removal o f Gram-negative 
bacterial endotoxins. The affinity ligand is the endotoxin-neutralising protein from 
L  polyphemus (one of the proteins present in the cascade reaction in the LAL test 
involved in gelation) and coated silica microspheres are the support. END-X® B 15 
resin was tested as a method of endotoxin removal (section 2.6.4) but was unable to 
reduce the endotoxin content of the CyaA preparations, presumably due to the high 
initial concentrations of endotoxin present in the samples, even after CyaA had been 
diluted, thereby leading to saturation of the resin. Unfortunatley the resin is supplied 
pre-packed in a micro-centrifuge tube and therefore no additional resin can be added 
to prevent saturation, and larger tubes with more resin were not available at the time 
of the investigation.
114
Results
3.6.4 Summary of endotoxin removal methods
Purified CyaA pro-toxin, CyaA* and CyaA were all found to contain high levels of 
endotoxin which in turn would hamper any immunological studies performed in the 
future. Methods were performed to try and reduce the endotoxin levels in each 
preparation but these all proved unsuccessful, suggesting that the endotoxin was 
tightly bound to CyaA or was forming micelles of a similar size, thereby hindering 
any size exclusion chromatography. The endotoxin content of each sample 
preparation and the amount present in a 15pg immunisation dose, is given in Table 
3.6. To overcome the problem presented by endotoxin contamination, an E. coli 
endotoxin standard (NIBSC, 94/580) was made available for immunological studies, 
along with a second control of boiled CyaA. Boiling the CyaA protein would 
denature the toxin but not inactivate the LPS, therefore acting as a suitable control. 
A value of 350 iu/ml o f LPS was chosen for the control as this was an approximate 
average value between the endotoxin levels calculated for CyaA and CyaA* 
preparations and was used subsequently in vaccination experiments.
Table 3.6: Endotoxin content of different CyaA preparations
Preparation Endotoxin content per ml Endotoxin content per 
ISpg protein
CyaA pro-toxin 90,000 iu/ml 3857 iu
CyaA* 18,000 iu/ml 450 iu
CyaA 9,000 iu/ml 208 iu
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3.7 IMMUNOLOGICAL PROPERTIES OF CyaA
The immunological properties o f CyaA were investigated by firstly studying the 
effects that were generated when mice were vaccinated with different purified CyaA 
preparations. Specific IgG antibody levels at different time points following CyaA 
immunisation, protective abilities of the CyaA preparations in mice following aerosol 
challenge with B. pertussis and cytokine expression were measured.
3.7.1 Mouse IgG antibody responses to CyaA preparations
ELISAs were used to determine the antibody response from mice immunised with 
15pg doses of protein. The mice were divided into two sets of four groups of five 
mice and each group received 0.5ml i.p of PBS, CyaA pro-toxin, CyaA* or CyaA 
preparations. Tail bleeds were taken at two, four and seven weeks post immunisation 
and a terminal bleed was done at 9 weeks from the first set of mice. The second set 
were boosted with an additional 15pg dose at seven weeks post immunisation and 
tail bleeds taken at 9 and 11 weeks before being terminally bled at 14 weeks post 
immunisation. Anti-CyaA IgG levels were determined by ELISA at each time point 
(section 2.14.1). The geometric mean titre of antibody to each antigen was 
calculated as described in Section 2.14.1
An example of the graph used to calculate the geometric mean titre is given in Figure
3.7.1.1 and the raw data in Appendix H .l. Substituting 0.5 for the y value in the 
trend lines shown in Figure 3.7.1.1 gives 3 values that can be used in the equation to 
obtain the geometric mean of the antibody titres. Figure 3.7.1.2 shows the geometric 
mean of the antibody titre at OD450nm 0.5 and it can be seen that there is a difference 
in the pattern of results obtained with each CyaA preparation. CyaA pro-toxin
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appears to generate an early anti-CyaA IgG response, apparent from the very first 
time point, whereas CyaA* and CyaA generate a more gradual increase in the 
antibody levels. There is no obvious reason as to why this should occur, as although 
the response being measrned is to the active, acylated CyaA toxin and not 
specifically to the non-acylated pro-toxin cross-reaction should occur with the 
polyclonal anti-CyaA sera. One possibility could be related to the toxicity exhibited 
by the acylated forms of CyaA, which might, interfere with antigen presentation, by 
macrophages or dendritic cells. Alternatively, it could be that the non-acylated, non­
active toxin is more immunogenic than the acylated form, although by 9 weeks the 
antibody levels were lower for the pro-toxin than acylated forms 
The effect of boosting is shown in Figure 3.7.1.3. A significant increase in anti- 
CyaA IgG production was seen two weeks after a further dose o f 15pg o f each 
protein was given, indicating a good memory response. This increased up to 4 weeks 
post-boost with pro-CyaA and CyaA* but only up to 2 weeks post-boost with CyaA, 
before the levels started to decrease. The highest anti-CyaA IgG responses were 
generated by the 2-dose immunisations with CyaA*, followed by CyaA pro-toxin, 
and the poorest responses were generated with CyaA itself.
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Figure 3.7.1.1
Example of calculation of anti-CyaA IgG antibody production in response to 
immunisation with CyaA preparations
Female NIH mice were vaccinated intraperitoneaily with 15pg o f pro-CyaA 
(prepared from pGW 44) in PBS as described in Section 3.7.1. Anti-CyaA IgG levels 
were determined by ELISA (section 2.13.1) using CyaA (prepared from pGW 44,54) 
as the coating antigen at a concentration o f  2|ig/ml. The absorbance at 450nm was 
recorded and the results for each dilution o f the sera plotted using a log scale to 
enable the drawing o f a trend line. The results o f the ELISA for mice immunised 
with CyaA pro-toxin at a time point o f 7 weeks is shown. The trend lines for three 
different mice from one group were used to interpolate the graph at a cut o ff point o f 
OD 4 5 0 nm 0.5 and obtain the geometric mean
y =-0.852x4-3.6047
log3 reciprocol dilution (x) = 3.644
Geometric mean (GM) = antilog ( l/n  X Zlog3 reciprical dilution)
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Figure 3.7.1.2
Time course showing the geometric mean of anti-CyaA IgG antibody titres
Anti-CyaA IgG levels for mice immunised with a single dose o f 15|ig o f either CyaA 
pro-toxin, non-enzymic CyaA* and CyaA were determined at different time points 
over 9 weeks. Tail bleeds were taken at each time point to perform ELISAs using 
CyaA as a coating antigen (section 2.13.1). The geometric mean o f the antibody titre 
for each CyaA preparation at different time points was calculated from the trend lines 
for each serum OD 4 $onm 0.5, as described in Figure 3.7.1.1.
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Figure 3.7.1.3
Effect of boosting on the anti-CyaA IgG antibody titres in response to 
immunisation with different CyaA preparations
The geometric mean titres were calculated as for Figure 3.7.1.1. Mice received a 
second immunisation o f 15|ig o f protein at 7 weeks post immunisation and tail 
bleeds were taken at 9, 11 and 14 weeks.
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3.7.1,1 Neutralisation effect of anti-CyaA sera on the cytotoxicity of CyaA
Sera obtained from tail bleeds at 7 weeks post immunisation from mice immunised 
with a single dose o f 15|Lig o f either CyaA* or CyaA preparations (section 3.7.1), 
were used to investigate any possible neutralisation of the cytotoxicity of CyaA on 
macrophage cells in vitro. The serum samples were pooled for each group of mice 
and then diluted in RPMI medium in doubling dilutions. A volume of 50)li1 of 
diluted sera, starting at 1:2 dilution, was added to a 50pi volume of CyaA toxin at 
65pg/ml and incubated for 1 hour at 37°C prior to the addition to J774.2 macrophage 
cell suspension in 96-well plates. The cytotoxicity was evaluated by MTT assay 
(section 2.10.2). Figure 3.7.1.1.1 shows a photograph of the tissue culture plate at 
the end of the reaction and Appendix H.2 details the raw data. Rows A and B 
contain CyaA toxin alone, starting at an initial dilution of 1 in 20 in RPMI medium, 
equivalent to a concentration o f 65pg/ml in the first well, and followed by a 2-fold 
dilution across rows A and B in duplicate for each dilution. The yellow colour 
across row A and at the start of row B is indicative of the cytotoxic nature of CyaA, 
which gradually decreases as the toxin becomes more dilute. Rows C and D contain 
the doubling dilutions of sera, taken at 7 weeks after a single dose, from PBS- 
immunised mice mixed with CyaA toxin at 65pg/ml in all wells. The continuous 
yellow colour throughout the wells confirmed that sera from PBS-immunised mice 
had no capacity to neutralise the cytotoxic effects of CyaA. Rows E and F contain 
the doubling dilutions of sera from CyaA*-immunised mice in duplicate with CyaA 
toxin at 65pg/ml in all wells. The first 4 wells of row E gave a purple colour, 
indicative o f a non-cytotoxic response, the same as shown by the control wells that 
contained only J774.2 macrophages (HI 1 and H12). Row H, wells 9 and 10 were
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left blanlt to enable the control wells to be clearly identified. Rows G and H (except 
H9-12) contain the doubling dilutions of sera from CyaA-immunised mice in 
duplicate with CyaA toxin at 65pg/ml. The results are similar to those for CyaA* 
except that the 6 wells of Row G are purple, indicating that the sera from CyaA- 
vaccinated mice had a slightly stronger neutralising capacity. These results prove 
that antibodies generated from mice immunised with either CyaA or CyaA* were 
able to neutralise the cytotoxicity o f CyaA on J774.2 macrophage cells in vitro. It 
was interesting to note that the antibodies generated to CyaA showed more 
neutralisation activity (down to a dilution factor of 1:8) than those generated to 
CyaA* (down to a dilution factor o f 1:4), which is in agreement with the data in 
Figure 3.7.1.2 where at 7 weeks post-immunisation anti-CyaA IgG levels were 
highest in mice vaccinated with a single dose of CyaA compared to those given 
CyaA*.
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Figure 3.7.1.4 Visualisation of the neutralisation effect of anti-CyaA sera
on the cytotoxicity of CyaA
The MTT dye reduction assay was used to demonstrate the cytotoxic activity o f 
CyaA on J774.2 mouse macrophage cells (Section 2.11.9). The neutralisation effect 
o f anti-CyaA serum was demonstrated by the addition o f immune sera to cells 
containing the cytotoxic CyaA.
Rows A + B: CyaA from E. coli BL21/DE3 (pGW 44,54)
Rows C + D: CyaA plus serum from PBS-immunised mice
Rows E + F: CyaA plus serum from CyaA*-immunised mice
Rows G + H: CyaA plus serum from CyaA-immunised mice (except H9-12)
H9 + H 10: CyaA only at 65pg/ml
H 1 1 + H 1 2 :  RPMI medium only
All wells contain J774.2 mouse macrophage cells at 5 X 10  ^ cells/ml. Rows C-H 
contain CyaA at 65pg/ml plus the relevant serum starting at a neat concentration 
followed by doubling dilutions in duplicate.
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3.7.2 Mouse protection with CyaA preparations
The different CyaA preparations were examined for their ability to protect mice 
against aerosol challenge with B. pertussis 18.323. Previous work carried out by 
Hormozi et al. (1999) showed that the active, acylated CyaA toxin was protective 
following intranasal challenge with B. pertussis, as indicated by the low lung weight 
and low cfu present in the lungs. The non-acylated CyaA protoxin was unable to 
protect and mice immunised with the preparation showed large, inflamed lungs and 
high bacterial counts after challenge. For this reason, only acylated CyaA toxins 
were examined in this study. The mice were immunised (ip) with two 25pg doses at 
a 4 week interval, with either CyaA* or CyaA, and subjected to a sublethal challenge 
from a suspension containing approximately 10  ^ cfu/ml B. pertussis 18,323 two 
weeks after the second immunisation (section 2.14.4 and 2.14.5). Five mice from the 
PBS immunised groups were sacrificed on day 0 post-challenge and the remainder 
from all groups were sacrificed at day 7 post-challenge and the lungs and trachea 
removed together, to estimate B. pertussis colonisation (section 2.14.4). Figure
3.7.2.1 shows the results of the combined lung and tracheal counts. From this it can 
be shown that the mean counts on day 0 for the PBS-immunised group were 
5.12xlO \ rising to 7.88x10^ on day 7 post-challenge. The day 7 post-challenge 
counts for CyaA- and CyaA*-immunised mice were 1.05x10^ and 3.15x10"^ 
respectively, indicating between a 1.5- and 2 log difference in colony numbers when 
compared with PBS-control mice. Although it appeared that CyaA* afforded a 
slightly better protection against colonisation than CyaA, there was no statistical 
significance at either the 5% or 10% student t-test level between CyaA- or CyaA*- 
immunised groups.
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A further experiment using the same conditions was conducted to further confirm the 
protective effect of CyaA preparations by using a different B. pertussis challenge 
strain. B. pertussis W28 is a less virulent strain than B. pertussis 18.323 and this is 
reflected in the results shown in Figure 3.7.2.2. In this experiment only the 
enzymically inactive, acylated CyaA* preparation was used and again the same 
pattern of an approximate 1 -2 log difference in cfu is observed after vaccination.
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, Figure 3.7.2.1
Mouse protection with CyaA preparations against aerosol challenge with E. 
pertussis 18.323
The protective activities o f the two acylated forms o f CyaA were examined in mice 
after an aerosol challenge with B. pertussis 18.323. Two groups o f 5 mice received 
either 25pg (ip) o f CyaA or CyaA* and 1 group o f 10 mice received PBS as a 
control. At 4 weeks post immunisation, the groups all received a second injection 
and 2 weeks later were subjected to an aerosol challenge o f B. pertussis 18.323 
(section 2.11.5). The lungs and trachea were removed from 5 mice o f the PBS group 
on the day o f challenge and at day 7 post-challenge the remainder o f the groups were 
sampled. Viable counts were performed on the combined lung and trachea 
homogenates and the mean log colony forming units (cfu) plotted at day 7 post­
challenge for each group.
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Figure 3.1.2.2
Mouse protection with CyaA preparations following aerosol challenge with B. 
pertussis 18.323 or B. pertussis W28
Two groups o f 10 mice were immunised with either PBS or a single dose o f 25jUg 
CyaA* and then further divided to give 4 groups. At 4 weeks post-immunisation all 
groups received a second injection. Two weeks later one PBS-immunised group and 
one CyaA*-immunised group, were subjected to an aerosol challenge o f 8. pertussis
18.323. The other two groups were subjected to an aerosol challenge o f B. pertussis 
W28. The mean lung and trachea log cfu was plotted at day 0 post-challenge for the 
PBS-immunised mice and at day 7 post-challenge for the remaining groups to 
investigate the difference in colonisation between the two B. pertussis strains.
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3.7.3 Production of nitric oxide by macrophages from mice immunised with 
CyaA preparations
Nitric oxide (NO) is known to be an important regulator of the immune system and 
inflammatory cells including monocytes produce NO following incubation with 
bacteria and cytokines. Recently Xing et al. (1998) demonstrated that NO 
production served as a marker of macrophage activation in mice immunised with 
WCV. NO production from peritoneal macrophages obtained from groups of 5 mice 
immunised with a single 15pg dose o f different CyaA preparations, was studied at 
day 14 post-immunisation (section 2.11.8, 2.11.9 and 2.11.10). In this experiment, 
control mice were immunised with either 15pg of boiled CyaA or 175 iu o f purified 
LPS from E. coli. From the results shown in Figure 3.7.3 and Appendix H.3, it can 
be seen that when B. pertussis heat-killed cells were used as the in vitro re-stimulant 
the levels of NO production did increase even from eontrol macrophages, although it 
is clear that immunisation with CyaA did not result in any significantly greater NO 
production when compared with the control groups of either PBS-or LPS-immunised 
mice.
3.7.4 Cytokine mRNA expression in mice immunised with CyaA preparations
Cytokines are important in modulating host responses to invasion by pathogens and 
therefore the detection and analysis of cytokine production can provide a greater 
understanding of the immune responses. RT-PCR technology is based upon the 
amplification of cDNA derived from mRNA extracted from cells o f immunised 
mice. Cytokine-specific primers enable the amplification of cDNA samples to levels 
that can be visualised by agarose gel electrophoresis. Spleen cell cultures were
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obtained from mice immunised with CyaA preparations and also control groups of 
mice immunised with boiled CyaA and E. coli LPS. They were re-stimulated in vitro 
with either B. pertussis heat-killed cells or CyaA* (section 2.11.9). Following RNA 
extraction and first strand cDNA synthesis (section 2.12), PCR amplification was 
performed using primers specific for IFNy, IL-2 and IL-4 as well as (3-actin. The 
intensities of the cytokine-specific amplicons were compared with the level o f P~ 
actin, a housekeeping gene that is known to have a constant level of expression 
(Walker, 1998), thus normalising for differences occurring between different samples 
and preparations.
Figure 3.7.4.1 shows an example of an agarose gel after PCR amplification of p- 
actin, IFNy, IL-2 and IL-4 from different spleen cell preparations stimulated in vitro 
with B. pertussis heat-killed cells. It can be seen that the amplicon intensity for p- 
actin varied between 3 separate spleen cell mRNA preparations (Figure 3.7.4.1, lanes 
2, 6 and 10). Digital analysis using Kodak ID gel analysis software produces a 
numerical value of the PCR product intensity as a percent of the P-actin intensity 
(Appendix H.4).
Figure 3.7.4.2 displays a difference in cytokine response of spleen cells from mice 
immunised with CyaA* or CyaA. CyaA* leads to a mixed Thl/Tli2 response, as 
indicated by the high levels of all 3 cytokines, whereas immunisation with CyaA 
shows a Thl bias, as indicated by higher IFNy and IL-2 levels and low IL-4 
produetion. Surprisingly, stimulation of spleen cells with lilcc from LPS-immunised 
mice produced very little cytokine mRNA response, although it should be noted that 
the LPS used in immunisations was from E. coli and the spleen cells were stimulated 
with B. pertussis heat killed cells. The concentrations of LPS used for immunisation, 
was similar to that present in CyaA preparations. The results could indicate that the
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cytokine profile found in the CyaA and CyaA* groups were not caused by the LPS 
contamination of these preparations.
Figure 3.7.4.3 demonstrates how stimulation of spleen cells in vitro with CyaA* 
produced almost no increase in cytokine production from mice immunised with 
CyaA* but much higher levels of all 3 cytokines from mice immunised with CyaA. 
No firm conclusions can be drawn from these results as the experiment was only 
performed once using a limited selection of cytokines. However it does lead to the 
suggestion of possible differences between the immune response generated when 
using either the enzymically-inactive or enzymically-active forms of CyaA.
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Figure 3.7.3
Production of nitric oxide by peritoneal macrophages from mice immunised 
with CyaA
Nitric oxide (NO) production was measured from macrophages obtained by 
peritoneal lavage from mice at 14 days post-immunisation with a single dose o f 15pg 
protein o f different preparations o f CyaA. Cells were re-stimulated in vitro with 
either a suspension o f B. pertussis heat-killed cells (hkc) at a concentration o f 2 x 10^ ’ 
cells/ml, or the different CyaA preparations at 2|Lig/ml. After an incubation period o f 
24 hours, NO production for each immunisation group was determined (section 
2.11.10). The results shown are the mean and SEM of three determinations.
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Figure 3.7.4.1 
Example of agarose gel electrophoresis of PCR-amplified cytokine mRNA
Cytokine mRNA detection using RT-PCR was carried out on spleen cells taken at 2 
weeks post-immunisation from immunised mice after in vitro stimulation with B. 
pertussis heat-killed cells. cDNA was amplified by PCR using cytokine specific 
primers which enabled visualisation o f amplimers by agarose gel electrophoresis 
(section 2.12. 2.3).
Lanes 1 + 14 
Lanes 2 + 6 + 10 
Lanes 3 + 7 + 11 
Lanes 4 + 8 + 12 
Lanes 5 + 9 + 13 
Lanes 2, 3, 4, 5 
Lanes 6, 7, 8, 9
100 base pair ladder 
p-actin expression 
IFNy expression 
IL-2 expression 
IL-4 expression
Spleen cells from PBS-immunised mice 
Spleen cells from LPS-immunised mice
Lanes 10, 11, 12, 13 Spleen cells from CyaA*-immunised mice
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Figure 3.T.4.2
Cytokine expression in spleen cells derived from mice immunised with different 
CyaA preparations and stimulated in vitro with B. pertussis heat-killed cells.
Digital analysis o f the RT-PCR products was carried out using Kodak ID gel 
analysis software. The intensity o f each band representing a different cytokine 
mRNA was calculated by the software package and given as a numerical value. The 
levels o f cytokine mRNA expression from each immunised group, when spleen cells 
were stimulated in vitro with heat-killed cells, were expressed as a percentage o f the 
intensity o f P-actin band.
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Figure 3.7.4.3
Cytokine expression in spleen ceils derived from mice immunised with different 
CyaA preparations and stimulated in vitro with CyaA*.
The levels o f cytokine mRNA expression from each immunised group when spleen 
cells were stimulated in vitro with CyaA* at a concentration o f 2pg/ml were 
expressed as a percentage o f  the intensity o f the p-actin band.
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3.8 IMMUNOLGICAL PROPERTIES OF CyaA WHEN ADMINISTERED 
IN COMBINATION WITH PURIFIED PERTUSSIS ANTIGENS
Hormozi et al. (1999) had reported that CyaA acted as an adjuvant to boost the IgG 
response to ovalbumin (OA) when CyaA was co-administered with ova. In order to 
investigate whether CyaA could act as an adjuvant for protective antigens commonly 
included in ACV’s, the different forms of CyaA were co-administered either with a 
combination of native FT, FHA and P.69 together or individually with detoxified PT, 
FHA and P.69. To assess any adjuvant effect, IgG antibody levels, protective 
capacities and cytokine expression were measured.
3.8.1 Mouse IgG antibody response to CyaA when co-administered with native 
PT, FHA and P.69 antigen mixture
Groups of 5 mice were immunised with a single 15pg ip dose of CyaA per mouse or 
15pg of CyaA plus a mixture of native PT, FHA and P.69 at 120ng, 25pg or lOpg 
per dose respectively. Terminal bleeds were taken at 5 weeks post-immunisation and 
anti-CyaA IgG levels measured by ELISA (section 2.13.1), An example of the 
geometric mean calculation, by interpolating at OD450nm 0.5, is shown in Figure
3.8.1.1. A difference in the anti-CyaA IgG levels was observed depending on 
whether the mice were immunised with CyaA* or the enzymically-active CyaA 
preparation (Figure 3.8.1.2). Mice receiving CyaA* plus the acellular components 
produced a lower level o f anti-CyaA IgG antibody compared to mice immunised 
with CyaA* alone. In contrast, the opposite was found when CyaA was used, with 
an increase in IgG antibody levels with CyaA co-administered with native PT, FHA 
and P.69 compared to CyaA alone. It is difficult to draw conclusions from these
135
Results
results as previous experiments with CyaA and CyaA* administered alone had also 
produced slight differences in anti-CyaA IgG levels at 4 weeks post-immunisation 
(Figure 3.7.1.2). In that case, however, immunisation with CyaA* alone produced 
only a slightly higher level of anti-CyaA IgG antibody compared to immunisation 
with CyaA alone.
3.8.2 Mouse IgG antibody response to native PT, FHA and P.69 when co­
administered with CyaA
ELISAs were used to determine anti-PT, anti-FHA and anti-P.69 IgG levels in mice 
immunised with CyaA together with PT, FHA and P.69 (section 3.8.1). Again the 
geometric mean was calculated by interpolating at OD450nm 0.5. Figure 3.8.1.2 
shows the differences in IgG antibody levels depending on the received 
immunisation. When CyaA* was co-administered with PT, FHA and P.69, higher 
titres of anti-PT, anti-FHA and anti-P.69 IgG were detected, compared to those 
obtained with PT, FHA and P.69 alone. However when CyaA was added to these 
components, only the anti-P.69 IgG titre showed a modest increase, whereas those 
for anti-PT and anti-FHA were lower.
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Figure 3.8.1.1
Example of calculation of anti-CyaA IgG antibody titres after immunisation 
with CyaA
Anti-CyaA IgG levels were determined by ELISA (section 2.13.1) using CyaA as the 
coating antigen at a concentration o f 2|ig/ml. The absorbance at 450nm was 
recorded and the results for each dilution o f each serum plotted on a log scale to 
obtain a trend line. The figure shows the results o f the ELISA for sera taken from 
mice immunised with CyaA* alone at 4 weeks post immunisation. The trend line for 
each serum was used to interpolate the graph at a cut off point o f OD 4 5 0 nm 0.5.
y = -1.0064x + 4.0036
log] reciprocol dilution (x) = 3.48
Geometric mean (GM) = antilog (1/n X Zlog3 recipricol dilution)
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Figure 3.8.1.2 
Anti-CyaA IgG antibody production in response to immunisation with CyaA in 
combination with native PT, FHA and P.69 antigens
Anti-CyaA IgG levels for groups o f mice immunised with a single dose o f 15|Ug o f 
non-enzymic CyaA* or CyaA alone, or together with a combination o f native PT, 
FHA and P.69 antigens at 120ng, 25 pg or lOpg/dose (PT, FHA and P.69 
respectively) were determined. Terminal bleeds were taken at 4 weeks post­
immunisation to perform ELISAs with CyaA as a coating antigen (section 2.13.1). 
The geometric mean o f the antibody titre for each immunisation group was 
calculated from the trend lines for each serum dilution as described in Figure 3.8.1.1.
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Figure 3.8.1.3
anti-PT, anti-FHA and anti-P.69 IgG antibody titres after immunisation with 
native PT, FHA and P.69 antigens with or without CyaA preparations.
Anti-PT, anti-FHA and anti-P.69 IgG levels were determined for the same groups o f 
vaccinated mice used for the results o f Figure 3.8.1.2. The relevant coating antigen 
o f either PT, FHA or P.69 was used to coat ELISA plates at a concentration o f 2 
pg/ml (section 2.14.1). The geometric mean o f the antibody titre for each 
immunisation group was calculated as described in Figure 3.8.1.1.
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3.8.3 Mouse IgG antibody response to detoxified PT (PTd), FHA and P.69 
antigens when co-administered with CyaA*
To investigate the effect CyaA* might have on the antibody response to each co­
administered antigen, mice were immunised ip with detoxified preparations of PT 
(PTd), FHA and P.69 at lOpg per dose either on their own or in various 
combinations with each other, plus or without 15pg of CyaA* (section 2.14.3). 
Terminal bleeds were taken at 5 weeks post-immunisation and anti-PT, FHA and 
P.69 IgG and IgGi levels determined by ELISA. An internal reference standard 
(97/642, NIBSC) (Gaines Das et al., 2001) containing loiown levels of anti-PT, FHA 
and P.69 was used on each ELISA plate to calculate the units of each antibody in the 
different samples. Again the absorbance at 450nm was plotted for each dilution of 
each mouse and reference serum and the geometric mean for each group was 
calculated by interpolating at OD450nm 0.5. By substituting this value into the 
formula detailed on Figure 3.8.3.1, the IgG antibody levels for each antigen in the 
different samples was determined. As 97/642 has only been signed unitage to total 
IgG and not to antibody subclasses, only the geometric mean of the IgGi antibody 
titres could be measured, with no specific value, as described in the legend to Figure
3.7.1.1.
When CyaA* was co-administered with PTd or with FHA, the anti-PT IgG levels 
were lower than with PTd alone. However when CyaA* was co-administered with 
PTd in combination with FHA and P.69, the anti-PT IgG levels were found to be 
boosted from a value of 719.53 EU/ml with PTd alone to 857.53 and 903.75 EU/ml 
with CyaA* in combination with PTd and P.69, and CyaA* in combination with 
PTd, FHA and P.69 respectively. When boiled CyaA* was co-administered with 
PTd, FHA and P.69 the levels were lower than immunisation with CyaA* in
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combination with PTd, FHA and P.69, which indicated that the enhanced anti-PTd 
response found in the latter response was due to the adjuvant effect of CyaA* rather 
than the LPS present in the preparation (Figure 3.8.3.2; Appendix H.6.1). As 97/642 
had not been asigned unitage to IgGi titres only the geometric mean of antibody 
levels could be measured and therefore a direct comparison between IgG and IgGi 
levels could not be made, although, however, the general pattern of results could be 
interpreted. Anti-PT IgG] levels followed a slightly different pattern (Figure 
3.8.3.2.1), in that immunisation with PTd alone produced the lowest level at 2513.7, 
and immunisation with PTd plus any other antigen increased the geometric mean 
levels. The greatest level was obtained when PTd was co-administered with P.69 
and CyaA*.
Anti-FHA IgG levels showed a marked increase when CyaA* was included in the 
immunisation mixture; levels increased from 1.31 EU/ml to 1237.47EU/ml when 
CyaA* was included. However, when a combination of antigens including PTd was 
given with CyaA* the IgG levels were not as elevated compared to the FHA plus 
CyaA* results. Immunisation with FHA in combination with PTd and CyaA resulted 
in a value of I237.47EU/ml and immunisation with FHA in combination with PTd, 
P.69 and CyaA* gave an anti-FHA IgG value of 800.38EU/ml, although both greater 
than with immunisation with FHA alone (Figure 3.8.3.3; Appendix H.6.2). Anti- 
FHA IgGi levels paralleled the anti-FHA IgG results (Figure 3.8.3.3.1). 
Immunisation with FHA alone produced an anti-FHA IgGi geometric mean antibody 
level of 32,1. Again, when CyaA* was included in the immunisation mixture, the 
antibody levels reached their maximum of 5819.5, and gradually decreased to a value 
of 1709.8 when PTd and P.69 plus CyaA* were included in the mixture (Figure 
3.8.3.3.1; Appendix H.7.2).
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When CyaA* was co-administered with P.69 or FHA or PTd, the anti-P.69 IgG 
levels were greater than immunisation with P.69 alone which produced a value of 
1.89EU/ml. When CyaA* was included in the immunisation mixture without PTd or 
FHA the greatest antibody level was obtained, a value of 1224EU/ml. The anti-P.69 
IgG levels for immunisation with P.69 in combination with either PTd and CyaA* or 
PTd, FHA and CyaA* were 798 and 476EU/ml respectively, both greater than 
immunisation with P.69 alone but lower than the value of 870EU/ml which was 
obtained when mice were immunised with boiled CyaA* in combination with PTd, 
FHA and P.69 (Figure 3.8.3.4; Appendix H.6.3). Anti-P.69 IgGi levels produced a 
slightly different pattern: of results. The greatest level was obtained when CyaA* 
and PTd were included in the immunisation mixture with P.69, a value of 997.5, 
although all were greater than immunisation with P.69 alone, which gave a geometric 
mean antibody level of 1.05. When P.69 was co-administered with CyaA*, the IgGi 
levels increased to 975.5 and then decreased to 178.8 and 1.14 when co-administered 
with PTd, FHA and boiled CyaA*, PTd and FHA respectively (Figure 3.8.3.4.1; 
Appendix H.7.3).
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Figure 3.8.3.1 
Example of calculation of IgG antibody titres after immunisation with CyaA 
plus PTd, FHA and P.69 antigens.
Anti-PT IgG levels were measured in each mouse serum after immunisation with 
either detoxified PT alone at lOpg/dose, in combination with other acellular pertussis 
vaccine components at lOpg/dose or with CyaA* at 15pg/dose. A reference standard 
(97/642 NIBSC) was included on the ELISA plate to give the ELISA units/ml 
(EU/ml) for each antigen. The absorbance at 450nm was recorded and the results for 
each dilution o f the sample sera and reference sera were plotted using a log scale to 
enable the drawing o f  a trend line. Calculating the geometric mean o f the samples 
using a cut o ff point o f OD 4 5 0 nm 0.5, dividing by the reference sera value, and 
multiplying by the ELISA units for the relevant antigen enabled the geometric mean 
antibody levels in EU/ml for each immunisation group to be plotted.
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Figure 3.8.3.1 (continued)
Trend lines obtained for 5 mice
y = -1.0603x + 5.2295 ie 0.5 = -1.0603x + 5.2295 .•. X  = 4.461
y = -0.9773x 4- 5.0399 X  = 4.645
y = -0 .9 1 66x + 4.8123 x = 4.705
y = -1.0240x + 5.3238 X  = 4.711
y = -0.9354X + 4.9504 x = 4.758
Geometric mean (GM) = antilog (1/n X Zlog3 recipricol dilution)
GM = antilog (1/n X 23.28 
= antilog (1/5 X 23.28)
= antilog 4.656 
= 45289.76
Trend line for reference serum 
y = -1.071x + 3.9851 x = 3.257 
GM = antilog 3.257 
= 1807
GM for unknown samples (previous example) = 45289.76
Specific EU/ml for PT, FHA, P.69 = 17, 143, 30 respectively
GM o f antibody levels (EU/ml) = GM o f unknown samples X specific EU
GM of reference serum 
GM o f anti-PT IgG = 45289.79 X 17
1807 
= 426.08 EU/ml
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Figure 3.S.3.2
Geometric mean of anti-PT IgG antibody responses after immunisation with 
detoxified PT and a combination of CyaA*, FHA and P.69 antigens
Geometric mean anti-PT IgG levels for the different immunisation groups were 
determined by ELISA as described in the legend to Figure 3.8.3.1.
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Figure 3.8.3.2.1
Geometric mean of anti-PT IgGi antibody titres after immunisation with 
detoxified PT and a combination of CyaA*, FHA and P.69 antigens
Geometric mean anti-PT IgG] levels for the different immunisation groups were 
determined by ELISA as described in the legend to Figure 3.7.1.1.
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Figure 3.S.3.3
Geometric mean of anti-FHA IgG antibody titres after immunisation with FHA 
and a combination of CyaA*, detoxified FT and P.69 antigens
Geometric mean anti-FHA IgG levels for the different immunisation groups were 
determined by ELISA as described in the legend to Figure 3.8.3.1.
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Figure 3.8.3.3.1
Geometric mean of anti-FHA IgGi antibody titres after immunisation with FHA 
and a combination of CyaA*, detoxified PT and P.69 antigens
Geometric mean anti-FHA IgGi levels for the different immunisation groups were 
determined by ELISA as described in the legend to Figure 3.7.1.1.
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Figure 3.S.3.4
Geometric mean of anti-P.69 IgG antibody responses after immunisation with 
P.69 and a combination of CyaA*, detoxified PT and FHA antigens
Geometric mean anti-P.69 IgG levels for the different immunisation groups were 
determined by ELISA as described in the legend to Figure 3.8.3.1.
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Figure 3.8.3.4.1
Geometric mean of anti-P.69 IgGi antibody titres after immunisation with FHA 
and a combination of CyaA*, detoxified PT and FHA antigens
Geometric mean anti-P.69 IgGi levels for the different immunisation groups were 
determined by ELISA as described in the legend to Figure 3.7.1.1.
1
c
(0
o
c
(00)
E
uc
0)
Eo0)O
1250
1000
750
500
250
I I g G i
y <?•?"
Immunisation groups
150
Results
3.8.4 Mouse protection with CyaA* in combination with native PT, FHA and 
P.69 antigen mixture against intranasal challenge with B. parapertussis
B. parapertussis causes a milder form of whooping cough in humans and, although 
not as severe as the infection caused by B. pertussis^ it would be important when 
creating new acellular vaccines to ensure that any antigens known to be protective 
against infection from both species of Bordetella were included. To investigate the 
possibility of CyaA* protecting against B. parapertussis, three groups of 5 mice were 
immunised (i.p) with either 25pg of CyaA* or native PT, FHA, P.69 antigens at 
120ng, 25pg and lOpg per dose respectively or a combination of CyaA* plus the 
antigen mixture. A fourth group o f 10 mice received PBS by the ip route as a 
control. At 4 weeks post-immunisation, mice received an intranasal challenge of 
lOpl per nostril containing a B. parapertusssis suspension o f 1.5x10^ cfu/ml. Five 
mice from the PBS immunised groups were sacrificed on day 0 of challenge and the 
remainder from all groups were sacrificed at day 5 post-challenge and the lungs and 
trachea removed together, to estimate B. parapertussis colonisation (section 2.11.6). 
Figure 3.8.4 shows the results of the combined lung and tracheal counts. CyaA* 
alone again offered some protection against challenge, in that the lung count was 
1.97x10^ cfu/ml compared to that of 7.1x10^ cfu/ml in the control PBS-immunised 
mice but when included with the antigen mixture, the degree o f protection against 
colonisation markedly increased. Mice receiving a mixture o f native PT, FHA and 
P.69 had a mean lung count of 3.23x10^ cfu/ml and this was further reduced to 
3.83x10"^ cfu/ml when CyaA* was included in the immunisation mixture. The 
decrease in cfu when CyaA* was included with the ACV components, was tested 
using the Student’s t-test at 5% level. The p value obtained was 0.003 which 
indicated that the decrease was significant, and highlighted the potential that CyaA*
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may have to confer or enhance protection against both B. pertussis and B. 
parapertussis infections.
3.8.5 Effect of adding CyaA to a current commercially-available acellular 
vaccine on mouse protection following aerosol challenge
In order to test the possibility that CyaA* may enhance the protection afforded by 
current acellular pertussis vaccines (ACV), a further aerosol challenge experiment 
was conducted to investigate the effect of adding CyaA to a commercially-available 
3-component ACV. Groups o f 5 mice were immunised ip with a single dose of 
either, 0.125 lU/mouse (approximately equivalent to 0.03 SHD) of WCV, 0.25 
SHD/mouse of a commercially available tlnee-component acellular vaccine ACV 
(25pg PTd, 25pg FHA and 8pg P.69), 25pg of CyaA* or CyaA, 25pg o f CyaA* or 
CyaA combined with ACV, and two control groups o f either boiled CyaA or E. coli 
LPS at 175 lU/dose combined with ACV. A further group of 10 mice received 0.5ml 
ip PBS. At 4 weeks post-immuisation all groups were subjected to an aerosol 
challenge from a suspension containing approximately 10  ^ cfu/ml B. pertussis
18.323. Five mice from the PBS immunised groups were sacrificed on day 0 of 
challenge and the remainder from all groups were sacrificed at day 7 post-challenge 
and the lungs and trachea removed together, to estimate B. pertussis colonisation. 
Figure 3.8.5 shows the results of the combined lung and tracheal counts. Mice 
receiving either CyaA* or CyaA immunisations gave mean lung counts o f 7.78x10^ 
cfu/ml and 5.54x10^ cfu/ml respectively, slightly lower than the lung counts of 
1.44x10^ cfu/inl from PBS-immunised mice. WCV-immunised mice gave the 
greatest protection against colonisation, demonstrated by the low lung counts of
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3.83x10^ cfu/ml, and those receiving the ACV gave lung counts o f 7,12x10"^ cfu/ml. 
The lung counts showed a slight reduction when mice received either CyaA* or 
CyaA co-administered with ACV (3.52x10^ and 2 . 4 9 x 1 cfu/ml respectively), in 
comparison to those receiving ACV alone. However statistical analysis by the 
Student’s t-test showed that the results between the ACV immunised group and the 
ACV co-administered with CyaA* or CyaA were not statistically significant at either 
the 5% or 10% level, indicating that addition of either CyaA* or CyaA to the ACV 
immunisation did not significantly enhance the protection afforded by the ACV alone 
under the experimental conditions used. Interestingly, both boiled CyaA* and LPS 
plus ACV gave quite high lung counts (1.94x10^ and 1.54x10^ cfu/ml respectively), 
however when these were compared to CyaA* plus ACV the difference still was not 
significant at either the 5% or 10% level..
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Figure 3.8.4 
Mouse protection with CyaA* in combination with native PT, FHA and P.69 
antigens against intranasal challenge with B. parapertussis
The protective activities o f CyaA* in combination with native PT, FHA and P.69 
antigens, were examined in mice after intranasal challenge with B. parapertussis. 
One group o f 5 mice received a single dose o f  25|ig/dose o f CyaA*, a second group 
o f 5 mice received a combination o f native PT, FHA and 69K antigens at 120ng, 25 
pg and lOpg/dose respectively and a third group received a combination o f CyaA* 
and antigen mixture. A fourth group o f 10 mice received PBS as a control. At 4 
weeks post immunisation the groups were subjected to an intranasal challenge o f B. 
parapertussis (section 2.11.7). The lungs and trachea were removed from 5 mice o f 
the PBS group on the day o f challenge and at day 5 post-challenge the remainder o f 
the groups were sampled. Viable counts were performed on the combined lung and 
trachea homogenate and the mean log colony forming units (cfu) and standard 
deviation plotted at day 5 post-challenge for each group.
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Figure 3.8.5
Comparison of the mouse protection with CyaA alone or in combination with a 
commercially available 3-component acellular vaccine against challenge with B. 
pertussis 18.323
Groups o f mice were immunised with PBS as a control, pertussis WCV at 0.025 
SHD/dose, ACV at 0.1 SHD/dose, CyaA* or CyaA alone at 25pg/dose or CyaA* and 
CyaA in combination with ACV. At 4 weeks post immunisation the groups were 
subjected to an aerosol challenge o f B. pertussis 18.323 (section 2.11.5). The lungs 
and trachea were removed from 5 mice o f the PBS group on the day o f challenge and 
at day 7 post-challenge the remainder o f the groups were sampled. Viable counts 
were performed on the combined lung and trachea homogenate and the mean log 
colony forming units (cfu) and standard deviation plotted at day 7 post-challenge for 
each group.
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3.8.6 Production of nitric oxide by macrophages from mice immunised with 
CyaA in combination with native PT, FHA and P.69 antigen mixture
Nitric oxide (NO) levels measured from macrophages taken from mice that had been 
immunised with only CyaA preparations were found to be no greater than the control 
groups of PBS" or LPS-immunised mice (Figure 3.7.3), therefore the effect of adding 
CyaA to a combination of native PT, FHA and P.69 antigens was investigated. NO 
production was determined from peritoneal macrophages obtained from groups of 5 
mice immunised (ip) with either, a single 15pg dose of different CyaA preparations, 
PT, FHA, P.69 at 120ng, 25pg and lOpg per dose respectively, 175 iu o f purified 
LPS from E. coli plus the antigen mixture, or a combination of CyaA* or CyaA plus 
the antigen mixture. In this experiment, control mice were immunised with either 
PBS, 15pg of boiled CyaA or 175 iu of purified LPS from E. coli. Mice were 
terminally bled on day 14 post-immunisation and the peritoneal cavity was lavaged 
with sterile PBS to recover macrophages (Section 2.11.8). Nitrite determinations 
were made on supernates taken from the cultured macrophage samples after 
stimulation (Section 2.11.10). The effects of different stimuli in vitro on the 
macrophage cells from different immunisation groups, is displayed in Figure 3.8.6 
and Appendix H.3. Stimulation with B. pertussis heat-killed cells, at a concentration 
of 2x10^ cells/ml, gave rise to an increase in NO production in all groups when 
compared with the levels from cells that did not receive any stimulation. Likewise, 
stimulation with CyaA* at a concentration of 2p.g/ml also resulted in an increase in 
NO production, although not as marked as stimulation with B. pertussis hkc. In 
contrast, stimulation with CyaA demonstrated lower NO levels in all immunisation 
groups. This was probably due to the fact that, at 2pg/ml, the concentration of CyaA
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is cytotoxic and may be killing the cells (Figure 3.5.3.1). As was demonstrated 
previously in Figure 3.7.3, immunisation with either CyaA* or CyaA did not result in 
an increase in NO production when compared to the PBS-, LPS- or boiled CyaA- 
immunised mice. However a marked increase in NO production was observed when 
macrophages from either CyaA* or CyaA in combination with PT, FHA, P.69 
antigen mixture were tested, in comparison to macrophages from mice immunised 
with antigen mixture alone or in combination with LPS. The best results were 
obtained when CyaA* was used as the adjuvant. The overall increase in NO 
production would indicate that, although CyaA does not appear to stimulate 
macrophage activation when used on its own as a vaccine, when administered in 
conjunction with other acellular components, CyaA* in particular is able to enliance 
macrophage activation.
3.8.7 Cytokine mRNA expression in mice immunised with CyaA plus native 
PT, FHA and P.69 antigen mixture
The effect of adding CyaA to an immunisation mixture of native PT, FHA and P.69 
antigens on cytokine expression in spleen cells was investigated as described for 
CyaA alone in section 3.7.4. The results shown in Figures 3.8.7.1 and 3.8.7.2 for 
mice vaccinated with CyaA or CyaA* alone support previous data (Figure 3.7.4.2 
and 3.7.4.3). Spleen cells from mice immunised with CyaA* and stimulated with 
hkc, produced high levels of IFNy, IL-2 and IL-4, whereas spleen cells from CyaA- 
immunised mice produced similar amounts of IFNy and IL-2, but lower levels of IL- 
4 (Figures 3.7.4.2 and 3.8.7.1). Similarly, cells from CyaA*-immunised mice 
stimulated with CyaA* produced little of these cytokines, whereas cells from CyaA- 
immunised mice produced high levels o f all these cytokines when stimulated with
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CyaA* (Figures 3.7.4,3 and 3.8.7.2). Unexpectedly, the data show that addition of 
CyaA or CyaA* to PT, FHA, P.69 mixture, did not result in an enhancement in the 
levels of IFNy, IL-2 or IL-4 cytokine expression from cells stimulated with hkc or 
CyaA* and, if anything, the cytokine response was repressed. This was an 
unexpected result as the addition of CyaA to native PT, FHA and P.69 antigen 
mixture in previous experiments had resulted in a clear adjuvant effect, by enhancing 
antibody production (Figures 3.8.2.1, 3.8.3.2, 3.8.3.3, 3.8.3.4), by enhancing 
protection against respiratory tract colonisation after B. pertussis or B. parapertussis 
challenges (Figures 3.8.4, 3.8.5) and by stimulating NO production from macrophage 
cells (Figure 3.8.6).
IFNy production in spleen cells taken from mice immunised with CyaA preparations 
alone or in combination with pertussis antigens was also measured by ELISA (Figure
3.8.7.3). Unfortunately, due to time constraints, a direct comparison between all the 
groups and the in vitro stimuli could not be made, but, several points can be 
addressed. Firstly, a greater level of IFNy was produced when mice had been 
vaccinated with the enzymically, active form of CyaA compared to CyaA* and the 
spleen cells were stimulated in vitro with CyaA*. This can be compared to Figure
3.8.7.2, in which a similar result was observed. However, when B. pertussis hkc 
were used as the stimulus the results differ from those obtained by RT-PCR. Mice 
vaccinated with both forms of CyaA gave quite high values for IFNy production 
when stimulated with hkc, as was evident by RT-PCR (Figure 3.8.7.1). Interestingly 
the effect that the enzymic activity of CyaA had on IFNy production was apparent 
when native PT was included in the immunisation protocol. When stimulated with 
hkc, spleen cells from mice given PT on its own gave IFNy levels of 18368pg/ml, 
similar to the value for CyaA* vaccination but much lower than that o f CyaA, which
158
Results
were 13568 and 46336pg/ml respectively. However, when the different forms of 
CyaA were included in the immunisation with PT an interesting result was obtained. 
The non-enzymically, active form of CyaA* acted to raise IFNy production to a 
value o f 41344pg/ml, compared to PT alone at 18638pg/ml, but the enzymically, 
active form of CyaA apparently inhibited the production of IFNy to a value of 
224pg/ml when co-administered with PT. These results indicate a clear difference in 
the two forms of CyaA, most noticeably when native PT was co-administered with 
CyaA. This may be related to the fact that both toxins act to increase intracellular 
cAMP levels and may perhaps work in an antagonistic manner toward each other. 
As with the data obtained by RT-PCR, inclusion of CyaA* with the antigen mixture 
for vaccination produced spleen cells only marginally responsive to stimulation by 
CyaA*.
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Figure 3.8.6 
Production of nitric oxide by macrophages from mice immunised with CyaA in 
combination with native PT, FHA and P.69 antigen mixture
Nitric oxide (NO) production was measured from macrophages obtained from groups 
o f 5 mice immunised ip with a single dose o f 15pg CyaA or CyaA* alone, or in 
combination with a mixture o f native PT, FHA and P.69 antigens at 120ng, 25 pg 
and lOpg/dose respectively. Cells were stimulated in vitro with either a suspension 
o f B. pertussis heat-killed cells (hkc) at 2 x 10  ^ cells/ml, or with the different CyaA 
preparations at 2pg/ml. After an incubation period o f 24 hours, NO production for 
each immunisation group was determined (section 2.11.10).
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Figure 3.8.7.1 
Cytokine expression from mice immunised with CyaA in combination with 
native PT, FHA and P.69 antigens, following stimulation in vitro with B. 
pertussis hkc
Cytokine mRNA expression using RT-PCR was carried out on spleen cells taken 
from mice immunised ip with a single dose o f 15pg o f different CyaA preparations 
alone or in combination with a mixture o f native PT, FHA and P.69 antigens at 
120ng, 25 pg and lOpg/dose respectively (section 2.11). cDNA from the different 
samples was amplified by PCR using cytokine specific primers which enabled 
visualisation by agarose gel electrophoresis (section 2.12. 2.3). The intensity o f each 
band representing a different cytokine was calculated by the Kodak 1D gel analysis 
software package and given as a numerical value. The levels o f cytokine mRNA 
expression from each immunised group, when spleen cells were stimulated in vitro 
with heat-killed cells, were expressed as a percentage o f the intensity o f P-actin band.
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Figure 3.S.7.2
Cytokine expression from mice immunised with CyaA in combination with 
native PT, FHA and P.69 antigens, following stimulation in vitro with CyaA*
The levels o f cytokine mRNA expression from each immunised group, when spleen 
cells were stimulated in vitro with CyaA* at 2pg/m l, were expressed as a percentage 
o f the intensity o f p-actin band.
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Figure 3.S.7.3
IFNy expression from mice immunised with CyaA preparations in combination 
with PT, FHA and P.69 antigens, following stimulation in vitro with B. pertussis 
hkc or CyaA*
IFNy expression was carried out on spleen cells taken from mice immunised ip with 
a single dose o f I5pg o f different CyaA preparations alone or in combination with 
native PT, FHA and P.69 antigens at 120ng, 25pg and lOpg/dose respectively 
(section 2.11). IFNy production was measured by ELISA (section 2.14.3) and 
expressed as a concentration in pg/ml. (n.d = not determined).
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CHAPTER 4 
DISCUSSION
4.1 PRODUCTION OF CyaA FROM RECOMBINANT E. coli STRAINS
A high level production of active CyaA was demonstrated by Sebo et al. (1991) using a 
reconstructed E. coli system. Plasmid pACT7 was constructed to contain the cyaA gene 
expressed under the control of the transcription and translation signals of lacZ. The 
remaining four genes o f the cya locus {cyaB, cyaD, cyaE and cyaC) were cloned into a 
low copy number vector that was compatible with pACT7 and included a strong 
inducible promoter and transcriptional terminators. The production o f CyaA in E. coli 
from cyaA alone resulted in a non-invasive and non-haemolytic toxin. However, the 
presence of the CyaC gene product was found to be sufficient to render the CyaA pro­
toxin invasive and haemolytic in the reconstructed system (Sebo et al., 1991). In the 
study reported here, an efficient T7 RNA polymerase system, previously developed in 
this laboratory (Westrop et al., 1996), was used for overexpression of cyaA and cyaC 
genes in a protease defective E. coli strain BL21/DE3, harbouring two separate 
compatible plasmids, pGW44 and pGW54. Westrop et al. (1996) demonstrated that 
strain BL21/DE3 (pGW44, pGW54) produced CyaA and CyaC in amounts that were 
similar to those obtained when the plasmids were carried separately, i.e. in strains 
BL21/DE3 (pGW44) and BL21/DE3 (pGW54), indicating that expression of one gene 
did not interfere with expression of the other gene. SDS-PAGE analysis of urea extracts 
produced in this study from strain BL21/DE3 (pGW44, pGW54) (Figure 3.1.1, lanes 6
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and 7) suggested that the levels of CyaC were less when the two plasmids were co­
expressed than when CyaC was expressed alone. This was contrary to the results of 
Westrop et al. (1996) but was likely to be an artifact of the gel, due to the difference in 
protein content of the urea extract loaded into these lanes. A third compatible plasmid, 
pGW44/188, was constructed from pACM188 (Ladant et ah, 1992) and encoded the 
CyaA pro-toxin that lacked enzymic activity due to a dipeptide amino acid insertion in 
the N-terminal end (Section 2.1). pGW44/188 was co-expressed with pGW54 to
produce a full length invasive toxin with little enzymic activity (BL21/DE3 
(pGW44/l 88,54). SDS-PAGE analysis demonstrated the same banding pattern for the 
enzymically-active form (CyaA) and the enzymically-inactive form (CyaA*) (Figure 
3.1.2). These constructs enabled the production of the different forms of CyaA in E. coli 
without the inconvenience of growing B. pertussis and the Icnowledge that they were 
free from other B. pertussis components that could have displayed toxic or 
immunostimulatory properties.
4.2 PURIFICATION OF CyaA FROM RECOMBINANT E. coli STRAINS
To examine the immunogenic and immunostimulatory properties of CyaA highly 
purified preparations were desirable. The enzymically-active and inactive forms of 
CyaA were purified by several methods. The most effective method was a combination 
of DEAE sepharose column chromatography followed by phenyl sepharose column 
cliromatography, as each method alone was not sufficient to remove contaminating
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proteins. Lai'ge quantities of 200kDa CyaA proteins were obtained by these purification 
steps with only a few lower molecular weight proteins present. The majority o f these 
were removed by including a further ultrafiltration and concentration step during the 
purification procedure (Figure 3.2.5). Any residual lower molecular weight proteins 
were assumed to be subsequent degradation products of CyaA as judged by 
immunoblotting with polyclonal antibody raised against 200 kDa CyaA in rabbits 
(Figure 3.2.6). The differences in molecular weight between the three forms of CyaA 
(CyaA pro-toxin, non-acylated; enzymically-active, acylated CyaA; and enzymically- 
inactive, acylated CyaA*) due to acylation or dipeptide amino acid insertion would not 
be expected to be detected by SDS-PAGE analysis and immunoblotting, and indeed it 
was not possible to differentiate the preparations by these methods (Figure 3.2.5 and
3.2.6).
4.3 ENDOTOXIN REMOVAL FROM CyaA PREPARATIONS
Recombinant proteins derived from E. coli are often contaminated with endotoxins due 
to the high quantities o f LPS in the cell envelope of this Gram-negative bacterium. The 
levels of endotoxin in each of the three CyaA preparations were determined using the L. 
amoehocyte lysate (LAL) test (Table 3.5). In preliminary studies, all CyaA preparations 
were found to be contaminated with LPS, a fact that represented a problem for any 
immunological studies due to the highly immunogenic and immunostimulatory nature of 
LPS. Commonly used tecliniques for removing endotoxin contaminants are ultra- 
filtration and ion exchange chromatography although, in the case of large proteins,
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ultrafiltration is not suitable and ion exchange methods are less specific. Other methods 
previously used include the use of polymyxin B and Triton X-114 phase separation 
(Morrison and Jacobs, 1976; Aida and Pabst, 1990). These methods were attempted to 
try to reduce the level of contaminating endotoxin but all proved unsuccessful (Section
3.6) which led to the conclusion that the endotoxin was probably tightly bound to the 
CyaA protein, as a reduction in endotoxin was accompanied by a reduction in CyaA 
content. A review by Petsch and Anspach (1999) found that chromatography with 
endotoxin adsorbers such as polymyxin B were ineffective in their ability to reduce 
endotoxins to an acceptable limit when large sample volumes were applied onto 
columns, and also that ultrafiltration with proteins greater in molecular weight than 
ISOlcDa was ineffective. Ultrafiltration will fail if  interactions between endotoxin and 
proteins prevent endotoxin monomers from permeating through the membrane. RTX 
toxins tend to form aggregates in aqueous solutions through hydrophobic interactions, 
and since LPS forms similar aggregates it may form complex aggregates with CyaA. It 
may be that an RTX-LPS complex is actually the biologically active moiety, as 
suggested by Czuprynski and Welch (1995). Their data showed that E. coli HlyA 
activity and antigenicity were lost when HlyA preparations containing LPS were loaded 
onto a polymyxin B column. More recent data has shown LPS to complex with P. 
haemolytica leukotoxin, resulting in enhanced and stabilised leukolytic activity (Li and 
Clinkenbeard, 1999). In the present investigations, because complete removal of LPS 
from CyaA preparations was not possible, additional immunological effects due to LPS 
were taken into account by including E. coli LPS and heated CyaA controls in the 
immunological studies. Endotoxins are very stable molecules requiring temperatures of
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between 180 and 250°C and alkali or acid of at least O.IM to destroy them. Therefore, 
by heating the CyaA preparations to 100°C, it was assumed that only the CyaA toxin 
was destroyed and any effect due to endotoxin alone would be revealed. However, such 
experiments would not show whether the observed effects were due to an interaction 
between LPS and CyaA. This would only be possible by having pure preparations of 
CyaA to which different amounts of LPS could be added.
4.4 PROPERTIES OF DIFFERENT CyaA PREPARATIONS
4.4.1 Adenylate cyclase (AC) enzymic activity
Two methods were used to measure the specific enzymic activity o f the purified CyaA 
preparations, the conventional ^^aP-ATP assay and a novel conductimetric assay (Figure
3.5.1). Although the conductimetric assay tended to produce greater deviations between 
replicate assays, particularly when the enzymic activity was high, it was nonetheless 
proven to be a much quicker and safer (non-radioactive) method for determining the 
levels of AC activity in different samples. Both CyaA pro-toxin and CyaA were 
enzymically active, although the pro-toxin displayed a lower level of activity than the 
acylated form in both methods (Table 3,5). This was not in keeping with the results 
reported by Westrop et al. (1996) and Hormozi et al. (1999), who, using the 
conventional ^^aP-ATP assay, found the pro-toxin to have a greater specific activity. 
The reasons for this discrepancy are not clear, but may reflect differences in the
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accuracy of the measurement of protein concentrations in the purified samples in the 
presence of urea. The specific activity of CyaA from native B. pertussis was not tested 
in this study however, the enzymically-active, acylated CyaA had a specific activity 
when measured by the conventional ^^aP-ATP assay which was similar to earlier work 
by Hormozi et al. (1999); 433pMol cAMP formed per mg protein per minute in this 
study, compared with 626pMol cAMP formed per mg protein per minute (Hormozi et 
al., 1999). The N-terminal modified CyaA* toxin demonstrated a very low, almost 
negligible value for cAMP production. Ladant et al. (1992) showed that modified CyaA 
proteins became highly susceptible to proteolysis in situ, except protein AC188LQ (from 
plasmid pACM188) from which pGW44/188 was derived. This was expressed at high 
levels and appeared to be as stable as the wild-type enzyme in terms of the lack of 
proteolysis, but was devoid of catalytic activity (less than or equal to 2.2pMol cAMP 
formed per mg protein per minute). The very low levels of enzymic activity obtained 
with CyaA* in the present work (less than 2.8pMol cAMP per mg protein per minute) 
presumably indicate some low residual activity and are in agreement with the data of 
Ladant et al. (1992).
4.4.2 Haemolytic activity of CyaA preparations
The homology of the genes for B. pertussis CyaA synthesis and secretion with those of 
E. coli alpha-haemolysin (HlyA), was extended by the finding of the cyaC gene (Barry 
et ah, 1991), a homologue of E. coli hlyC which is laiown to be required for the
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production of a functional haemolysin molecule in E. coli (Wandersman and 
Delepelaire, 1990). The cyaC gene product was shown to be essential for invasive and 
haemolytic activities of CyaA (Ban-y et a i ,  1991; Sebo et a l, 1991). This was 
supported by the present work where it was found that CyaA protoxin had no detectable 
haemolytic activity. Bellalou et al. (1990) characterised the molecular features of CyaA 
and demonstrated that the haemolytic activity o f CyaA was calcium-dependent, like that 
of HlyA, but that its haemolytie activity was at least 100 times lower than that of E. coli 
HlyA. The weakly haemolytic nature of the CyaA preparations was demonstrated in 
Figure 3.5.2, where it can be seen that 50 % haemolysis was obtained only when CyaA 
at a protein concentration of between 30 and 40 p.g/ml was incubated with turkey 
erythrocytes for a long incubation period of 18 hours. The lack o f AC enzymic activity 
had little effect on the haemolytic properties of the toxin, as expected (Table 3.5).
4.4.3 Cytotoxic effect of CyaA preparations
The CyaA pro-toxin was shown to be non-cytotoxic against J774.2 mouse macrophage 
cells, which was in keeping with earlier findings that the toxin must be acylated by 
CyaC modification to bestow any toxicity (Rogel et al., 1989). The acylated CyaA toxin 
demonstrated a high level of cytotoxic activity, which corresponded with the enzymic 
and haemolytic and activities (Table 3.5). Although CyaA is poor at forming pores and 
only weakly haemolytic, the primary biological function o f CyaA is presumably to 
deliver its enzymic activity into cells, ultimately resulting in their intoxication by the
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production of cAMP, rather than the formation of membrane channels. This may 
suggest why only single acylation at lysine 983 is sufficient for membrane insertion and 
cell-invasive activities of B. pertussis CyaA but with E. coli HlyA, acylation at two sites, 
lysine 564 and lysine 680, is optimal for the formation of membrane channels (Basar et 
aï., 2001). Stanley et al. (1994) demonstrated that both acyl modifications must be 
present for HlyA to form channels and that loss of either acyl groups results in the 
virtual abolition of cytolyitc ability.
Interestingly the N-terminally modified CyaA* toxin, which has little AC activity, also 
displayed a degree of cytotoxicity, as measured in the MTT assay, at higher protein 
concentrations, although to a much lesser extent compared to CyaA (Figure 3.5.3.1 and 
Table 3.5). This 100-fold difference between the cytotoxicity profiles of the two toxin 
preparations perhaps suggests that cell killing by CyaA toxin is due mainly to the 
intrinsic AC enzymic activity o f the protein after it has entered the target cell and, if  this 
activity is removed, only residual toxicity is observed. This effect of CyaA* could be 
due to either the very low residual level of adenylate cyclase activity of the protein or to 
its pore-forming haemolytic effect. Khelef et al. (1993) demonstrated that B. pertussis 
killed macrophages through apoptosis and that adenylate cyclase expression was 
essential for B. pertussis to promote cell death. It was suggested that apoptosis was 
induced by the increase in cAMP production, as this molecule has been shown to be 
responsible for changes in protein phosphorylation (Duprez et al., 1993). The possibility 
that apoptosis may be induced by the pore-forming properties of CyaA was ruled out by 
IClrelef and Guiso (1995). They determined the DNA fragmentation induced by different 
CyaA preparations in J774A.1 macrophages and were able to demonstrate that a mutated
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CyaA lacking adenylate cyclase activity but retaining haemolysin activity, did not 
induce death of murine J774A.1 macrophages. The present study suggested that cell 
killing was due to intracellular AC activity provided by CyaA, but any future work 
should examine the mechanism of killing, whether by apoptosis or by cell lysis.
4.5 ANTIBODY RESPONSES TO CyaA
4.5.1 Anti-CyaA IgG response
Betsou et al. (1995) demonstrated that when anti-5, pertussis CyaA polyclonal antibody 
was used in Western blotting, the recombinant E. coli CyaA polypeptide of 200kDa was 
recognised. In this study, the mice developed specific anti-CyaA IgG antibody 
responses after vaccination with 15pg of the enzymically-active and inactive CyaA 
forms, the peak production occuring at 7 weeks post-immunisation for CyaA pro-toxin 
and enzymically-active, acylated CyaA. Interestingly, immunisation with the 
enzymically-inactive, acylated CyaA gave rise to the greatest specific IgG levels, with 
the peak production occuring at 9 weeks post-immunisation (Figure 3.7.1.2). There is 
no obvious reason as to why this should have occurred, as the IgG response was 
measured by ELISA, using the active, acylated form in all cases. One possibility could 
be the inherent toxicity of the acylated CyaA preparations which may impair the 
functioning of antigen presenting cells such as macrophages. This would affect antigen 
processing and presentation.
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When a second immunisation dose was administered at 7 weeks post initial 
immunisation the effects o f boosting were clearly observed 2 weeks later and indicated a 
significant rise in anti-CyaA IgG production, thereby demonstrating a good memory 
response (Figure 3.7.1.3).
Antibodies against both acylated forms of CyaA, whether enzymically active or inactive, 
were able to neutralise the cytotoxic effect of the recombinant active CyaA on J774.2 
cells in vitro, following incubation of the toxins with the sera from mice immunised with 
either CyaA or CyaA* before addition to J774.2 cells (Figure 3.7.1.1.1). Rogel et al. 
(1988) reported that when purified CyaA was incubated with immune serum from 
guinea pigs, inliibition o f CyaA activity was obtained, in comparison to incubation with 
non-immune sera, which had no effect on activity. Further work by Moullem et al. 
(1990) and Farfel et al. (1990) demonstrated that sera taken from pertussis patients was 
able to inhibit cAMP accumulation in comparison to control sera taken from a patient 
who did not contain any anti-PT or anti-CyaA antibodies. However, it was also shown 
that the enzymic properties of the toxin were not neutralised, when inhibition o f enzymic 
activity and inhibition of penetration of the enzyme into target cells (Mouallem et al. 
1990; Farfel et al. 1990) were compared. This disagrees with data presented by Betsou 
et al. (1995), who reported that antibodies against a truncated protein consisting of the 
N-terminal domain and the last 217 amino acids of CyaA were able to neutralise both 
the enzymic and cytotoxic activities of recombinant CyaA. However, a preliminary 
experiment carried out in this study suggested that the enzymic activity, as measured by 
the conductimetric assay, remained unaltered after incubation for 1 hour at 37°C with
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mouse immune sera containing CyaA antibodies, although further investigation is 
required to confirm this.
4.6 ADJUVANT EFFECT OF CyaA ON OTHER PERTUSSIS ANTIGENS
Hormozi et a l  (1999) demonstrated that co-administration o f 15qg active recombinant 
CyaA with OA (subcutaneous route, (s.c) 2 doses at a two-week interval) enhanced the 
specific IgG response to ovalbumin compared to immunisation with ovalbumin alone, 
thereby indicating the potential adjuvant effect that CyaA may be able to exert. In a 
preliminary study, the levels of anti-CyaA IgG were monitored after a single vaccination 
(ip) with CyaA alone or in combination with native PT, FHA and P.69 (120ng, 25qg and 
10pg respectively). Surprisingly anti-CyaA IgG was found to be lower when CyaA* 
was co-administered with the other antigens, but higher for CyaA (Figure 3.8.1.2). It is 
difficult to draw any direct conclusions from these results since they conflict with results 
o f previous experiments when CyaA and CyaA* were administered alone under the 
same conditions and lower levels of antibody were produced against CyaA than against 
CyaA* (Figure 3.7.1.2.).
4.6.1 Anti-PT, anti-FHA and anti-P.69 IgG response
The effects that CyaA* and CyaA had when co-administered with each o f the thi'ee 
ACV components was studied, firstly when administered in combination with native PT, 
FHA and P.69 as a mixture and secondly when co-administered with detoxified PT
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(dPT), FHA and P.69 individually. When native PT was used in the immunisation 
mixture, mice received 120ng of PT per dose, plus 25pg of FHA and lOpg o f P.69. 
When detoxified PT was used in the immunisation mixture, mice received lOpg o f all 
tliree antigens, as there was no problem of toxicity with PT so the dose could be 
increased. In all cases a single dose of 15pg of CyaA was administered either on its own 
or in combination with the other antigens. When CyaA* was co-administered with the 
antigen mixture, anti-PT, anti-FHA and anti-P.69 IgG levels all increased in comparison 
to those obtained with the antigen mixture alone. However, when CyaA was co­
administered with the mixture, only anti-P.69 IgG levels increased, while anti-PT and 
anti-FHA IgG levels decreased, compared to those for PT, FHA and P.69 alone (Figure
3.8.2.1). The difference between the two forms of CyaA is the lack o f enzymic activity 
in CyaA*. It is possible that the difference in antibody production when co­
administered with other purified pertussis antigens was due in part to the enzymic 
activity of CyaA. Alternatively, it may be related to mutually antagonistic interactions 
between active PT, a Imown adjuvant, and the potential adjuvant effects of CyaA as both 
these toxins act to raise intracellular cAMP levels. However, as the adjuvant effect of 
CyaA* seemed to be as good as, if  not better than CyaA, only CyaA* was used in 
subsequent experiments to determine the adjuvant effect on responses to individual 
antigens (dPT, FHA and P.69) with PTd replacing active PT in these experiments. Anti- 
PT IgG levels decreased when either CyaA* or FHA was co-administered with PTd, but 
were boosted when P.69 was included in the immunisation, suggesting that P.69 is able 
to over shadow the effects of CyaA* and FHA and direct the antibody response back 
towards PT. CyaA* was shown to act as an adjuvant to PT but only when administered
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in combination with P.69. This was demonstrated by the lower anti-PT IgG response 
generated to the control group which received boiled CyaA*, PTd, FHA and P.69 in 
comparison to a similar group that included CyaA* (Figure 3.8.3.2). Anti-PT IgGi 
levels increased with any combination o f antigens compared to immunisation with PTd 
alone. The greatest effect was when P.69 and CyaA* were co-administered with PTd, 
again demonstrating the adjuvant effect that CyaA* exerts when in combination with 
P.69 (Figure 3.8.3.2.1). Unfortunately, no IgGza data was available so no IgGi:IgG2a 
ratio could be determined and compared between the groups. Both anti-FHA IgG and 
IgG] levels increased when CyaA* was included in the immunisation mixture, although 
an increase in the number of antigens in the mixture resulted in a reduction in the 
specific antibody response (Figures 3.8.3.3; 3.8.3.3.1). This may be related to antigen 
competition as for example, CDl lb  may act as a binding site for CyaA, FHA and P.69. 
Damn et al. (2001) compared the antibody response to Haemophilus influenzae type b 
capsular polysaccharide (PRP) after one, two or three doses of DTaP vaccine combined 
with a PRP-tetanus conjugate (PRP-T) vaccine and found that the anti-PRP and anti­
tetanus toxoid antibody responses decreased with an increasing dose of DTaP/PRP-T. 
The mechanism by which the DtaP/PRP-T combination vaccine was able to depress the 
antibody responses is unclear, but may possibly reflect antigenic competition. 
Previously, Dagan et al. (1998) showed that recipients of a pneumococcal-tetanus toxoid 
conjugate vaccine had diminished PRP and anti-tetanus antibody responses compared to 
the pneumococcal-diphtheria toxoid conjugate vaccine recipients, and that both the anti- 
PRP and anti-tetanus toxoid antibody responses were inversely related to the total 
amounts of tetanus toxoid received in the combination vaccines. A similar pattern was
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followed for anti-P.69 IgG and IgGi, in that the greatest response was when CyaA'*' was 
co-administered with P.69 and as more antigens were included the antibody response 
decreased. Except, however when a mixture of boiled CyaA*, PTd, FHA and P.69 was 
given. In this instance the anti-P.69 IgG levels were greater in comparison to those that 
received FHA or PTd, but still not as great as the response to P.69 and CyaA* together 
(Figures 3.8.3.4; 3.8.3.4.12). The adjuvant effect cannot be explained by the presence of 
EPS in CyaA"^ preparations, as the antibody responses to these antigens in the boiled 
CyaA"^ group were poor but the possibility of an interaction between the effects due to 
EPS and CyaA* cannot be excluded. The overall conclusion was that inclusion of 
CyaA'’' in the immunisation mixture did seem to enhance the specific antibody responses 
to individual components, particularly when co-administered with P.69.
4.7 PROTECTIVE ACTIVITIES OF CyaA FOLLOWING IMMUNISATION 
WITH CyaA ALONE OR IN COMBINATION WITH OTHER 
PERTUSSIS ANTIGENS AGAINST B. pertussis INFECTION
Betsou et al. (1993) showed that CyaC-mediated modification of CyaA was essential for 
protective activity and Hormozi et al. (1999) also confirmed that only the acylated form 
of CyaA was able to afford any protection against an intranasal challenge of B. pertussis 
after receiving two 15pg subcutaneous doses of either native or recombinant CyaA. 
This has led to the suggestion that CyaA should be considered as a potential component 
of future ACY’s. In addition it is known that B. pertussis mutants deficient in the
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expression of CyaA are impaired in their ability to cause a lethal infection in mice 
(Weiss and Goodman, 1989; Guiso et al., 1989) so neutralisation o f CyaA toxin by 
antibodies present after vaccination should have a similar effect on B. pertussis 
virulence. This study therefore focused initially on the protection afforded to mice 
against B. pertussis infection when immunised with either the enzymically-active, 
acylated CyaA or the enzymically-inactive, acylated CyaA*. Mice received two 15pg 
doses of either CyaA or CyaA*, or PBS as a control, i.p. After aerosol challenge with B. 
pertussis 18.323, the number of bacteria in the lungs of mice immunised with CyaA 
showed an approximate 2-log reduction compared to the control group of mice given 
PBS alone. A further half-log reduction was obtained when mice were given CyaA* 
(Figure 3.7.2.1). These results are comparable to those of Betsou et al. (1993, 1995) 
who showed that mice immunised subcutaneous 1 y with two doses at a two-week interval 
of ISpg CyaA and infected intranasally at 2 weeks post-immunisation gave an 
approximate 1.5-log reduction in lung counts of B. pertussis. Similarly, Hormozi et al. 
(1999) demonstrated an approximate 2.5-log reduction when comparing the mean B. 
pertussis lung counts in mice given the active, recombinant CyaA in two doses.
Because the unmodified, toxic form of CyaA would be unlikely to be considered as an 
antigen for inclusion in an acellular vaccine preparation, subsequent work focused more 
on the capacity of the non-toxic CyaA* to enhance protection afforded by other known 
protective antigens of B. pertussis, particularly those included in the current ACV’s, 
although CyaA was still included as a comparison. Mice received a single 25pg dose of 
either CyaA or CyaA* alone or in combination with 0.1 single human dose o f a current 
commercially-available three-component ACV, or the acellular vaccine or WCV (0.025
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single human dose) alone as a positive control (Figure 3.8.5). Mice that received PBS or 
E. coli LPS or boiled CyaA plus the ACV were included as control groups. As 
expected, WCV-immunised mice gave the greatest protection against aerosol challenge 
of B. pertussis, demonstrated by the low lung counts, while those receiving the ACV 
gave lung counts of approximately 1-log higher. The lung counts in mice given CyaA* 
or CyaA co-administered with ACV were slightly lower in comparison to those 
receiving ACV alone. However statistical analysis by the Student’s t-test indicated that 
the results between the ACV-immunised group and the group where ACV was co­
administered with CyaA* or CyaA were not statistically significant at either the 5% or 
10% level. This showed that in this instance, the addition of either CyaA* or CyaA to 
the ACV immunisation did not significantly enhance the protection afforded by the 
ACV alone. However, this work should be repeated as the lung counts from mice 
immunised with ACV plus LPS or ACV plus boiled CyaA were noticeably higher than 
those from mice immunised with ACV alone, which would indicate an element of 
experemental variation that demands further analysis. Indeed, it should be noted that the 
level of protection afforded by CyaA or CyaA* alone was noticeably lower than that 
achieved in the previous experiment (Figure 3.7.2.1) with only an approximate half-log 
reduction in lung counts compared to the PBS-vaccinated control, although this can be 
explained by only a single vaccination of CyaA in the latter experiment. If, however, 
CyaA contributed an additive element toward protection against challenge, this would 
not have been so apparent in this experiment.
Xing et al. (2000) reported that results from an aerosol challenge demonstrated that with 
mice previously given a dose o f 120ng of PT (ip), the lung counts were not much lower
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when compared to the control group of mice given PBS. However, when PT was 
administered in combination with either FHA, P.69 or Fims (25|_ig, lOpg or lOpg 
respectively) the protection was greatly boosted, indicating that PT is expressing a 
synergistic effect on other B. pertussis antigens when given in small quantities. 
However, the PT included in the ACV formulations is in the detoxified form and the 
precise mechanism of interaction between dPT and other antigens still remains to be 
established.
4.8 PROTECTIVE ACTIVITIES OF CyaA FOLLOWING IMMUNISATION 
WITH CyaA ALONE OR IN COMBINATION WITH OTHER 
PERTUSSIS ANTIGENS AGAINST B. parapertussis INFECTION
Whooping cough can be caused by either B. pertussis or B. parapertussis. Ideally a 
pertussis vaccine should be efficacious against both species and this was tested during 
the study. Khelef et al. (1993) found that, despite a high degree of homology between 
B. pertussis and B. parapertussis species, no cross-protection was observed. They used 
a murine respiratory model to examine the efficacies of single doses of purified P.69, 
PTd, FHA and CyaA (8pg per dose o f PTd, FHA or P.69, or 20qg CyaA) B. pertussis 
and B. parapertussis antigens against intranasal infection with B. pertussis or B. 
parapertussis. They found that B. pertussis antigens administered subcutaneously, 
protected against B. pertussis intranasal infection and similarly B. parapertussis antigens 
were able to protect against B. parapertussis infection. However, no cross-protection
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was obtained. Willems et al. (1998) studied the efficacy of a WCV against B. pertussis 
and B. parapertussis infections in a mouse model and showed that vaccination with the 
Dutch WCV induced protection against a respiratory challenge with either B. pertussis 
or B. parapertussis, although the protection against B. parapertussis was less 
pronounced. More recently, Watanabe and Nagai (2001) demonstrated that mice 
immunised by aerosol infection with either B. pertussis or B. parapertussis and then 
allowed to recover for 6 weeks before each group was challenged with a second aerosol 
infection of either B. pertussis or B. parapertussis, showed a significant decrease in lung 
counts from both groups of infected mice two weeks later. This indicates that cross 
protection between the two species was apparent. Perhaps the reasons for the conflicting 
results were the different types of immunisation, i.e mice immunised with a bacterial 
suspension by the aerosol route compared with those immunised with a range of selected 
antigens administered subcutaneously.
In the present study, protection against an intranasal challenge with B. parapertussis was 
observed following an ip immunisation with a single dose of native PT, FHA and P.69 
(120ng, 25qg and lOjug), and further enhanced when 25pg of CyaA* was included with 
the antigen mixture, as demonstrated by a further one-log reduction in lung counts 
(Figure 3.8.4). In this case CyaA* is having an additive effect and indicates the 
potential that CyaA* may have in affording increased protection against the two species. 
The results differ from those stated by Khelef et al. (1993) but there are two main 
differences in the experiment. Firstly, in this study, CyaA* was purified from the 
recombinant E. coli form and not from B. pertussis, although it is considered unlikely 
that this would account for the different results. Secondly, native PT at a low dose was
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used in this immunisation compared to detoxified PT used by Khelef at a higher dose. 
As previously noted, Xing et al. (2000) had shown that native PT at small doses was 
able to have a synergistic effect on the protective properties of other pertussis antigens 
against aerosol infection, and this may be the case in this experiment with CyaA*. It 
would be interesting to repeat this experiment using a higher dose o f dPT instead of the 
native PT or using a commercially available ACV.
4.9 EFFECTS OF CyaA ON NITRIC OXIDE PRODUCTION
NO and reactive nitrogen intermediates have been associated with the antimicrobial 
functions of macrophages (Ding et al., 1988) and by using NO production as a marker of 
macrophage activation, Xing et al. (2000) have shown that it is possible to identify the 
relevant components of any vaccine that are responsible for activation of macrophages. 
Xing et al. (1997) demonstrated that macrophage activation might play an important role 
in the immunity produced by vaccination with whole cell pertussis vaccine. 
Macrophage and spleen cells taken from mice immunised with WCV were able to 
respond in vitro to selected antigens by synthesis of NO, a signal o f macrophage 
activation. The relationship between NO production in vitro and the protection afforded 
in vivo against intra-cerebral challenge indicated that macrophage activation was 
probably involved in protective immunity and may play a role in controlling intracellular 
infection of mice caused by B. pertussis.
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In this study, preliminary work used macrophages taken from mice immunised with the 
acylated forms of the toxin which were re-stimulated in vitro with CyaA or CyaA*. 
However, little additional increase in NO synthesis was observed in comparison with 
LPS- or boiled CyaA-immunised mice, control groups used to ensure any observed 
response was due to the effects of CyaA and not LPS (Figure 3.7.3). These results 
would imply that macrophage activation does not play a major role in the protective 
properties afforded by CyaA and suggests that perhaps the humoral side of the immune 
system is more important, as indicated by the high levels of anti-CyaA antibody. In 
addition, little NO production was seen by macrophages from mice vaccinated with a 
PT, FHA, P.69 antigen mixture when stimulated by hlcc or CyaA preparations. This is in 
keeping with the reported lack o f stimulation of the CMI response by ACV’s. However, 
when mice received CyaA preparations in combination with native PT, FHA and P.69 
antigen mixture, CyaA or CyaA* clearly acted as an adjuvant to enhance the production 
of NO by the cell-mediated arm of the immune response following in vitro stimulation 
with either B. pertussis like or CyaA* (Figure 3.8.7). Moreover, immunisation with 
CyaA* in combination with the PT, FHA, P.69 antigen mixture resulted in greater NO 
production from macrophages following stimulation with B. pertussis hlcc or CyaA*, in 
comparison to immunisation with CyaA plus the antigen mixture. This may be related 
to the greater potential toxicity of CyaA for cells of the immune system. This can be 
seen when CyaA was used to stimulate macrophages at a concentration of 2pg/ml which 
was previously found to be cytotoxic to the cells (Figure 3.5.3.1; 3.5.3.2) and therefore 
no further enhancement of NO production was observed. These results therefore 
indicated that addition of CyaA* to the components of the ACV would not only enhance
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its protective properties with regard to colonisation, but may also CMI responses in a 
similar manner to WCV. Canthaboo et al. (2001) suggested that CMI may have a 
pivotal role in activating macrophages to eliminate completely the bacteria that have 
escaped immune defences mediated by antibodies and this may explain why CyaA or 
CyaA* had an enliancing effect on protection afforded by dPT, FHA and P.69.
4.10 CYTOKINE mRNA EXPRESSION
Thl cells are characterised by the secretion of IFNy, IL-2 and TNFa and are adept at 
macrophage activation and stimulation of production of immunoglobulin isotypes that 
mediate antibody-dependent cellular cytotoxicity and complement activation. Such cells 
have been shown to activate appropriate defence mechanisms against intracellular 
pathogens. Th2 cells produce IL-4, IL-15 and IL-5 and are involved in the development 
of humoral immunity for protection against extracellular pathogens. He et al. (1998) 
examined cytokine mRNA expression, by reverse transcription PGR, for IFNy, IL-2, IL- 
4 and lL-5 in the peripheral blood mononuclear cells (PBMCs) of schoolchildren and 
adults after natural infection or booster immunisation with diphtheria-tetanus-trivalent 
acellular pertussis vaccine (DTaP)(SKB, Belgium). The mRNA transcripts for both Thl 
and Th2 cytokines were detected in the PBMC’s of the vaccinated subjects and infected 
individuals after in vitro stimulation with B. pertussis antigens. These results are in 
agreement with earlier studies which found that induction of Thl or Tli2 cytokines is a 
vaccine- and antigen-dependent phenomenon related to the use of either whole cell or
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acellular vaccines (Ausiello et al., 1997). McGuirk and Mills (2000) used a murine 
respiratory-infection model to demonstrate that priming with a Thl or Tli2 vaccine can 
influence the local inflammatory response and immune effector cells in the lungs 
following aerosol challenge with B. pertussis. It is well known that B. pertussis can be 
taken up by macrophages and PMNs, therefore recruitment and activation of 
macrophages and PMNs may be a critical element of protective immunity to B. pertusis 
in the respiratory tract.
In this study, a difference was observed in the response of spleen cells after vaccination 
with the two forms of CyaA. Stimulation of spleen cells from CyaA* immunised mice 
with heat killed cells produced a cytokine mRNA response typical of a mixed T hl, Th2 
profile, in that high levels of IFNy, IL-2 and IL-4 were produced. On the other hand, 
CyaA-immunised mice produced a cytokine mRNA response biased towards a Thl 
profile with high levels of IFNy and IL-2 but very little IL-4 production (Figure 3.7.4.2,
3.7.4.3). In contrast, when spleen cells were taken from mice immunised with a 
combination of CyaA plus a mixture of native PT, FHA and P.69 antigens and 
stimulated in vitro with hkc or CyaA*, the total cytokine response was repressed. The 
levels of IFNy, IL-2 and IL-4 all decreased in comparison with those of mice immunised 
with the antigen mixture alone (Figure 3.8.7.1, 3.8.7.2), which in turn were markedly 
less than those obtained when CyaA or CyaA* were used as vaccines. The reason for 
these unexpected results is not clear, as NO production and protection experiments 
displayed an adjuvant or additive effect respectively when CyaA was co-administered 
with the other purified B. pertussis antigens. The RT-PCR results for cytokine
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expression do not represent conclusive data and need to be repeated and corroborated 
with cytokine determinations by ELISA.
The difference between the two forms of CyaA was also apparent in the levels of IFNy 
produced as measured by ELISA. Spleen cells taken from mice immunised with either 
the enzymically, active or non-active form of CyaA, produced high levels of IFNy when 
stimulated in vitro with hkc, 46336 and 13568pg/ml respectively, with the greatest level 
produced from cells taken from mice that had received the enzymically, active form of 
CyaA (Figure 3.87.3). However, when either form was co-administered with PT there 
was a clear difference in the levels of IFNy produced. The non-enzymic form, CyaA*, 
acted to enhance the levels of IFNy following co-administration with PT, with IFNy 
levels rising from 18368pg/ml in spleen cells taken from mice immunised with PT 
alone, to 41344pg/ml in cells taken from mice immunised with CyaA* in combination 
with PT following stimulation in vitro with hkc. In contrast, when spleen cells were 
taken from mice immunised with CyaA plus PT and stimulated with hkc, the level of 
IFNy produced decreased to 224pg/ml, a dramatic fall in the amount of IFNy compared 
to the amounts when PT was given either alone or in combination with CyaA*. It is 
likely that both CyaA and PT, when administered together, were acting in an 
antagonistic manner, as both toxins have a similar mode of action related to cAMP 
production and therefore must compete with each other, as when either toxin was 
administered on its own, the levels of IFNy produced were significantly higher 
compared to the value obtained when the two were co-administered.
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4.11 CONCLUSIONS
The traditional vaccines against whooping cough, containing whole-killed B. pertussis 
cells, have been used successfully to control the disease in most developed countries. 
However, concerns over the reactogenicity of these vaccines and also the requirement of 
both humoral and cell-mediated responses, have motivated the development of newer, 
ACV’s. The ACV’s, however, are generally not as efficacious as most European whole­
cell vaccines. The rationale for the present work was to investigate any benefits that 
CyaA might have when included in the current ACV’s.
It was reported previously that only the enzymically-activate, acylated form of CyaA 
and not the enzymically-active, non-acylated pro-toxin form was protective when used 
to immunise mice against intranasal or aerosol challenge. The protective properties of 
CyaA were further investigated in the present work to show that the enzymic nature of 
CyaA was not important for protection as long as the toxin was acylated. This was 
demonstrated by the similar levels of protection afforded by the CyaA preparation 
regardless of the presence or absence of enzymic activity. Evidence for an adjuvant 
effect of CyaA on antibody response to OA had been reported but nothing had been 
described previously about the possible effects that CyaA might exert on immune 
responses to other B. pertussis antigens such as PT, FHA and P.69. This study aimed to 
investigate the immune responses generated upon immunisation with CyaA or CyaA* 
preparations, in combination with other B. pertussis antigens, and to determine a role, if 
any, for increased intracellular cAMP levels in target cells by noting any differences in 
responses when either CyaA or CyaA* was used. The activation of specific cytokines is 
important in the protection against infection and therefore the ability to bias the response
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towards Thl or Th2 cytokines is undoubtably a key factor in protection. Immunisation 
o f mice with WCV has been demonstrated to selectively prime Thl cells, whereas 
immunisation of mice with ACV generates T cells that secrete IL-4 an IL-5, plus low 
levels of IFNy, features associated with a Th2 response.
The data presented here depicts a difference in the mRNA cytokine expression profile 
between immunisation with the two forms of CyaA. Immunisation with CyaA* 
followed by in vitro stimulation of spleen cells with B. pertussis heat-killed cells 
resulted in a mixed Thl/Th2 profile demonstrated by high levels of IFNy, IL-2 and IL-4, 
However, immunisation with CyaA followed by the same treatment directed the 
cytokine response to Thl, indicated by high levels of IFNy and IL-2, and low levels of 
IL-4 production. A similar difference between the two forms of CyaA was evident 
following IFNy production as measured by ELISA. Immunisation with CyaA, CyaA* or 
native PT followed by in vitro stimulation with heat-killed cells resulted in high levels of 
IFNy. However, when CyaA or CyaA* were co-administered with PT a difference 
related to the enzymic property of CyaA was apparent. CyaA* acted as an adjuvant 
towards PT to entrance the levels of IFNy, whereas the enzymic form of CyaA served to 
dramatically reduce the amount of IFNy produced. This difference is likely to be due to 
the action of the toxins working to increase cAMP levels and possibly having a mutually 
antagonistic effect upon each other. To further investigate cytokine production and 
understand the cellular response alternative methods of measurement could be 
employed. In addition to ELISA, enzyme-linked ELISPOT assay is available for the 
elucidation of Thl and Th2 cytokine producing cells. The advantage over ELISA is that 
it is able to determine the frequency o f cytokine producing cells in the single cell
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population. Thus the frequency and number of Thl and Th2 producing cells in different 
fractions (CD4^ or CD 8 ^) from various tissues can be determined. The best results will 
undoubtedly come from performing at least two different assays, ELISA, ELISPOT or 
RT-PCR, thereby confirming the results describing the profile of Thl and Th2 cytokine 
responses by immunisation. Alternative methods for measuring macrophage activation 
could be to calculate the levels of secreted products, such as superoxide or IL-12. In the 
same way that NO production was measured, superoxide levels could also be detected. 
A positive control would include macrophage cells that have been stimulated with 
phorbol-12-myristate 13-acetate (PMA). The release of superoxide from macrophages is 
tightly regulated, therefore freshly isolated cells produce negligible levels of superoxide 
in the absence of further stimulus. Bioassays are useful assays to measure bioactive 
TNFa, also an important regulator of macrophage activation.
Protection against both B. pertussis and B. parapertussis was enhanced when mice were 
immunised with CyaA or CyaA* co-administered with a purified pertussis antigen 
mixture compared to protection obtained with the antigen mixture alone. However the 
reduction in the number of bacteria in the lungs from mice immunised with CyaA in 
combination with a commercially-available thi'ee-component vaccine, was found not to 
be statistically significant when compared to the lung counts of those mice receiving the 
ACV alone. However taken in conjunction with the other experiments, CyaA does have 
an adjuvant effect on the antibody production to other protective antigens. It also has 
the effect of boosting NO production by macrophages when used in conjunction with 
other antigens for immunisation and this potential for boosting the cell-mediated arm of 
the immune system when used in conjunction with an ACV demands further work.
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Moreover, AC enzymic activity does not appear to be essential for protective or adjuvant 
effects of the toxin, demonstrated by the results of immunisation with CyaA*.
Problems with endotoxin removal led to the necessity of including additional controls of 
E. coli LPS and boiled CyaA in immunological studies. This was not an ideal solution 
because any observed effects may have been caused by an interaction between LPS and 
CyaA, and ideally this would have been tested, by adding different amounts of LPS to a 
pure preparation of CyaA. It would have been preferable to reduce the amount of 
endotoxin in the crude lysate prior to further purification methods. Ultrafiltration is a a 
particularly effective method in eliminating large aggregates of up to one million 
daltons, however, monomers are also present and therefore this method can be 
ineffective. As endotoxin is negatively charged, the use of positively charged 
membranes has been employed for its removal. Such membranes include polyamides or 
bonded amines and in particular polymyxin B which has a very high binding affinity for 
the lipid A moiety of endotoxin. Unfortunately the levels of endotoxin could not be 
reduced sufficiently in this study, although additional work has since indicated that 
endotoxin levels could be further reduced. An alternative method could have been to 
investigate the potential of producing the recombinant protein strains in a Gram-positive 
bacterium or yeast, such as Pichia pastoris, thereby eliminating the problem of LPS 
contamination.
In summary, this study has demonstrated that CyaA, both in the enzymic and non- 
enzymic form, has an adjuvant effect on the antibody response to other protective 
pertussis antigens and has the potential to enhance protection via the cell-mediated arm 
of the immune response, an important response to ensure complete bacterial elimination,
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Discussion
in particular those bacteria that have avoided the immune response via a humoral 
mechanism. It will be of great importance to further investigate these adjuvant 
properties and take full advantage of the methods available to understand fully the nature 
of the immune response if CyaA is to be included in a vaccine formulation.
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Appendix A; Media composition
A .l Luria Bertani broth (LB)
Tryptone (BDH Laboratory supplies) 10 g 
Yeast extract (BDH) 5 g
Sodium chloride 10 g
Add 1.2 % (w/v) agar for solid media
Made up to 1 litre in distilled water
A.2 SOC medium
Tryptone (BDH) 20 g
Yeast extract (BDH) 5 g
Salts I (250 mM KCL, 1 M NaCl) 10 ml
Made up to 1 litre in distilled water
After autoclaving, add 10ml of 2 M sterile glucose and 10 ml of Salts II (1 M 
MgCL.ôHsO, 1 MMgSO4.7H20)
A.3 Casamino acid solution
NaCl 6  g
Casamino acids (BDH) 10 g
Made up to 1 litre in distilled water, pH to 7.
A.4 Phosphate Buffered Saline (PBS)
NaCl 10.0 g
KCL 0.75 g
Na2HP04.12H20 1.44 g
KH2PO4 0.125 g
Made up to 1 litre in distilled water
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Appendix B: DNA Solutions
B .l TAE Buffer (50X 1 L)
Tris 242 g
EDTA (0.5M, pH 8.0) 100 ml
Glacial acetic acid 57.1 ml
B.2 6 X DNA loading buffer
Tris 60 mM
EDTA 6  mM
Sucrose 40 % (w/v)
Bromophenol blue 0.25 % (w/v)
Appendic C: CyaA expression and purification buffers
C .l Buffer A
Tris (1 M, pH 8.0) 5 ml
CaCl] (0.1 M) 0.2ml
Made up to 100 ml in distilled water
C.2 Buffer B
Add 9.6g Urea to 20 ml of buffer A to give an 8  M urea solution
C.3 DEAE Sepharose Chromatography
C.3.1 Buffer 1
Tris 12.12 g
Made up to 100ml, pH to 8.0
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C.3.2 Buffer 2
Tris 0.606 g
Made up to 100ml, pH to 8.0
C.3.3 Buffer 3
Tris 0.606 g
NaCl 0.292 g
Urea 48 g
Made up to 100ml, pH to 8.0
C.3.4 Elution protocol
Buffer 3 with adjusted NaCl content,
Blutant volume
NaCl 250 mM 2 X 1ml
NaCl 500 mM 2 X 1 ml
NaCl TOM 1 X 2 ml
NaCl 1.5 M 1 X 4 ml
NaCl 2.0 M 4 X 4 ml
C.4 Phenyl Sepharose Chromatography
C.4.1 Solution A
Tris 0.303 g
NaCl 2.922 g
Made up to 50 ml, pH to 8.0
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C.4.2 Wash Buffer
Tris
NaCl
Urea
Made up to 50 ml, pH to 8.0
0.303 g 
2.922 g
6.0 g
C.4.3 Solution B
( 1 ) Tris
NaCl
EDTA
Urea
0.303 g 
1.461 g 
0.037 g
6 . 0  g
(2) Tris
NaCl
EDTA
Urea
0.303
0.705
0.037
6 . 0  g
(3) Tris
EDTA
Urea
0.303 g 
0.037 g 
24.024 (
Ail made up to 50 ml
Appendix D: Protein analysis solutions
D .l Separating gel (10 %)
Acrylamide/Bis solution 
dHzO
Tris-HC1(1.5M, pH 6 .8 )
20 % (w/v) SDS 
TEMED
1 0  ml
11.05 ml
7.5 ml 
150 j L i l  
15 pi
10 % (w/v) Ammonium persulphate (APS) 300 pi
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D.2 Stacking gel (6 %)
Acrylamide/Bis solution 4 ml
dHsO 10.69 ml
Tris-HCl (0.5 M, pH 6 .8 ) 5 ml
20%  (w/v) SDS 100 pi
TEMED 10 pi
10 % (w/v) Ammonium persulphate (APS) 200 pi
D.3 Electrode buffer (10 X)
Tris base 30 g
Glycine 144 g
SDS 10 g
Made up to 1 litre in distilled water, pH to 8.3
D.4 Protein sample buffer
Glycerol 5 ml
20 % (w/v) SDS 2.5 ml
2 -mercaptoethanol 0.5 ml
Tris (0.5M pH 6 .8 ) 2.5 ml
Bromophenol blue 0.25 % (w/v)
D.5 Coomassie gel stain
Coomassie blue 0.5 g
Methanol 500 ml
Acetic acid 100 ml
dHzO 400 ml
For destain, omit the coomassie blue
196
D.6 Electroblotting buffer
Tris base 7.2 g
Glycine 33.4 g
CIH2 O 2400 ml
Methanol 600 ml
pH to 8.0
D.7 Blocking buffer
Skimmed milk 6  g
dH2 0  2 0 0  ml
Tween 20 400 pi
D.8 DAB solution
3-3’ Diaminobenzidine (DAB) 0.05 g
PBS 98 ml
C0 CI2 2  ml
H2O2 1 0 0  pi
Appendix E: Tissue culture 
E .l RPMI medium
Foetal Calf Serum (Gibco BRL) 50 ml
Glutamine 5 ml
Fungizone (Gibco BRL) 5 ml
Dissolve in 500ml RPMI-1640 medium
E.2 Trypan blue solution
Trypan blue 0.2 g
NaCl 4.25 g
Dissolve each component individually in 100 ml dHzO, then mix 4 parts trypan 
blue with 1 part saline
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E.3 Greiss reagent 
Solution A
0.1 % (w/v) N-[l-naphthyl] ethylenadiamine dichloride in dHgO 
Solution B
1 % (w/v) Sulfanilamide in 5 % H 3PO4
15 ml of solution A is mixed with 15 ml solution B and kept chilled until use. 
Used within 12 h.
Appendix F: CyaA enzymic assays
F .l Reaction Mixture
Tris-HCl pH 8.0 
MgClz
CaCl2
BSA
Calmodulin
non-radio active cAMP
tritiated cAMP (Amersham Pharmacia)
60 mM 
7 mM 
0.1 mM 
1 mg/ml 
100 nM 
0.1 mM
O.lmM (50 Ci/nmol)
F.2 Substrate solution
non-radioactive ATP 
^^aP-ATP (Amersham Pharmacia)
20 mM
2mM (3000Ci/nmol)
F.3 Bicine buffer
Bicine
Mg(C2H]0 3 ) 2  
ATP 
pH to 8.0
lOmM 
1.5 mM 
0.5 mM
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Appendix G: Immunological assays
G .l Carbonate Coating Buffer
NaiCOa anhydrous 1.59 g
NaHCO] 2.95 g
NaNs 0.5 g
Made up to 1 litre in distilled water, pH to 9.5
G.2 Wash Buffer (IgG)
PBS
Tween 20 0.05 %
G.3 Diluent and Blocldng buffer
PBS
Tween 20 0.05 %
Foetal Calf Serum 10 %
G.4 Acetate Buffer (X 10)
NaCHsCOOH.SHzO 68.04 g
Glacial acetic acid 1632 pi
Made up to 1 litre in distilled water
G.4.1 Substrate solution
Acetate buffer (X 10) 25 ml
Distilled water 225 ml
3,3’- 5,5’ Tetramethyl benzidine 
dihydrochloride (TMB) in 
Dimethylsulphoxide (DMSO) 2.5 ml
Hydrogen Peroxide 75 pi
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G.5 Blocking buffer (IFNy)
PBS
BSA 1 % (w/v)
G.6 Diluent (IFNy)
PBS
Tween 20 0.05 % (v/v)
BSA 1 % (w/v)
2 0 0
Appendix H .la Anti-CyaA IgG levels
2 weelis post immunisation 4 weelcs post immunisation
Logs
reciprocal
dilution
pro-
CyaA CyaA* CyaA
pro-
CyaA CyaA* CyaA
2 1.534 0.878 0.821 1.784 1.541 1.634
1.393 1.017 0.85 1.821 1.982 1.693
1.450 1.734 1.076 1.242 1.428 1.878
2.477 1.085 0.479 0.269 1.346 0.915 0.973
0.826 0.465 0.262 1.363 1.713 1.166
0.900 1.213 0.409 0.696 0.719 1.290
2.954243 0.660 0.246 0.153 0.782 0.409 0.468
0.438 0.247 0.162 0.78 1.060 0.573
0.522 0.555 0.180 0.481 0.316 0.678
3.431364 0.400 0.175 0.458 0.152 0.211
0.309 0.166 0.505 0.428 0.232
0.325 0.234 0.399 0.176 0.258
7 weeks post immunisation 9 weelis post immunisation
Logs
reciprocal
dilution
pro-
CyaA CyaA* CyaA
pro-
CyaA CyaA* CyaA
2 1.682 1.685 1.702 1.754 1.566 1.632
1.717 1.703 1.698 1.687 2.079 1.760
1.624 2.266 1.869 1.678 2.004 1.893
2.477 1.086 1.240 1.202 1.136 0.915 0.906
1.453 1.178 1.260 1.085 1.733 1.335
1.162 1.818 1.569 1.047 1.642 1.580
2.954243 0.622 0.608 0.591 0.546 0.409 0.414
0.921 0.585 0.678 0.479 1.128 0.710
0.625 1.174 1.101 0.492 1.095 1.085
3.431364 0.321 0.218 0.168 0.243 0.185
0.462 0.268 0.180 0.443 0.223
0.369 0.520 0.429 0.466 0.414
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Appendix H .lb Anti-CyaA IgG levels at 2, 4, 7 and 9 weeks post
immunisation
Log3 reciprocol dilution at OD^ gonm = 0.5
Time post 
immunisation
Pro-CyaA CyaA* CyaA
2 weeks 3.096 2.671 2.536
3.032 3.117 2.373
3.398 2.603 2.347
M ean  ± s.d 3.175 + 0.160 2.797 ± 0.228 2.419 + 0.084
4 weeks 3.368 2.899 2.831
3.338 3.430 3.174
2.861 2.975 3.307
M ean ± s.d 3.189 ± 0.232 3.101 + 0.234 3.104 + 0.201
7 weeks 3.209 3.131 3.096
3.427 3.482 3.455
3.164 3.138 3.137
M ean ± s.d 3.267 + 0.115 3.250 + 0.164 3.229 ± 0.160
9 weeks 2.987 3.457 3.178
2.937 3.449 3.434
2.938 3.018 2.996
M ean ± s.d 2.954 + 0.023 3.308 ± 0.205 3.203 + 0.180
2 0 2
Appendix H .le Anti-CyaA IgG levels following boosting at 7
weeks post immunisation
7 weeks post immunisation 9 weelcs post immunisation
Log]
reciprocal
dilution
pro-
CyaA CyaA* CyaA
pro-
CyaA CyaA* CyaA
2 1.929 1.452 1.978 2.851 3.650 2.301
1.895 1.347 1.653 2.793 3.136 2.718
1.78 2.045 2.979 3.176 2.228
2.477 1.497 0.793 1.572 2.339 3.065 2.191
1.392 0.602 1.03 2.320 2.662 2.353
1.347 1.737 2.484 2.732 2.016
2.954243 1.053 0.352 0.594 1.925 2.479 1.886
0.816 0.28 0.385 1.802 2.188 1.953
0.921 1.185 1.989 2.288 1.682
3.431364 0.63 0.191 0.329 1.596 1.893 1.359
0.447 0,161 0.164 1.457 1.714 1.458
0.508 0.247 1.381 1.843 1.097
11 weeks post immunisation 14 weeks post immunisation
Log]
reciprocal
dilution
pro-
CyaA CyaA* CyaA
pro-
CyaA CyaA* CyaA
2 2.987 2.243 2.327 2.448 2.114 2.306
2.586 2.214 2.252 2.225 2.266 2.002
2.414 2.354 2.295 2.502 2.28 2.33
2.477 2.460 2.051 1.832 2.019 1.988 2.088
2.161 2.049 1.839 1.941 2.164 1.624
2.083 2.304 2.016 2.099 2.161 2.115
2.954243 1.932 1.927 1.980 1.795 1.863 1.894
1.733 1.911 1.500 1.636 1.998 0.88
1.752 2.126 1.785 1.838 1.978 1.954
3.431364 1.405 1.619 1.674 1.308 1,542 1.412
1.307 1.631 0.791 1.07 1.655 0.351
1.421 1.915 1.361 1.517 1.646 1.798
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Appendix H .Id Anti-CyaA IgG levels at 7 ,9 ,11  and 14 weeks 
post immunisation following boosting at 7 weeks
Log] reciprocol dilution at OD^ gonm = 0.5
Time post 
Immunisation
Pro-CyaA CyaA* CyaA
7 weeks 3.570 2.938 3.214
3.334 3.541 3.003
3.434 2.831
Mean ± s.d 3.446 ± 0.097 3.103 ± 0.313 3.109 ± 0.106
9 weeks 3.800 4.654 4.901
3.168 4.874 4.561
4.082 4.566 4.324
Mean ± s.d 3.683 ± 0.382 4.698 ± 0.130 4.595 + 0.237
11 weeks 4.250 6.206 6.545
4.760 6.385 3.822
4.334 8.062 4.753
Mean ± s.d 4.448 ± 0.223 6.884 ± 0.836 5.040 + 1.130
14 weeks 4.257 6.285 5.080
4.359 6.350 3.314
4.259 6.182 6.249
Mean ± s.d 4.292 ± 0.048 6.272 ± 0.069 4.881 +1.206
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Appendix H.2: MTT neutralisation data
Absorbance (540nm)
Protein
concentraion
(pg/ml)
CyaA 
mean ± sd
CyaA + sera 
from PBS 
immunised 
mice
mean + sd
CyaA + sera 
from CyaA* 
immunised 
mice
mean + sd
CyaA + sera 
from CyaA 
immunised 
mice
mean ± sd
65.00 0.141 + 0.0015 0.186 + 0.0140 1.068 + 0.0695 0.949 + 0.0330
32.50 0.117 + 0.0055 0.155 + 0.0035 0.523 + 0.038 0.756 + 0.0570
16.25 0.122 + 0.0050 0.140 + 0.0028 0.190 + 0.0015 0.450 + 0.0225
8.13 0.159 + 0.0300 0.147 + 0.0070 0.169 + 0.0206 0.166 + 0.0035
4.06 0.168 + 0.0130 0.172 + 0.0012 0.153 + 0.0115 0.126 + 0.0025
2.03 0.226 + 0.0120 0.136 + 0.0030 0.140 + 0.0030 0.119 + 0.0000
1.02 0.672 + 0.0480 0.139 + 0.0051 0.134 + 0.0005 0.170 + 0.0085
0.51 1.034 + 0.0410 0.146 + 0.0042 0.132 + 0.0007 0.114 + 0.0035
0.25 1.147 + 0.1240 0.143 + 0.0085 0.121 + 0.0010 0.117 + 0.0000
0.13 1.277 + 0.2100 0.147 + 0.0068 0.135 + 0.0035 0.061 + 0.0005
J774.2 cells 1.243 + 0.022
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Appendix H.3 Nitric oxide levels
Immunisation group no
stimulation 
mean ± sd
+ hkc 
mean ± sd
± CyaA* 
mean ± sd
+ CyaA 
mean ± sd
PBS 3.260 ±0.31 11.310 ± 1.52 4.240 ±0.38 3.140 ±0.38
LPS 1.830 ±0.22 15.250 ± 1.53 5.230 ±0.78 5.080 ±1.65
Boiled CyaA 6.340 ±2.28 12.590 ±0.13 6.520 ±5.81 3.931 ±1.14
CyaA* 2.055 ±0.19 11.281 ±1.13 3.715 ±0.41 4.505 ±1.15
CyaA 2.525 ±0.16 8.510 ±1.32 6.290 ±0.45 5.795 ±1.12
PT,FHA,P.69 4.605 ±0.90 13.445 ±2.75 8.695 ±1.68 5.905 ±0.26
LPS+PT,FHA,P.69 4.295 ±0.60 19.230 ±2.77 17.575 ±2.45 10.865 ± 1.91
CyaA*+PT,FHA,P.69 6.370 ±0.52 44.362 ±1.72 35.783 ± 1.49 16.077 ±2.27
CyaA+PT,FHA,P.69 8.957 ±1.38 29.420 ±2.27 26.880 ±4.08 17.400 ±2.42
Appendix H.4 % (3-Actin intensity
Immunisation
group
+ hkc +CyaA*
IL-2 IL-4 IFNy IL-2 IL-4 IFNy
PBS 248.76 201.72 74.30 89.91 65.38 63.85
LPS 76.88 69.65 37.80 107.46 79.21 78.32
CyaA* 554.49 472.46 395.72 82.85 75.32 86.53
CyaA 491.99 373.85 85.44 428.85 402.46 367.94
PT, FHA, P.69 243.65 156.90 172.02 238.67 272.83 225.23
LPS+ PT, FHA, 
P.69
86.04 73.21 59.98 158.04 162.21 141.58
CyaA*+ PT, FHA, 
P.69
159.90 103.14 61.62 121.60 111.15 114.02
CyaA± PT, FHA, 
P.69
114.22 8&63 97.26 128.78 94.47 20.32
206
Appendix H 5a Anti-CyaA IgG results
Log]
reciprocal
dilution
Immunisation groups
CyaA CyaA* CyaA± PT, 
FHA, P.69
CyaA*+ PT, 
FHA, P.69
2 2.239 1.978 2.003 1.954
2.342 L928 2.198 2.239
2.155 2.039 1.634 1.919
2.477 1.790 1.291 1.378 1.300
1.761 1.063 1.791 1.861
1.487 1.239 0.874 1.453
2.954243 1.012 0.568 0.656 0.768
0.997 0.491 0.768 1.236
0.797 0.56 0.425 0.875
3.431364 0.673 0.210 0.211 0.356
0.641 0.179 0.356 0.814
0.431 0.230 0.089 0.571
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Appendix H 5b Anti-CyaA IgG results
Immunisation Group Log] reciprocol dilution at
OD450nin 0.5
Mean ± s.d
CyaA 3.481 3.545 ± 0.062
3.629
3.525
CyaA* 3.004 2.968 ± 0.038
2.916
2.984
CyaA + PT,FHA,P.69 3.076 3.071 ±0.175
3.283
2.854
CyaA* + PT,FHA,P69 3.248 3.471 ± 0.194
3.721
3.443
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Appendix H.6.1b Anti-PT IgG levels
Log] reciprocol dilution at OD450nm = 0.5
Immunisation
group
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mean ± sd
PT alone 4.613 4.440 4.502 4.631 4.478 4.535 ± 0.076
PT + CyaA* 4.011 4.365 4.328 4.324 4.342 4.274 ± 0.132
PT +
FHA+CyaA*
4.310 4.349 4.555 4.542 3.818 4.315 + 0.267
PT
+P.69+CyaA*
3.367 4.769 4.720 4.577 4.790 4.445 + 0.544
PT +
FHA+P.69+Cy
aA*
4.724 4.647 4.839 4.565 4.590 4.673 + 0.099
Boiled CyaA* + 
PT,FHA,P.69
4.344 4.276 4.381 4.600 4.171 4.354 + 0.142
Appendix H.6.2b Anti“FHA IgG levels
Log] reciprocol dilution at OD45o„m= 0.5
Immunisation
group
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mean ± sd
FHA alone 0.511 1.872 2.032 2.522 2.502 1.888 ± 0.734
FHA + CyaA* 3.751 3.707 4.220 4.316 3.840 3.967 ± 0.251
FHA + PT
+CyaA*
3.881 3.767 3.828 4.045 4.417 3.988 ± 0.234
FHA +PT 
+P,69+CyaA*
3.856 3.603 3.930 4.045 4.108 3.908 ± 0.176
Boiled CyaA* + 
PT,FHA,P.69
2.256 2.909 2.983 2.846 2.826 2.764 ± 0.260
Appendix H.6.3b Anti-P.69 IgG levels
Log] reciprocol dilution at OD45o„,„ = 0.5
Immunisation
group
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mean ± sd
P.69 alone 0 0 0 0 0 0
P.69 + CyaA* 3.022 2.970 3.753 3.287 3.197 3.246 + 0.278
P.69 + PT
+CyaA*
2.596 2.800 3.320 3.110 2.953 2.956 ± 0.249
P.69 +PT
+FHA+CyaA*
3.006 2.457 3.064 2.931 2.836 2.859 ± 0.215
Boiled CyaA* + 
PT,FHA,P.69
3.075 2.401 2.551 2.795 3.206 2.906 ± 0.304
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Appendix H.7.1b Anti-PT IgGj levels
Log] reciprocol dilution at OD^ sonm = 0.5
Immunisation
group
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mean ± sd
PT alone 3.364 3.430 3.566 3.305 3.324 3.398 ± 0.094
PT + CyaA* 3.099 3.309 3.441 3.608 3.720 3.435 ± 0.219
PT +
FHA+CyaA*
2.983 3.135 3.504 3.765 3.674 3.412 ± 0.304
PT
+P.69+CyaA*
3.441 3.263 3.560 3.553 4.254 3.61410.337
PT +
FHA+P.69+Cy
aA*
3.202 3.438 3.385 3.377 3.997 3.480 1 0.271
Boiled CyaA* + 
PT,FHA,P.69
3.167 3.247 3.352 3.368 3.729 3.373 1 0.193
Appendix H.7.2b Anti-FHA IgGi levels
Log] reciprocol dilution at OD^ sonm = 0.5
Immunisation
group
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mean ± sd
FHA alone 1.527 0.790 1.618 1.823 0 1.152 ± 0.673
FHA + CyaA* 4.277 3.899 3.458 3.878 3.009 3.704 ± 0.434
FHA + PT
+CyaA*
2.993 3.257 3.379 3.179 3.680 3.298 ± 0.229
FHA +PT 
+P.69+CyaA*
3.002 3.148 3.308 3.143 3.167 3.154 ± 0.097
Boiled CyaA* + 
PT,FHA,P.69
2.262 2.426 2.752 3.027 2.255 2.544 ± 0.301
Appendix H.7.3b Anti-P.69 IgG, levels
Log] reciprocol dilution at OD^ sonm = 0.5
Immunisation
group
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mean ± sd
P.69 alone 0 0 0 0 0 0
P.69 + CyaA* 2.544 2.958 2.910 3.017 3.358 2.957 ± 0.260
P.69 + PT
+CyaA*
2.767 3.063 3.121 2.997 2.798 2.949 ± 0.142
P.69 +PT
±FHA+CyaA*
0.100 2.010 2.598 2.600 0 1.827 ± 1.026
Boiled CyaA* + 
PT,FHA,P.69
0 0 0 0 0 0
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